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The intramolecular aza-Michael reaction has been used effectively in the synthesis of nitrogen 
heterocycles, with several efforts made in recent years to do so asymmetrically. The selection 
of the Michael acceptor can play an important role in both the rate and enantioselectivity of 
the reaction. The research in this thesis demonstrates how the use of a chiral phosphoric acid 
can catalyse the intramolecular asymmetric aza-Michael reaction of a protected amine with 
an α,β- unsaturated thioester. The scope of the reaction was demonstrated in the synthesis 
of 2,2- and 3,3-spirocyclic pyrrolidines in high yields and enantioselectivity (Scheme 1). The 
synthesis of an unsubstituted pyrrolidine provided the core of two natural products (R)-
bgugaine and (R)-irnidine and both succumbed to total synthesis. (R)-Bgugaine was 
synthesized in a 33% overall yield in 6 steps while (R)-irnidine was synthesized for the first 
time in an overall yield of 18% over 6 steps. 
 
Scheme 1. Asymmetric synthesis of spirocyclic pyrrolidines 
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1. Introduction – The Enantioselective Synthesis of Pyrrolidines 
1.1. Pyrrolidines in pharmaceuticals 
A recent report on the number of nitrogen heterocycles present in FDA approved 
pharmaceuticals highlights the prevalence and structural diversity of these compounds.1 
From a database of 1086 unique small molecule drugs, 910 (84%) contained at least one 
nitrogen atom with 640 (59%) containing a nitrogen heterocycle. Out of these 640, the 
aromaticity, ring size and substitution patterns were analysed to determine the prevalence of 
each type of ring system. The most common five-membered non-aromatic nitrogen 
heterocycle by far was the pyrrolidine, which ranked 5th overall for frequency out of 25 
distinct heterocycles.1 The structure was present in more drugs than all other five-membered 
non-aromatic nitrogen heterocycles combined. The report also noted that the vast majority 
(92%) of pyrrolidine drugs showed substitution on the nitrogen atom with 62% substituted at 
the 2-position as the second most common site of substitution. A common motif present 
which contains a pyrrolidine ring is that of proline and is seen in many ACE inhibitor drugs 
used to treat hypertension, such as captopril 1 (Figure 1).2 The application of pyrrolidine 
containing drugs is very wide ranging from the antibiotic clindamycin 5, antihistamine (S,S)-
clemastine 3 and the hepatitis C drug ledipasvir 4. 3–5 While not used as a drug, the small 
molecule (-)-kainic acid 2 is useful in studying mammalian nervous system disorders such as 




Figure 1. Pyrrolidine containing pharmaceuticals and biologically active molecules 
A key feature to note in all the structures shown in Figure 1, is that there is at least one or 
more stereocenters on the pyrrolidine ring. Over half (56%) of drugs currently in use are chiral, 
with 88% of these chiral drugs used as a racemate.8,9 While these drugs are used effectively 
as a racemate, in recent years there has been efforts to understand the effect of different 
enantiomers on the body, in terms of efficacy, toxicology and pharmacokinetics.9,10 As such, 
in 1992 the FDA released a policy statement indicating new measures for the introduction of 
chiral drugs involving the study of various properties of both enantiomers in order to gain 
approval.11 The policy also suggested using synthetic methods to prepare single enantiomers 
in order to properly assess the properties of both isomers.  
There is a clear need and desire to synthesise compounds as a single enantiomer, or otherwise 
separate enantiomers for study. Although chiral separation techniques exist, if the specific 
stereochemistry can be introduced via a synthetic step, separation would not be required. 
Due to the prevalence of N-heterocycles in pharmaceutical compounds, the stereoselective 
synthesis of these motifs has been of interest for several years. Many methods have been 
developed to enable efficient and stereo-controlled production of pyrrolidines. A selection of 
15 
 
these approaches is presented below to demonstrate the variety of reactions available in the 
literature.  
1.2. Chiral pool synthesis 
One of the most direct methods of producing compounds as a single enantiomer is using 
enantiomerically pure starting material, i.e. using the chiral pool. This typically involves 
utilising materials widely available in nature as the starting material for a synthetic route in 
order to form the key chiral structures of a compound.12  Some common materials from the 
chiral pool include α-amino acids, carbohydrates, terpenes and hydroxy acids. The chiral pool 
and derivatives thereof have also been widely used in the field of enantioselective catalysis,13–
15 for example ʟ-proline has been used to catalyse asymmetric aldol reactions since the 
1970s.16  
Building pyrrolidine scaffolds from the chiral pool is possible through various synthetic 
modifications and one of the most obvious starting materials for this is ʟ-proline.17 The 
functionalisation of ʟ-proline has been performed in multiple ways to enable its use as a chiral 
synthon, such as the Arndt-Eistert homologation,18 and the Henry-Nef reaction.19 Due to the 
low cost and accessibility of ʟ-proline it also makes a very useful starting material for large 
scale synthesis.  A report by Fujieda demonstrates the use of an ʟ-proline derivative in the 
synthesis of a glucokinase activator, a potential treatment for type 3 diabetes, on a multi-kilo 
scale (Scheme 3).20 In the first-generation synthesis of the key intermediate 9 a racemic 
mixture was obtained and an optical resolution was required to access the desired 
enantiomer, making the maximum theoretical yield for that step 50%. To get around this in 
later generation syntheses, N-Boc-ʟ-proline methyl ester 6 was functionalised through a 
chloromethylation to give the α-chloroketone 7 in 97% yield, followed by alkylation with 
methylacetoacetate to give compound 8 in 73% yield. The use of a sulfating reagent (in this 
case Lawesson’s reagent) allowed for the Paul-Knorr thiophene synthesis of the key 




Scheme 3. Synthesis of key intermediate of a glucokinase activator 
The key to the success of this application is that the desired stereochemistry of the product 
matched that of the naturally occurring ʟ-proline which greatly reduces the cost. The 
unnatural enantiomer, ᴅ-proline, can be up to 20x more expensive than the natural 
enantiomer, which can severely limit accessibility or feasibility.21 Another limitation when 
using the chiral pool is that functionalisation around the pyrrolidine ring can be more difficult 
or involve multistep syntheses. If the functionality of the starting material is not desired in 
the product (e.g. the carboxylic acid group of an amino acid), then extra synthetic steps may 
be required to remove or modify that group. This can make alternative methods, where 
unwanted motifs are never present in the molecule during the forward synthesis, particularly 
attractive. 
1.3. Chiral auxiliaries  
If an unnatural enantiomer of a pyrrolidine or specific chemical groups are required for the 
synthesis of a product, then an alternative asymmetric procedure may be required. A way to 
get around this can be through the use of a chiral auxiliary, where a chiral compound is 
incorporated into a molecule and then removed later in the synthesis. By having a chiral 
auxiliary covalently bound to a molecule, any introduction of stereocenters into the 
compound will result in the potential formation of diastereomers. As diastereomers generally 
have different physical properties to each other, separation and purification can be much 
easier than with enantiomers.  
17 
 
There are many chiral auxiliaries available for asymmetric synthesis and a number of these 
have been used in the synthesis of pyrrolidines. Both (R)-phenylglycinol 10 and (S,S)-
pseudoephedrine 11  (Figure 2) have both been used in diastereoselective reactions, which 
have led to the production of single enantiomers of substituted pyrrolidines, after sacrificial 
loss of the auxiliary.22,23 Another use for chiral auxiliaries is for the resolution of a racemic 
mixture. (+)-Pinanediol 12 (Figure 2) has been used to synthesise the boronate ester of 
racemic N-Boc-pyrrolidine-2-boronic acid, allowing for separation and chiral resolution of the 
two enantiomers.24  The high price of (+)-pinanediol 12 has also led to the development of 
processes to enable efficient recycling of the auxiliary.25 
 
Figure 2. Examples of chiral auxiliaries 
One common class of chiral auxiliary is the oxazolidinone, which was popularised by Evans for 
the use in enantioselective aldol condensations.26 This oxazolidinone has also been exploited 
in the synthesis of pyrrolidines by setting up stereocenters within a molecule prior to 
cyclisation of a pyrrolidine ring. Using the Evans auxiliary, Warren and co-workers were able 
to achieve an asymmetric aldol reaction with an α-SPh aldehyde to give aldol addition product 
14 with high yield and diastereoselectivity (Scheme 4).27 Removal of the auxiliary from the 
major diastereomer was achieved through a transamination procedure with ammonium 
chloride and trimethylaluminium to give amide 15 in 72% yield. Further transformations led 




Scheme 4. Use of Evans auxiliary in the synthesis of spirocyclic pyrrolidines 
Another example of a well-used auxiliary is the N-tert-butanesulfinamide (Ellman auxiliary), 
which was used by Fustero et. al. in a base mediated intramolecular aza-Michael reaction for 
the synthesis of pyrrolidines and piperidines (Scheme 5).28 The procedure was demonstrated 
on both methyl vinyl ketones and tert-butyl acrylates, but an interesting selectivity was 
observed when varying the temperature of the reaction. The cyclisation of enone 17 with 
potassium tert-butoxide gave a diastereoselectivity of 85:15 with pyrrolidine 18a as the major 
isomer and thermodynamic product when the reaction was performed at room temperature. 
However, by lowering the temperature to -40 °C, the selectivity was inverted to favour 
pyrrolidine 18b as the kinetic product in a ratio of 80:20. This inversion of stereochemistry 
was possible due to the reversibility of the reaction, which was further demonstrated when 
the reaction was performed at -40 °C then warmed to room temperature and left for 12 hours. 
When this was done, the product was isolated as a ratio of 81:19 for 18a to 18b, showing 




Scheme 5. Use of the Ellman auxiliary in the asymmetric intramolecular aza-Michael reaction 
There is clear precedent for the use of chiral auxiliaries to synthesise enantiomerically 
enriched pyrrolidines. The availability of auxiliaries, especially of both enantiomers, gives a 
good access to the desired stereochemistry of a molecule, and as most reactions lead to the 
formation of diastereomers, the purification of a single stereoisomer can also be achieved 
more easily. However, the inclusion of the auxiliary in the final product is not always required, 
and due to the stoichiometric quantities needed, the atom economy of the reaction can be 
significantly reduced. While some auxiliaries can be recycled, this is not always the case and 
the addition and removal of an auxiliary adds extra steps to a synthetic plan.  
1.4. Chiral lithium amide bases 
Introduction of the specific stereochemistry needed in a final product can be achieved in a 
single step through the use of other chiral reagents. A valuable method that can do this is 
asymmetric induction with chiral lithium amide bases. These reagents are analogous to widely 
used bases in organic chemistry, such as lithium diisopropylamide, but contain stereogenic 
centres within the structure of the base. The core structures can be derived from organic 
molecules, such as α-methylbenzylamine and phenylglycine, or can be isolated from natural 
sources, as in the case of sparteine. These reagents have found various applications in 
asymmetric organic synthesis, such as the deprotonation of prochiral ketones and epoxide 
rearrangement to allylic alcohols.29 For the asymmetric synthesis of heterocycles, sparteine 
has been widely used in the enantioselective lithiation of N-Boc pyrrolidine.30 
The seminal work by Beak and co-workers demonstrated the use of (-)-sparteine 25 and sec-
BuLi to deprotonate N-Boc pyrrolidine 19 next to the nitrogen.31 Asymmetric deprotonation 
can take place due to the coordination of the lithium cation with the nitrogen atoms of the (-
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)-sparteine ligand. The chiral carbanion formed is also stabilised by coordination of the 
carbonyl of the Boc group to the lithium atom, which helps prevent racemisation of the 
stereocentre.  The lithiated species could then be trapped with an electrophile to give an 
isolated product in high enantiomeric excess. In the case of TMSCl, this led to the isolation of 
2-trimethylsilyl-N-Boc pyrroldine 21 in 76% yield and 96% ee. When dimethyl sulfate was 
used, successive additions were able to take place to introduce methyl groups for a double 
sparteine-lithiation to give a 2,5-disubstituted pyrrolidine 24 (Scheme 6).32 
 
Scheme 6. Sparteine mediated asymmetric lithiation and trapping of N-Boc pyrrolidines 
Since this work, there have been various applications of Beak’s procedure to the asymmetric 
synthesis of pyrrolidines. Trapping of the lithiated intermediate with electrophiles has been 
extended to the boron trifluoride assisted ring opening of ethylene epoxide to create β-
homoproline derivatives.33 Transmetalation can also be performed on the lithiated 
intermediate to give potential cross coupling partners. Beak demonstrated this in the 
synthesis of a tributylstannane pyrrolidine with the potential for use in Stille reactions.32 
Another development of the procedure was demonstrated by Campos in a transmetalation 
to give a chiral zincate 26 that then underwent a Negishi coupling with a variety of substituted 
aryl bromides (Scheme 7).34 This led to the formation of α-arylated pyrrolidines 27 with high 




Scheme 7. Pd-catalysed arylation of N-Boc pyrrolidine 
While these demonstrate the utility of sparteine, lack of availability of the ligand has led to 
limitations in its application. In order to overcome this shortage, the synthesis of sparteine 
like chiral diamines has been investigated by several research groups.35 One compound that 
has matched the synthetic capabilities of sparteine is the sparteine surrogate 30 developed 
by the O’Brien group (Scheme 8).36 The surrogate is accessible in two steps from the natural 
product (-)-cytisine 28 extracted laburnum anagyroides seeds. When tested in the 
deprotonation of N-Boc pyrrolidine with sec-BuLi and trapping with TMSCl, the (+)-sparteine 
surrogate gave the same enantioselectivity and yields as (-)-sparteine but with the opposite 
absolute stereochemistry. 
 
Scheme 8. Synthesis of sparteine surrogate 
The use of these reagents has enabled easy access to both enantiomers of 2-substituted 
pyrrolidines and the lithiated intermediates have wide synthetic applications. However, this 
process is not effective in synthesising 3-substituted pyrrolidines, as the stabilisation of the 
Boc protecting group is necessary for retaining the enantioselectivity. Similarly, the necessity 
of the Boc group can also limit the synthetic procedures used. The stoichiometric quantities 
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of the ligand can reduce the atom efficiency of the reaction, but unlike using chiral auxiliaries, 
the ligand does not need to be removed in a separate step and allows for direct introduction 
of the desired stereocentre. The use of organometallic reagents also warrants the use of 
cryogenic temperatures which can hinder some applications and limits large scale industrial 
use. 
1.5. Asymmetric transition metal catalysis 
A way to combat some of the shortcomings of using stoichiometric reagents, such as chiral 
auxiliaries and amide bases, is through the use of asymmetric catalysis. With design and 
optimisation of catalytic systems, low catalyst loading can be achieved which leads to greater 
atom efficiency of the reaction. It also enables the modification of the selectivity of a reaction 
to gain access to multiple stereoisomers by variation of the catalyst.37  
One branch of asymmetric catalysis is that of transition metal catalysed reactions where the 
chirality is introduced by a chiral ligand around a metal centre.  When synthesising 
pyrrolidines, the ring system can either be introduced at the start of a synthesis (such as when 
using chiral lithium amide bases) or formed in a cyclisation step. Many asymmetric transition 
metal catalysed reactions introduce chirality during this cyclisation of pyrrolidines, and this 
will be the focus of this section. However, it is worth mentioning an important method that 
introduces the chiral centre before the cyclisation.  
A widely used enantioselective reaction is the Sharpless epoxidation, which uses catalytic 
quantities of a titanium (IV) isopropoxide and a diethyl tartrate ligand with stoichiometric t-
BuOOH to form an enantioenriched epoxide from allylic alcohols.38 This technique was 
exploited by Riera to synthesise allylic amines 34 as a single enantiomer (Scheme 9).39 The 
asymmetric epoxidation of cinnamyl alcohol 31 gave epoxide 32 in high yields and 
enantiomeric excess. Ring opening of the epoxide with allyl amine and Boc protection gave 
diol 33 in 92% yield, and subsequent deoxygenation gave the bis-allylamine 34 in 72% yield. 
Using another catalytic process of a ring closing metathesis, the bis-allylamine 34 was 
subjected to Grubbs first generation catalyst to form pyrrolidine 35 in near quantitative yields. 
Further manipulations gave access to the proline derivative (2S,3R,4S)-3,4-dihydroxyproline 




Scheme 9. Synthesis of (2S,3R,4S)-3,4-dihydroxyproline 
One of the disadvantages of this method is that the desired stereochemistry is introduced in 
the first step of the reaction. If the opposite enantiomer was required, then the whole 
synthesis would need to be repeated from the asymmetric epoxidation step. This can make 
enantiomeric derivatives more difficult to access than methods where the stereochemistry is 
introduced at a later stage. 
1.5.1. Intermolecular cyclisation 
Introduction of chirality in the cyclisation step can be achieved both intermolecularly and 
intramolecularly. Intermolecular reactions can introduce a large amount of functionality in a 
single step, while intramolecular reactions can offer greater control over the reaction, as well 
faster rates of reaction. In metal catalysed reactions, the coordination of organic molecules 
to the metal centre can have multiple effects on the reaction mechanism and scope. For both 
inter- and intramolecular reactions, the coordination of two or more functional groups to the 
metal atom can help tether the reactive groups bringing them into closer proximity. This can 
promote a faster rate of reaction and, by using chiral ligands, potentially introduce chirality 
into the molecule. In some cases, the metal can also act as a Lewis acid, lowering the LUMO 
energies of some functional groups, such as carbonyls. A powerful method for synthesising 
ring systems that utilises the coordinating ability of metals is the cycloaddition reaction. Many 
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methods have been developed for racemic cyclisations, but the introduction of asymmetry 
remains challenging. One method that dominates the field of pyrrolidine synthesis is the 
azomethine dipolar addition. 
The dipolar cycloaddition of azomethine ylides onto a dipolarophile can lead to the formation 
of a number of nitrogen heterocycles, such as pyrrolines and pyrrolidines, and has been 
known since the 1960s.40 Two of the earliest catalytic asymmetric examples of this reaction 
were reported in 2002 by Jørgensen and Zhang in separate reports but with both using chiral 
ligands and a transition metal catalyst.41,42 Jørgensen’s method utilised a chiral BOX ligand 
with zinc triflate as the catalyst for the asymmetric cycloaddition of aryl iminoesters 37 with 
methyl acrylate 38 (Scheme 10).41 Screening of the reaction conditions showed that zinc 
triflate was imperative in achieving high enantioselectivity, as when copper triflate was used 
a racemic product was acquired. It was also shown that using that switching to the ethyl 
acrylate as the dipolarophile caused a noticeable drop in yields and enantiomeric excess, 
while tert-butyl acrylate led to very poor yields and enantioselectivity. 
 
Scheme 10. Jørgensen azomethine cycloaddition 
Zhang shortly after demonstrated the use of silver acetate with a chiral bidentate phosphine 
ligand in the cycloaddition of aryl iminoesters 40 with dimethyl maleate 41 (Scheme 11). 42 
The reaction favoured the endo product to give highly substituted pyrrolidines 42 in high 
yields and enantiomeric excess. The reaction was also extended to alkyl iminoesters, but 





Scheme 11. Zhang azomethine cycloaddition 
In both of these cycloaddition reactions, the ylide is formed from an iminoester in situ. In 
order to stabilise the ylide and promote the reaction, an electron withdrawing group (such as 
a methyl ester) is required on the imine. Not only does this allow for easier abstraction of the 
α-proton by the nitrogen, the carbonyl can stabilise the ylide through coordination to the 
metal catalyst.  Since these initial reports there have been a number of developments into 
the asymmetric azomethine cycloaddition, and a selection of recent reports are shown below. 
A strategy reported by Singh employs (1,3)-dipolar cycloadditions of iminoesters 44 with  an 
unusual α,β-unsaturated pyrazole amide dipolarophile 43 to produce highly substituted 
pyrrolidines 45 with good enantioselectivity (Scheme 12).43  After screening multiple ligands, 
metal salts, and conditions the group found that the chiral ligand (R)-DM-SEGPHOS 46 with 
silver triflate gave the best combination of yield, diastereoselectivity and enantioselectivity. 
The scope of the reaction was also tested with various aryl and ester substituents giving good 
to excellent, selectivity. However, when alkyl or alkenyl substituents were introduced at the 
5-position or groups other than pyrazole were used on the Michael acceptor, the reaction 




Scheme 12. Enantioselective (1,3)-dipolar cycloadditions of azomethine ylides 
A related reaction by Zhang shows a similar cycloaddition reaction of iminoesters 48 with aryl 
enones 47 as electrophiles (Scheme 13).44 However, the researchers were able to develop an 
interesting switching of regioselectivity through variation of the catalyst and conditions. The 
switching ability was aided by the electron withdrawing CF3 group, which can pull charge from 
the double bond of the dipolarophile. This leads to both carbons of the double bond being 
susceptible to nucleophilic attack instead of just the β-carbon. Utilising ligand L1 the 
cycloaddition led to the CF3 group located in the 3-position of the pyrrolidine 49, while ligand 
L2 led to the CF3 in the 4-position 50. The selectivity was explored through DFT calculations 
and experimental data to investigate the different coordination modes between the ligands 
and enones to the copper atom. In the case of L1, both the phosphine and nitrogen atom of 
the oxazoline coordinate to the nitrogen as a bidentate ligand. This prevents coordination of 
the enone carbonyl to the metal leading to the formation of pyrrolidine 49. For ligand L2, the 
phosphine still coordinates to the copper, but the NMe2 does not, which allows for the enone 
carbonyl to interact with the copper atom and drive the selectivity, giving pyrrolidine 50 as 
the major product. Application of the methodology to a range of substitution on both the 
enone and the iminoester produced a wide variety of pyrrolidine products with four distinct 





Scheme 13. Asymmetric cycloaddition of iminoesters and enones 
1.5.2. Intramolecular cyclisation 
While the intermolecular azomethine cycloaddition reaction can be very effective in the 
asymmetric synthesis of pyrrolidines, the use of intramolecular reactions can offer greater 
control over reactivity and selectivity. Indeed, the application of the azomethine 
cycloaddition to an intramolecular reaction has also been widely investigated, with an in-
depth review by Coldham and Hufton on this area of research.45 However, while this reaction 
is powerful in constructing a pyrrolidine, there are other methods available to the synthetic 
chemist.  
A recent example of an intramolecular cyclisation used to synthesise pyrrolidines is the 
asymmetric alkyne cycloaddition reaction. In a report by Tang the Nickel-catalysed reductive 
cyclization of N-alkynones 51 was able to produce pyrrolidines containing a tertiary alcohol 
52 in high enantiomeric ratio  (Scheme 14).46 The use of a chiral bidentate ligand L3 to form a 
dimeric nickel complex enabled the coordination of two molecules of the N-alkynone 51 to 
the catalyst. When compared to the monodentate version of ligand, the bidentate ligand L3 
showed enhance reactivity and enantioselectivity. The researchers suggested that the 
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formation of the dimer was crucial to this enantioselectivity, due to the increased steric 
hindrance during the cycloaddition step.  
 
Scheme 14. Nickel-catalysed enantioselective reductive cyclization of N-alkynones 
One other powerful method for constructing ring systems, and one that has garnered much 
attention in recent years, is a radical cyclisation. Research performed by Zhang demonstrated 
a newly emerging metalloradical approach to synthesising 5 membered ring systems.47 The 
approach differs from a traditional radical cyclisation which proceeds through radical addition 
followed by H-atom abstraction to give the desired compound. Instead, metalloradical 
reactions proceed through a different process where a metalloradical firsts abstracts a H-
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atom and then undergoes radical substitution to produce the desired compound (Scheme 15). 
The use of a chiral porphyrin based cobalt complex and suitably bulky R groups on the diazo 
precursor 53 (aryl, heteroaromatic and cyclohexyl were reported) allows for the production 
of 2-substituted pyrrolidines 54 with most examples obtaining enantiomeric excesses of 
>85%. Replacing the N-Boc with oxygen, sulphur or carbon enabled synthesis of related 5-
membered cycles and demonstrated good yields and enantioselectivity under the reaction 
conditions. One exception was the formation of a benzyl substituted pyrrolidine which had 
significantly lower enantioselectivity than other substituents. It is also noted that, besides 
cyclohexyl, no aliphatic substituents were reported. 
 
Scheme 15. Metalloradical cyclisation for the synthesis of 2-substituted pyrrolidines 
Transition metal catalysed reactions have a clear value in the asymmetric synthesis of 
pyrrolidines, allowing for fine tuning of a reaction as well as effecting a large variety of 




1.6. Asymmetric organocatalysis 
Metal free acid catalysis has become an area of interest over the past years and offers a few 
advantages over metal catalysed reaction.48 Some of the problems that come with the use of 
transition metals, such as high price, toxicity, pollution, etc. can be overcome by using 
organocatalysts.49 These catalysts can also demonstrate less sensitivity to moisture and air 
often exhibited in transition metal catalysis. The area of asymmetric organocatalysis has been 
researched as far back as the 1970s,16 but has been investigated to a much greater degree in 
recent years as an attractive and green method of synthesis.50,51 Pyrrolidines, such as proline, 
have been used effectively as organocatalysts themselves, but methodologies have been 
developed to synthesise pyrrolidines as scaffolds for natural products and drug candidates.52 
1.6.1. Intermolecular cyclisation 
As in the case of transition metal catalysed reactions, organocatalysed reactions can occur 
both inter- and intramolecularly. While the transition metal catalysed cycloadditions of 
azomethine ylides have already been explored in the previous section, organocatalysts have 
also been shown to be efficient in this type of reaction. Research by Vicario demonstrated the 
first use of a proline derived catalyst 57 in the cycloaddition of azomethine ylides to enals 56 
through an iminium intermediate (Scheme 16).53 The presence of the diethyl esters on the 
iminoester 55 aids in the formation and stabilisation of the azomethine ylide in situ. Iminium 
formation with prolinol catalyst 57 and enal 56 both lowers the LUMO energy of the 
dipolarophile and promotes selectivity through attack of the less hindered Re face. The 
methodology was applied to a range of aryl iminoesters and both alkyl and aryl enals, with 
most examples achieving high yields and enantioselectivity with the endo product favoured 




Scheme 16. Asymmetric organocatalysed cycloaddition of azomethine ylides to enals 
A later report by Vicario showed that greater diastereoselectivity could be achieved by 
replacing one of the ethyl esters with a nitrile (Scheme 17).54 In the 1,3-dipolar addition of 
azomethine ylides, the geometry of the starting ylide is exclusively what determines the 
relative stereochemistry of any 2,5-susbitution on the pyrrolidine product. However, there is 
also a necessity for (mulitiple) electron withdrawing groups on the iminoester for the α-
hydrogen to be acidic enough to form the ylide in situ. By having two esters on the iminoester 
59, the acidity of the α-hydrogen is increased but there is also competitive hydrogen bonding 
between the two carbonyl groups. Replacing one ester with a nitrile (60) removes the 
competitive hydrogen bonding as the nitrile does not take part in H-bonding but maintains 
the acidity of the α-hydrogen. This effectively locks the geometry of the ylide as depicted in 
Scheme 17 through the H-bonding with the single ester unit. As stated, the ylide geometry is 
essential for control over the 2,5-relative stereochemistry and the use of the nitrile as an 
electron withdrawing group lead to greater control of the diastereoselectivity of the dipolar 
addition. 
 
Scheme 17. Electron withdrawing group effect on azomethine geometry 
32 
 
Organocatalysed intermolecular reactions are not just limited to azomethine cycloadditions. 
An alternative strategy involving a Mannich cyclisation reaction was investigated by Kumar et 
al to synthesise 2,3-disubstituted pyrrolidines 63 (Scheme 18).55 The authors report the 
reaction as a formal [3+2] cycloaddition reaction catalysed by ʟ-proline with succinaldehyde 
62 as a novel 1,3-carbon dipole. The proposed mechanism is shown in Scheme 18 where ʟ-
proline formed an enamine with the succinaldehyde, followed by a Mannich reaction with the 
aryl imine 61. Cyclisation onto the second aldehyde formed the pyrrolidine, and removal of 
the proline with water gave the hemiaminal product. In situ reduction of the hemiaminal with 
sodium borohydride gave the 2,3-disubstituted pyrrolidine 63 in high yields and very high 
enantioselectivity for most aryl imines tested. The methodology was successful in the reaction 
of imines derived from electron poor aryl aldehydes, but imines derived from electron rich 
aryl aldehydes (such as p-anisaldehyde) or alkyl aldehydes failed to produce any desired 
product. 
 
Scheme 18. Proline catalysed Mannich reaction 
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Recently a strategy for the asymmetric construction of pyrrolidines from an isothiocyanates 
64 with barbiturates 65 was developed by Albrecht (Scheme 19).56 When treated with a chiral 
organocatalyst 66 featuring a squaramide core and cinchona alkaloid moiety, heterocyclic ring 
systems could be synthesised with high enantioselectivity. This strategy sets up two 
quaternary centres (one of which is chiral) and a separate stereogenic centre in a highly 
functionalised spirocyclic pyrrolidine scaffold 67. Certain substituents on the barbiturate 65 
led to reduced stereoselectivity or afforded lower yields with notable examples; 4-NO2C6H4 
giving a yield of 52% and er of 82.5:17.5 and i-Pr giving a yield of 40%.  
 
Scheme 19. Isothiocyanate strategy for the synthesis of spirocyclic pyrrolidines. 
1.6.2. Intramolecular cyclisation 
An organocatalysed intramolecular cyclisation offers some benefits to intermolecular 
cyclisations, in the same way they do when catalysed by transition metals. Greater selectivity 
(endo vs exo selectivity can be easier to control) and potential increased reaction rate are 
some of the advantages that an intramolecular reaction can have. Coupled with the “greener” 
credentials of organocatalyst, this are of research has been of interest in recent years for 
constructing heterocyclic rings. As with intermolecular reactions, there a number of methods 




A well-studied reaction in organic chemistry that can be used for the construction of ring 
systems is the ene reaction. Intermolecular ene reactions are challenging, whereas 
intramolecular ene reactions have entropic, regio- and stereoselective advantages.57 A highly 
enantioselective carbonyl-ene reaction was developed by List for the synthesis of spirocyclic 
pyrrolidines 70 (Scheme 20).58 Asymmetric carbonyl-ene reactions had previously been 
reported with transition metal catalysts, but this research demonstrated the first 
organocatalysed carbonyl-ene reaction. One of the findings the research group reported was 
the necessity for the dimeric BINOL based catalyst 69 in order to achieve high 
enantioselectivity. When a monomeric BINOL based phosphoric or sulfuric acid catalyst was 
used, high conversions and regioselectivity were achieved but with poor enantioselectivity. 
DFT calculations suggested that the imido-diphosphate was necessary as both phosphate 
groups take part in the transition state of the reaction. 
 
Scheme 20. Asymmetric carbonyl-ene cyclisation 
Another useful method for synthesising ring systems is through halocyclization. Catalytic 
enantioselective variations of this reaction have been applied to O-heterocycle synthesis since 
2003, but extension to N-heterocycles was first reported by Yeung in 2011.59 The application 
of a quinuclidine thiocarbamate catalyst 72 to N-sulfonyl alkenes 71 in the presence of an 
excess of NBS led to the formation of bromo-pyrrolidines 73 in high yields and very high 
enantioselectivity (Scheme 21). The structure of the catalyst was key to effecting the 
cyclisation reaction. In the proposed mechanism the sulfonamide of the starting material 
coordinated to the nitrogen of the quinuclidine, while the NBS coordinated to the 
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thiocarbamate. This led to a controlled geometry of the transition state and selective site for 
the bromination to occur.  
 
Scheme 21. Asymmetric cyclobromination of sulfonyl amines. 
While these reactions offer a flavour of asymmetric pyrrolidine synthesis, one method that 
has been widely investigated and was of interest to our research group is that of the 
intramolecular aza-Michael reaction  
1.7. Asymmetric intramolecular aza-Michael reactions 
The addition of nitrogen containing nucleophiles to Michael acceptors has been widely 
explored and has enabled the synthesis of pyrrolidines and piperidines in high 
stereoselectivity.60,61 The intermolecular aza-Michael reaction has been used to construct 
chiral amines that can then be used to form pyrrolidines, but a more direct approach is 
through the intramolecular aza-Michael, as this can introduce chirality in the same step as 
heterocycle formation. This stereocontrol can come from the substrate itself (i.e. from a chiral 
auxiliary) or from a chiral catalyst and both methods will be examined. 
The Michael reaction is an example of a conjugate addition, and an early report by Spalluto 
shows a tandem intermolecular Michael/intramolecular conjugate addition reaction for the 
synthesis of pyrrolidines.62 While this could be argued as not a true intramolecular aza-
Michael, it does demonstrate the simplicity with which ring systems can be constructed using 
these methodologies. Using Michael donor/acceptors 74 and nitroethylene 75 as a Michael 
acceptor led to the formation of an nitronate intermediate 76 followed by cyclisation to 
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produce the substituted pyrrolidines 77 (Scheme 22). The trans relationship of the nitro- and 
carbonyl-substituents was confirmed by the reduction of the nitro group to the free amine 
and subsequent attempts at lactamisation. These attempts were not met with success, 
resulting in the assignment of the trans stereochemistry, as the cis isomer would be expected 
to cyclise. Although this route is not enantioselective, it is diastereoselective with no reports 
of the cis isomer being isolated.  
 
Scheme 22. Intermolecular conjugate addition for the synthesis of pyrrolidines 
Although diastereoselective reactions are useful in organic synthesis, greater stereocontrol in 
a reaction can be desirable. One such method was developed by Fustero where 
stereoselectivity could be switched depending on the conditions used.63 Cbz protected 
amines 79 were synthesised as a single enantiomer through the use of a chiral tert-
butanesulfinamide auxiliary. A cross metathesis reaction with methyl vinyl ketone 78 was 
performed in the presence of BF3.OEt2 as a tandem metathesis/cyclisation reaction to give 
the pyrrolidine 80 (Scheme 23). One of the most interesting aspects to this reaction is the 
effect of time and heating on the stereochemistry of the pyrrolidine. When the reaction was 
heated to a lower temperature of 45 °C over 4 days, the 2,5-trans product was isolated, in 
good to high yields for the R groups tested. However, when the reaction was heated by a 
microwave to 100 C for 20 mins, high yields were still achieved, but the selectivity was 
switched in favour of the 2,5-cis isomer. While the authors do not comment on the selectivity, 
it could be conceived that the trans isomer is the kinetic product, while the cis-isomer is the 
thermodynamic product and was only accessible at the very high temperatures of 100 °C. 
Reactions were also performed on achiral Cbz amines which led to racemic pyrrolidine 




Scheme 23. Tandem metathesis and cyclisation reaction of substituted Cbz amines 
Building in the desired stereochemistry through the use of a chiral auxiliary is a successful 
method for producing asymmetric pyrrolidines. However, if the opposite enantiomer is 
required, this could potentially mean a protracted synthetic route that needs to be tailored 
to each specific product. Therefore, introducing the stereochemistry at a later stage can be 
advantageous and is most easily achieved with a chiral catalyst in the cyclisation step.  
One catalytic method by Azuma et. al. utilized a dual system of an aryl boronic acid 82a and 
a chiral aminothiourea catalyst 82b for the intramolecular hetero-Michael reaction with α,β-
unsaturated carboxylic acids 81 (Scheme 24).64 The reaction was successful in the racemic 
synthesis of pyrrolidines when only the boronic acid was used, although only with 
sulfonamide protected amines, with no reaction observed for the Cbz protected amine. The 
oxy-Michael reaction worked well to give a variety of dihydrobenzofuran scaffolds which were 
obtained with high enantioselectivity when the chiral aminothiourea catalyst 82b was 
introduced to the reaction. However, when testing the chiral catalyst, N-tosyl pyrrolidine 83 
formation gave only moderate ee’s (50%) and poor yields (25%). No other asymmetric aza-
Michael reaction was reported, which shows the significant limitations of this methodology 




Scheme 24. Dual aryl boronic acid and aminothiourea catalytic system for heterocycle synthesis. 
The poor results from this aza-Michael reaction may be due to both the difference in 
nucleophilicity of the sulfonamide vs. the hydroxyl group, as well as the electrophilicity of the 
Michael acceptor. Fustero had already demonstrated the capability of methyl vinyl ketone as 
a Michael acceptor in a non-asymmetric aza-Michael reaction.63 In a report by Yu, the 
enhanced reactivity of the enone was explored in the chiral Bronsted acid catalysed 
cyclisation of enone carbamates.65 A range of aryl and alkyl enones 84 were synthesised and 
subjected to the (R)-TiPSY catalyst in toluene at -20 °C (Scheme 25). The cyclised pyrrolidines 
85 were isolated in high yields and with good enantioselectivity, although some reactions 
required up to 40 hours to reach completion. 
 
Scheme 25. Enantioselective cyclisation of enone carbamates 
A related paper by Yang demonstrated another asymmetric aza-Michael reaction onto 
enones, but utilising a different catalytic system.66 The cinchona alkaloid 9-amino-9-deoxy-
epi-quinine 87 was used alongside diphenyl hydrogen phosphate (DPP) as a co-catalyst to 
effect the aza-Michael cyclisation (Scheme 26). In this study only the methyl enone was used 
as the Michael acceptor, but the cyclisation was extended to synthesise both pyrrolidines and 
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piperidines, as well as the related heterocycles; oxazolidine, thiazolidine, morpholine, and 
thiomorpholine, all with good enantioselectivity 88. The advantage of the cocatalyst system 
over that of (R)-TiPSY, is that these reactions were run at room temperature, so cryogenic 
temperatures did not need to be maintained for extended reaction times.  
 
Scheme 26. Cyclisation of enone carbamates with co-catalyst system 
While these systems demonstrate the application of enones in asymmetric aza-Michael 
reactions, there are some limitations to the procedures. The cyclisations reported both 
require extended reaction times and did not demonstrate any substitution around the ring. 
The use of enones also limits the synthetic applications after cyclisation. Any functionality 
needed in a side chain would necessitate incorporation at the beginning of a synthesis within 
the enone. Other carbonyl derivatives such as esters and aldehydes offer handles that can be 
more easily functionalised at a later stage. The use of other Michael acceptors has been 
explored by other research groups to enable this. 
An alternative procedure to synthesise pyrrolidines (and piperidines) through a Michael 
reaction was reported by Carter using α,β-unsaturated aldehydes 89 (Scheme 27).67 In the 
proposed mechanism the proline catalyst 90 forms a chiral α,β-unsaturated iminium species 
to activate the Michael acceptor and utilises sterically demanding groups to force attack from 
one side of the molecule. The method was applied to the synthesis of gem-dimethyl 
pyrrolidines and piperidines 91 with most substrates showing good yields and ee’s. The 
exceptions to this was of the 6,6’-dimethylpiperidine which gave poor conversion and the 
2,2’-dimethylpyrrolidine which showed a reduced ee of 79%. Also, in order to prevent 
racemisation or decomposition of the cyclised product, the aldehyde group was reduced to 
the alcohol with sodium borohydride after cyclisation. While this loses the carbonyl 




Scheme 27. Asymmetric intramolecular hetero-Michael reaction 
While aldehydes have great synthetic utility and ability to undergo a large variety of 
transformations, the sensitivity of aldehydes towards decomposition and potential for 
scrambling of stereocentres can limit their application. Reduction to an alcohol, as 
demonstrated by Carter, followed by an oxidation back to the aldehyde can help with long 
term stability and storage of a compound but this is not an efficient method for synthesis.  
However, there have been methods developed that allow for retaining carbonyl functionality 
without the need for an extra step in the synthesis.  
In a report by Nagorny, the sensitivity of aldehydes was overcome through the use of a novel 
Michael acceptor, which enabled the asymmetric synthesis of spirocyclic piperidines.68 The 
reaction utilised an unsaturated dimethyl acetal 92, which in situ formed an αβ-unsaturated 
oxocarbenium ion with the chiral catalyst via loss of methanol. This makes the unsaturated 
acetal analogous to a protected enal, showing good reactivity towards Michael addition for 
the formation of the piperidine ring. The use of the acetal group presumably helps to reduce 
any racemic background reaction that may occur when using the aldehyde equivalent as well 
as preventing aerobic auto-oxidation which might also be anticipated of unsaturated 
aldehydes. The enol ether produced in the reaction can be seen as a masked or protected 
aldehyde to prevent against such decomposition. The methodology was applied to the 
synthesis of several substituted piperidines 93, specifically gem-dimethyl, fused phenyl, and 




Scheme 28. Asymmetric synthesis of spirocyclic piperidines and selected examples of synthesised products 
A common trend among the reactions was that extending the reaction time would lead to an 
increase in selectivity, at the expense of yield. The authors postulated that the presence of 
small amounts of MeOH that were not adsorbed by the molecular sieves were reacting with 
the product 93 to form a new saturated acetal product. It is also worth noting that these 
reactions were performed at -20 °C in CCl4 which poses both health and procedural concern, 
due to the toxicity69 of CCl4 and the feasibility of running reactions at cryogenic temperatures 
for long periods of time. The use of CCl4 would also make this reaction less desirable for use 
in industrial settings due to the associated health hazards. 
One of the stipulations for improving the enantiomeric excess of the reaction reported by 
Nagorny, was the reduction of temperatures to allow for greater selectivity, as when 
performed at room temperature a significant decrease in the enantioselectivity was observed 
from 71% to 57% ee. This is common in asymmetric reactions, as generally low temperatures 
lead to an increase in enantioselectivity. However, lower temperatures will also decrease the 
rate of reaction, so conditions for increasing the rate, while maintaining the selectivity are 
essential when creating new methodologies. The use of more reactive Michael acceptors, 
such as enals and enones, can increase reaction rate but can also lead to an increase in 
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background racemic reactions. If less reactive unsaturated Michael acceptors are needed, 
then alternatives must be considered. Nagorny’s use of unsaturated acetals is one option, 
although they are not as easy to access as aldehydes and there are limitations to the reaction 
as previously stated.  
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2. Asymmetric synthesis of spirocyclic pyrrolidines 
The stereoselective synthesis of heterocycles has been an integral research area within the 
Clarke group, and has supported efforts towards the total synthesis of natural products.70–74 
Due to the prevalence of heterocyclic rings, especially chiral ring systems, in natural products, 
there has been substantial interest in the group to devise new strategies to facilitate the 
construction of these heterocycles.  
Expanding on methodologies for the synthesis of tetrahydropyran-4-ones,75 the one-pot 
synthesis of functionalised piperidin-4-ones 100 was achieved through ring opening of 
diketene in the presence of tosyl-aldimines 98 to give a β-amino-ketone intermediate 99. This 
intermediate was then intercepted with an aldehyde to give the piperidin-4-one 100 (Scheme 
29).76 
 
Scheme 29. Multicomponent Maitland-Japp reaction for the synthesis of highly substituted piperidin-4-ones 
This was then later developed into a synthesis of spirocyclic piperidines by substituting the 
aldehyde for a cyclic ketone to introduce the spirocyclic functionality (Scheme 30).77 The use 
of ketones with N-tosyl aldimines inhibited cyclisation of the piperidine under the conditions 
shown in Scheme 29. However, it was found that the reaction of N-Boc imines 101 generated 
in situ with the Weiler dianion allowed for the formation of the Boc protected β-amino-ketone 
intermediate 102. The use of Boc instead of tosyl as the nitrogen protecting group allowed 
for reactivity with ketones and facile synthesis of the functionalised piperidines 103 (Scheme 




Scheme 30. Modification of aza-Maitland-Japp reaction for the synthesis of spirocyclic piperidines 
Not only does the methodology allow for the formation of highly functionalised piperidines, 
but the introduction of a spirocyclic motif increases the amount of three-dimensionality, or 
sp3 character, of the molecules. This has been of interest in the field of fragment-based drug 
discovery as it populates an under explored area of chemical space with accessible molecules. 
By introducing more three-dimensionality into a molecule, drug discovery can identify 
potential compounds that move away from the more common sp and sp2 rich systems seen 
in the majority of “lead-like” molecules.77  
While this approach allows for novel, highly functionalised fragments to be synthesised with 
good diastereoselectivity, there are limitations when it comes to synthesising other 
stereoisomers or single enantiomers. One area of research that has been investigated by the 
Clarke group is the use of α,β-unsaturated thioesters in intramolecular Michael reactions. The 
first use of thioesters within the group was employed for the stereodivergent synthesis of 2,6-
functionalised tetrahydropyrans as a route towards the C20-C32 core of the phorboxazoles.71 
In the cyclisation of precursor 104 with buffered TBAF conditions, both the oxo- and thioester 
led to the formation of the 2,6-trans-tetrahydropyran 106. When acidic conditions (CSA or 
TFA) were used in an attempt to form the 2,6-cis-tetrahydropyran 105, the oxoester showed 
either decomposition or no cyclisation, while the thioester led to the production of the cis 




Scheme 31. Stereodivergent synthesis of the C20-C32 tetrahydropyran core of phorboxazoles and the C22 epimer 
The utility of the thioester moiety and mechanism of reaction was then further explored 
through experimental and computational studies.74 It was found that the 4-hydroxyl group 
was essential for the stereodivergence seen in this reaction as, under the buffered TBAF 
conditions, the hydroxyl could participate in hydrogen bonding with the cyclising alkoxide and 
enable a boat-like transition state 107, yielding the 2,6-trans-tetrahydropyran (Figure 3).  
 
Figure 3. Computational transition states for TBAF mediated cyclisation 
Investigation of the acid mediated cyclisation, where decomposition of the oxo-ester was 
observed, showed that the lowest energy transition state was a chair 113, where the 4-
hydroxyl group did not take part in the cyclisation (Figure 4). The role of the trifluoroacetic 
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acid was that of a proton shuttle. Protonation of the thioester group increased the 
electrophilicity of the Michael acceptor, whilst simultaneous deprotonation of the alcohol 
raised its nucleophilicity. Interestingly, the transition state energy for the oxoester was 7.6 
kcal mol-1 higher than that of the thioester, making the oxoester rate of cyclisation much 
slower. This would then allow for competing decomposition pathways to occur, hence the 
selection of the thioester over the oxoester in the acidic mediated cyclisation.  
 
Figure 4. Computational transition states for TFA mediated cyclisation 
With this knowledge of the thioester reactivity, the group then examined the possibility of 
using chiral phosphoric acids (CPAs) as a means of inducing enantioselectivity during the 
Michael reaction.78 It was hypothesised that the CPA could replace the trifluoroacetic acid 
used to catalyse the Michael addition, through a similar proton shuttle mechanism. The 
cyclisation of 2,2-dimethyl and unsubstituted alcohols, 117 using (R)-TRIP as the chiral 




Scheme 32. Asymmetric Michael reaction for the synthesis of THFs and THPs 
When cyclised using (R)-TRIP in cyclohexane, it was found that both the alcohol substitution 
and substitution of the thioester played important roles in both the conversion and the 
selectivity (Scheme 32). For the 2,2-dimethyl THF with p-tolyl as the thioester substituent 
(119), full consumption of starting material was observed at both 50 °C and 75 °C with ees of 
the THF products being 45% and 46% respectively. However, when a mesityl thioester was 
used (120), the ee dropped to 31% for 50 °C and 21% for 75 °C. It was also observed, that 
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when unsubstituted alcohols were cyclised, both conversions and ees decreased (121 and 
122). In the case of the 2,2-dimethyl THP synthesis, the cyclisation of the p-tolyl thioester 
(123) at 50 °C led to a lower conversion of 60% and an ee of only 13%. For the same reaction 
with the mesityl thioester (124), the conversion reached 96% with an ee of 69%, the highest 
selectivity achieved in this methodology. When the unsubstituted mesityl THP was 
synthesised (125), the conversion remained high at 98% but ee dropped to 44%. 
From this work, we can see that substitution around the alcohol tends to increase the 
selectivity of the reaction for both THFs and THPs.  Modulating the thioester functionality can 
also allow for tuning of the reaction depending on the intended ring size. With this knowledge 
and previous reports on asymmetric aza-Michael reactions, we believed that thioesters could 
offer a middle ground of reactivity between aldehydes and oxoesters. Consequently, we 
hypothesised that the use of a CPA in the formation of nitrogen heterocycles through aza-
Michael addition onto a thioester may be used effectively in the asymmetric synthesis of 
pyrrolidines.  
2.1. Comparison of the Michael acceptor reactivity   
In order to test the asymmetric aza-Michael reaction and confirm its viability for the 
asymmetric synthesis of functionalised pyrrolidines, a series of questions needed to be 
answered: 
1. Do thioesters offer advantages over aldehydes/ketones or esters in the intramolecular 
aza-Michael reaction to form pyrrolidines? 
2. What substrate scope can be used to test the limits of the method and what 
functionality can be introduced into the products? 
3. Does varying the reaction conditions, such as catalyst, solvent and temperature, affect 
the yield and selectivity? 
The first step to answering these questions was to synthesise precursors that would allow for 
testing the thioester moiety against other Michael acceptors. To do this, the 3,3-dimethyl 
precursors 126 were selected as we anticipated that they would be easily accessible and 
should offer enhanced rate of cyclisation due to the Thorpe-Ingold effect (Scheme 33).79,80 
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The synthesis of the p-tolyl thioester was a well-practiced procedure within the group so was 
selected for the initial tests and, to allow for a more direct comparison of reactivity, the p-
tolyl ketone and p-tolyl oxoester were also selected for screening. 
 
Scheme 33. Proposed precursors for the testing of Michael acceptors 
The synthesis of the 3,3-dimethyl substituted compounds was adapted from a literature 
procedure,81 where isobutyronitrile 128 was deprotonated with LDA and alkylated with allyl 
bromide to form the quaternary nitrile 129 in 48% yield. The nitrile was then reduced using 
lithium aluminium hydride to give the free amine, which was followed by protection with 
benzyl chloroformate, to afford the Cbz protected amine 130 in 58% yield (Scheme 34).  
 
Scheme 34. Synthesis of 3,3-dimethyl-substituted precursor 
The next precursor compounds required were the acrylates which would act as 
intramolecular Michael acceptors when coupled to the Cbz amine. To this end, enone 132 and 
thioacrylate 134 were synthesised using literature procedures in 22% and 68% yield 
respectively.82,83 While other methods exist for synthesising the acrylate 136, the same 
method used for producing thioacrylate 134 was also fruitful in synthesising acrylate 136 in 




Scheme 35. Synthesis of acrylates 
With the Cbz amines and acrylates in hand, the next step was to form the Michael acceptors 
needed for cyclisation through cross metathesis. Cross metathesis with the relevant 
thioacrylate has been performed by the group before, however acrylates pose several 
problems when used for metathesis reactions. A report by Grubbs shows that olefins can be 
categorized in a general model according to the levels of homodimerization observed and the 
reactivity of the homodimers when exposed to different metathesis catalysts.84 Acrylates are 
categorised as a Type II olefin, which means they homodimerize slowly when subjected to the 
second-generation Grubbs catalyst. While homodimerization of the Cbz amine occurs rapidly, 
the homodimer itself is still a candidate for metathesis, as this can then undergo a further 
reaction with the slower reacting acrylate to form the desired product.  
Previous work in the group found that when performing a metathesis with thioacrylates, 1 
equivalent of the second-generation Hoveyda-Grubbs catalyst was required.85 However, the 
use of 15 mol% copper iodide allowed for effective cross metathesis with 10 mol% of the 
catalyst. This was effect was originally reported by Lipshtuz showing that the inclusion of 
copper iodide or sodium iodide in conjunction with Grubbs catalysts, gave a rate 
enhancement when coupling acrylates with other olefins.86 This  is reported to be due to both 
the ability of copper (I) to scavenge the phosphine ligand, and the stabilisation effect of the 
iodide ion on the catalyst. In the case of the reaction of the Cbz amine 130 it was found that 
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the addition of 1 equivalent of copper iodide led to facile production of the α,β-unsaturated 
thioester product 126b in 75% yield (Scheme 36). This procedure was then also applied to the 
acrylate 136 to yield the α,β-unsaturated ester 126c in 86% yield. 
 
Scheme 36. Cross metathesis procedure for thioacrylates 
When Cbz amine 130 was submitted to the metathesis conditions with enone 132, the only 
compound isolated was the cyclised pyrrolidine (±)-127a, obtained in 88% yield. Though this 
was unexpected, it does support out initial hypothesis that ketones and aldehydes may be 
too reactive, and have a significant racemic background reactivity, and are therefore 
unsuitable as electrophiles in the asymmetric intramolecular aza-Michael reaction.  
 
Scheme 37. Metathesis reaction of p-tolyl enone to form keto-pyrrolidine 
52 
 
A report by Fustero shows a similar metathesis reaction of methyl vinyl ketone and other alkyl 
enones were coupled to Cbz amines. In the presence of a Lewis acid, and with microwave 
heating, they were able to obtain high yields of racemic pyrrolidines 139 (Scheme 38). 
 
Scheme 38. Tandem metathesis IMAMR of enones 
When compared to this report, it is perhaps unsurprising that we obtained a cyclised product 
(±) 127a when using the p-tolyl enone under these metathesis conditions. This result also 
meant that we were not able to submit the enone to asymmetric conditions, as we were 
unable to isolate the uncyclised product, which lends credence to using less reactive Michael 
acceptors in stereoselective reactions.  
As we had ruled out the use of enones as intramolecular aza-Michael acceptors, the next 
comparison we wished to draw was between the α,β-unsaturated ester 126c and α,β-
unsaturated thioester 126b. To do this, conditions were selected based on the previous work 
in the group on the asymmetric synthesis of tetrahydrofurans.78 The combination of 
cyclohexane and (R)-TRIP had shown to be fruitful in achieving higher yields and 
enantioselectivity for the cyclisation of the 5-membered rings. There was also an indication 
that higher temperatures were not detrimental to the enantioselectivity of the reaction but 
did offer increased yields. For example, in the case of the 2,2-dimethyl THF synthesis, an ee 
of 45% was achieved at 50 °C and 46% at 75 °C. To that effect, initial screening of the 
asymmetric reaction was performed at 80 °C as this would be near reflux for cyclohexane and 
the upper limit for the reaction temperature in this solvent. This would hopefully allow for 
enantioselective reactions of the α,β-unsaturated thioester 126b to occur as well as enabling 
cyclisation of the, theoretically, less reactive α,β-unsaturated ester 126c. When subjected to 
these conditions the ester did react but with a low yield of 20%, however, a high enantiomeric 
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ratio of 95:5 was achieved (127c). While this yield was lower than we had hoped, it did lend 
credence to the hypothesis that the thioesters may offer enhanced reactivity. Gratifyingly, 
the cyclisation of the thioester led to the formation of pyrrolidine 127b in a high yield of 83% 
and with excellent enantioselectivity of 98:2 er. (Scheme 39). 
 
Scheme 39. Asymmetric cyclisation of αβ-unsaturated thioester and αβ-unsaturated ester 
This result supports our hypothesis that the thioester sits in a middle ground of reactivity 
between the ketones/aldehydes and esters. The higher yields observed when using the 
thioester over esters demonstrate the increased reactivity, while the ability to isolate the α,β-
unsaturated thioester means having control over the enantioselectivity of the reaction, which 
we did not have when using the ketone.  
2.1.1. HPLC determination of enantiomeric ratio 
Several methods can be used to determine the enantiomeric ratios in a chiral mixture, but 
the most appropriate and accessible method for this work was the use of chiral HPLC. The 
ratios reported in Scheme 39 were determined using this technique.  
In order to determine an enantiomeric ratio, a racemic standard is needed to assign the peaks 
of both enantiomers. To do this, a cyclisation was performed using an excess of racemic (±)- 
camphorsulfonic acid (rac-CSA), with pyrrolidine (±)-127b isolated in 90% yield and an 




Scheme 40. Racemic cyclisation of αβ-unsaturated thioester 
With the racemate in hand, screening of chiral HPLC conditions could be performed. Initial 
screens were performed by testing a series of CHIRALPAK® columns, namely the IA, IB, IC and 
IG immobilised polysaccharide columns.87 In these columns, the polysaccharide stationary 
phase (either amylose or cellulose) has various organic selector molecules bound to the 
sugars, and different interaction between the two enantiomers and the selectors enables 
resolution of the mixture. When developing the method, it was found that varying the chiral 
column had a greater effect on improving the resolution of the mixture, while changing 
solvent ratios (hexane/IPA), flow rate or temperature, gave some control over resolution but 
was more useful in fine-tuning retention times. After screening of conditions, it was found 
that the CHIRALPAK® IB column eluting with hexane/2-propanol (95:5) at a flow rate of 1.0 
mL/min at 25 °C afforded separation of both enantiomers in a short time (Figure 5). The 
integrated area of both peaks shows a 50:50 ratio confirming that the rac-CSA did indeed 











































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.76 4395871.500 49.967 0.289
2 8.55 4401762.000 50.033 0.320  
Figure 5. HPLC chromatogram for cyclisation of pyrrolidine (±)-127b with rac-CSA 
With the method developed, the enantiomer ratio of the asymmetric reaction could be 
determined. Submitting the product of the (R)-TRIP reaction to HPLC analysis gave the 
chromatogram depicted in Figure 6 with the major peak having a retention time of 7.7 mins, 
and the minor peak at a retention time of 8.5 mins. Integration of the peaks gave an 









































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.67 10851146.000 97.931 0.302
2 8.54 229300.266 2.069 0.311  
Figure 6. HPLC chromatogram for cyclisation of pyrrolidine 127b with (R)-TRIP 
While this method gave excellent separation and resolution for the 3,3-dimethyl substituted 
pyrrolidine, modification of the conditions or use of alternate chiral columns was easily 
performed to improve the HPLC traces on other substrates. This data is reported in the 
experimental section of this thesis.  
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With these promising results, the next step was to see if the cyclisation conditions were 
universal for other substituents at the 3,3-position, or would other substrates require 
screening of the reaction conditions. 
2.2. Scope of the reaction for 3,3-disubstitution  
The geminal-dimethyl group offered a simplistic substrate for comparing the different 
Michael acceptors, but altering the substitution at the 3-position could offer greater synthetic 
complexity and show the limits of the reaction. As discussed earlier, the formation of 
spirocycles allows for an increase in sp3 character in a molecule and is of interest in the field 
of fragment-based drug discovery. Therefore, the introduction of spirocyclic functionality to 
the pyrrolidine was investigated. 
To synthesise the spirocyclic compounds, the procedures used in the production of the 
geminal dimethyl precursor was used almost directly with only minor modifications required. 
To modify the 3,3-susbtitution, a range of cycloalkane nitriles, as well as diphenylacetonitrile, 
were selected to see how they tolerate the cyclisation reaction (Figure 7). 
 
Figure 7. Nitriles selected to test 3,3-subsitutted scope 
Following a similar procedure to the dimethyl precursors, the cycloalkyl nitriles were alkylated 
using LDA and allyl bromide to yield the cyano-alkene. This was then reduced with lithium 
aluminium hydride and protected with CbzCl in good yields. The metathesis using CuI with 
the p-tolyl thioacrylate gave good yields for the cyclobutyl 143a and cyclopentyl 143b 
precursors (84% and 86% respectively) but a lower yield of 66% for the cyclohexyl 143c 




Scheme 41. Synthesis of 3,3-spirocyclic precursors 
For the diphenyl substituted precursor, the synthetic steps proceeded in much the same way, 
with the exception that LiHMDS was used for the deprotonation of diphenylacetonitrile 140d 
instead of LDA (Scheme 42). The decision to change the base was made for both convenience, 
as LiHMDS was commercially available as a molar solution, and this specific transformation 
was reported in the literature with LiHMDS as the base.88 Alkylation with allyl bromide yielded 
the cyano-alkene in 141d in 90% yield. Reduction and protection to give the Cbz amine 142d 
followed as for the cycloalkyl products with a good yield of 78%. However, the metathesis of 
the diphenyl compound gave a lower yield of 54%. While this was lower than the other 





Scheme 42. Synthesis of 3,3-diphenyl precursors 
With the precursors in hand, the conditions that had been successfully used to cyclise the 3,3-
dimethyl pyrrolidine (cyclohexane, (R)-TRIP at 80 °C) were applied to the substrates (Figure 
8). 
 
Figure 8. Asymmetric cyclisation to form 3,3-spirocyclic pyrrolidines. 
Fortuitously, the (R)-TRIP conditions afforded high yields for all the 3,3-disubstituted 
pyrrolidines, with particularly high yields observed for the 3,3-cyclohexyl spiropyrrolidine 
144c (99%) and for the 3,3-diphenyl substituted pyrrolidine 144d (97%). Slightly lower yields 
of 78% for the 3,3-cyclobutyl and 87% for the 3,3-cyclopentyl spiropyrrolidine were observed, 
but both are good yields and are similar to the yield observed for the 3,3-dimethyl pyrrolidine 
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127b (83%). The enantioselectivity of the reaction was also very high, with both cyclobutyl 
and cyclopentyl attaining 98:2 er, and cyclohexyl achieving 97:3 er. The enantioselectivity 
dropped slightly for the diphenyl pyrrolidine to yield an er of 90:10. 
The high yields and enantioselectivity observed for the 3,3-disubstituted pyrrolidines while 
using (R)-TRIP at 80 °C in cyclohexane were very encouraging. It was decided that further 
screening of reaction conditions would not be useful at this point, as any gains in 
enantioselectivity or yield would be minimal, and the current set of conditions avoided the 
use of toxic solvents or bespoke catalysts. However, it was unknown how these results would 
translate to 2,2-disubstituted compounds. 
2.3. Scope of the reaction for 2,2-disubstitution  
To mirror the reactions performed on the 3,3-disubstituted pyrrolidines, initial tests were 
performed using the 2,2-dimethyl compounds as a representative example. The approach 
used to synthesise the 2,2-dimethyl-precursor was to utilise a Curtius rearrangement, as had 
been reported in the literature.67,89 The Curtius rearrangement required a carboxylic acid in 
order to form the intermediate acyl azide, so the first synthetic step was to alkylate ethyl 
isobutyrate with 4-bromobut-1-ene after deprotonation with LDA (Scheme 43). This formed 
the alkenyl ester 146 in a good yield of 70%. Subsequent hydrolysis of the ester led to 
formation of the carboxylic acid 147 in 64% yield, which was then treated with DPPA and Et3N 
to form the intermediate acyl azide. Upon heating, the acyl azide underwent the Curtius 
rearrangement to give an isocyanate with loss of N2. In the literature reports, this isocyanate 
is then hydrolysed at reflux with water to produce a free amine. However, as we intended to 
form the Cbz protected amine at the end of the synthesis, an opportunity for telescoping the 
reaction arose. To both bypass the amine synthesis, and to reduce the step count of the 
reaction, benzyl alcohol was added to the reaction after isocyanate formation. Upon heating, 
this underwent nucleophilic addition to the isocyanate to form the Cbz group in situ with a 
yield of 67% over the two steps. Utilising the same cross metathesis conditions as used for 





Scheme 43. Synthesis of 2,2-dimethyl-substituted precursor through the Curtius rearrangement 
With the precursor 149 synthesised, the cyclisation could then be tested. Using the same 
conditions as the 3,3-disusbsitutted reaction (cyclohexane, (R)-TRIP at 80 °C) gave a good yield 
of 77% (Scheme 44). However, a small drop in er of 96:4 was noted, when compared to 98:2 
er for the 3,3-dimethyl pyrrolidine. While this drop is not large, there was potentially room 
for improvement if conditions were modified. 
 
Scheme 44. Cyclisation of 3,3-dimethyl precursor with (R)-TRIP catalyst 
For the screening and optimisation of conditions, there were four parameters that could be 




The work performed on THFs and THPs used cyclohexane as it was believed the low polarity 
of the solvent would prevent solvation of the catalyst and interference with the transition 
state. However, the solubility of more polar substrates in cyclohexane could be problematic, 
especially at lower temperatures. Therefore, toluene and 1,2-DCE were selected as 
alternative solvents for screening.  Both solvents have high boiling points (110 °C and 84 °C 
respectively) which could allow for a range of temperatures to be screened and toluene also 
offers a safer alternative to benzene as an aromatic solvent, while 1,2-DCE has toxicity and 
carcinogenicity hazards associated with it, however it is useful as a high boiling point 
chlorinated solvent which could dissolve more polar substrates. 
Catalysts were selected based on their commercial availability for two main reasons. Firstly, 
it allowed for rapid testing of conditions as CPA catalysts require multistep syntheses to make; 
secondly, if the catalyst can be purchased from a chemical supplier, it becomes more viable 
in both research and industrial settings. To that end, the catalysts selected were (R)-TRIP, (R)-
TiPSY, (R)-phen and (R)-anth as shown in Figure 9. 
 
Figure 9. Structure of CPA catalysts used in reaction screening 
Initial screening was done by variation of the temperature and the time of the reaction. Table 
1, entry 1 shows the already tested conditions of cyclohexane, (R)-TRIP at 80 °C for 24 hours, 
which gave 77% yield and 96:4 er. When the temperature was lowered to 50 °C (Table 1, entry 
2), the yield nearly halved to 38%, but no increase in er was observed. Indeed, the er for the 
reaction dropped marginally to 95:5. The decrease in yield is not particularly surprising as with 
lower temperatures, the rate of reaction would also be expected to drop. Extending the 
reaction time to 48 h may be expected to increase the yield, but these conditions only saw a 
small increase in yield to 46% and a marginal increase in enantioselectivity to 97:3. These 
slight differences in enantioselectivity are very minor and effectively show that time and 
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temperature have minimal to no effect on the enantioselectivity of the reaction, but they do 
have an impact on the yield. 
Table 1. Conditions screen for p-tolyl, 2,2-dimethyl pyrrolidine 
 
Entry CPA Solvent T / °C t / hrs Yield % er  
1 (R)-TRIP cyclohexane 80 24 77 96:4 
2 (R)-TRIP cyclohexane 50 24 38 95:5 
3 (R)-TRIP cyclohexane 50 48 46 97:3 
4 (R)-TRIP toluene 50 24 18 96:4 
5 (R)-TRIP 1,2-DCE 50 24 12 95:5 
6 (R)-TiPSY cyclohexane 80 24 22 79:21 
7 (R)-phen cyclohexane 80 24 21 73:27 
8 (R)-anth cyclohexane 80 24 99 81:19 
To screen the different solvents in the reaction, the catalyst remained unchanged but the 
lower temperature of 50 °C was used for 24 hours. The use of the lower temperature would 
make for easier comparisons for the effect of solvent on the yield and enantioselectivity. If 
any major increases in yield were observed through varying the solvent, they would be more 
apparent when increasing from 38 % yield (50 °C) than from 77% yield (80 °C). Any decrease 
in yield, while less pronounced when using 38% as the baseline, would still be apparent but 
not as important as those conditions would not be pursued. As can be seen when comparing 
Table 1, Entries 2, 4, and 5, the effect of solvent had a marked impact on the yield of the 
reaction, but a negligible effect on the enantioselectivity. Cyclohexane at 50 °C gave a yield of 
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38%, while both toluene and 1,2-DCE saw a drop to 18 and 12% respectively. The 
enantiomeric ratio remained at 95:5 for 1,2-DCE and gave a slight increase to 96:4 for toluene. 
Cyclohexane at 80 °C for 24 hours seemed to be the ideal conditions for the reaction to 
achieve high yields while variation of these conditions did not seem to greatly affect the 
enantioselectivity. While this allows for some flexibility when trying to attain higher yields for 
the reaction, it seemed that the only way to affect the enantioselectivity would be through 
catalyst choice. Screening of catalysts (Table 1, Entries 6, 7, and 8) showed moderate 
enantioselectivity for both (R)-TiPSY (79:21 er) and (R)-phen (73:27 er) but low yields of 22% 
and 21% respectively. (R)-anth also showed a moderate er of 81:19 but gave an exceptionally 
high yield of 99%. These results show that the most influential method for affecting 
enantioselectivity is the choice of catalyst. While the yields of the reactions were also 
affected, catalyst choice gave the most marked change to enantiomeric ratio for the reaction. 
This screen shows that our initial conditions used when synthesising the 3,3,’-dimethyl 
substituted pyrrolidine were fortunate in also providing high yields and enantioselectivities 
for the 2,2-diemthyl substituted pyrrolidine. As those initial conditions were based on the 
asymmetric synthesis of THFs performed in the group,78 it is gratifying to know that the 
chemistry can be translated well from the oxy-Michael reaction to the aza-Michael. 
Another potential way of affecting the enantioselectivity of the reaction would be to change 
the substituent on the thioester. In the THF/THP work, changing the p-tolyl thiol to mesityl 
thiol improved enantioselectivity for the tetrahydropyrans, but led to poorer 
enantioselectivity for tetrahydrofurans (Scheme 32). As the effects of the thiol substituent 
were unknown for the synthesis of pyrrolidines, this seemed to be a prudent choice for 
investigation. Mirroring the p-tolyl thioacrylate, the mesityl thioacrylate 152 was synthesised 




Scheme 45. Synthesis of mesityl thioacrylate 
The newly formed mesityl thioacrylate could then be coupled to the 2,2-dimethyl Cbz amine 
148 under the metathesis conditions, and this proceeded smoothly to give the product 153 
in 92% yield (Scheme 46). 
 
Scheme 46. Synthesis of 2,2-dimethyl mesityl thioester precursor 
Cyclising the mesityl thioester with (R)-TRIP at 80 °C in cyclohexane gave a very high yield of 
94% and an er of 92:8 (Table 2, entry 1). The high yield of the reaction is very promising, but 
the lower enantioselectivity than that of the p-tolyl thioester (er 96:4) was deemed to be 
significant. Therefore, further screening was necessary to see if the selectivity could be 
improved upon. As the previous screen demonstrated that solvent had minimal effect on 
enantioselectivity, and that yields were highest when performed with cyclohexane, it was 
decided to continue only with the cyclohexane and screen temperature, time and catalyst.  
As in the case of the p-tolyl, reducing the temperature to 50 °C showed a marked decrease in 
the yield to 41%, but a slight increase in selectivity to give an er of 93:7 (Table 2, entry 2). 
Extending the reaction time to 48 hours did increase the yield to 68%, but saw a small drop in 
er to 90:10 (Table 2, entry 3). This ties in with the results seen in Table 1 that increasing the 
temperature is more beneficial to reaction rate than extending the reaction time, and that 
the temperature has a small but noticeable effect on enantioselectivity. It is also worth noting 
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that the mesityl thioester showed higher yields but lower enantioselectivity when compared 
to the p-tolyl thioester when cyclised with (R)-TRIP.  
Perhaps the largest difference between the p-tolyl and mesityl thioester was seen in the 
results for (R)-TiPSY, (R)-phen and (R)-anth (Table 2, Entries 4, 5, and 6). In all cases the yields 
and enantiomeric ratios were lower than that of the p-tolyl thioester, and all were 
significantly lower than that of (R)-TRIP. The er of 92:8 recorded when (R)-TRIP was used does 
still represents a reasonably high enantioselectivity, though it is a drop from 96:4 when the 
same conditions were used in the p-tolyl thioester. It seems apparent that the added steric 
bulk from the mesityl group does not lead to any significant gains in enantioselectivity, but 
with specific catalysts can give increased yields. 
Table 2. Conditions screen for mesityl, 2,2-dimethyl pyrrolidine 
 
Entry CPA Solvent T / °C Time / hrs Yield % er 
1 (R)-TRIP cyclohexane 80 24 94 92:8 
2 (R)-TRIP cyclohexane 50 24 41 93:7 
3 (R)-TRIP cyclohexane 50 48 68 90:10 
4 (R)-TiPSY cyclohexane 80 24 14 65:35 
5 (R)-phen cyclohexane 80 24 5 55:45 
6 (R)-anth cyclohexane 80 24 59 59:41 
While the screening of the reaction was necessary, it did demonstrate that the initial 
conditions used for the 3,3-disubstituted pyrrolidines (cyclohexane, (R)-TRIP, 80 °C) gave the 
best results. It also demonstrated that the substitution of the thioester could affect the yields 
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and enantioselectivity, with the mesityl giving better yields under the (R)-TRIP conditions than 
the p-tolyl, but poorer selectivity. For this reaction, the enantioselectivity was given priority 
over yield and so the p-tolyl was selected as the thioester of choice for investigating 
substitution at the 2-position. 
Like the 3,3-disubstituted precursors, the 2,2-disubstituted precursors were synthesised by 
replacement of the ethyl isobutyrate with the relevant substituted esters. The same 
carbocycle and diphenyl functionality was included in the selection of substituents, however 
commercial availability of other esters meant we were able to introduce heterocycles into the 
precursors, namely 4-tetrahydropyranyl and N-Cbz-piperidinyl (Figure 10).  
 
Figure 10. Esters selected to test 2,2-disubstituted scope 
These esters were alkylated in the same method as the 2,2-dimethyl substrate (Scheme 43) 
using LDA and 4-bromobut-1-ene, although in the case of the N-Cbz-piperidinyl ester 155e 
LiHMDS was used as decomposition occurred with LDA and no product was isolated. (Scheme 
47). Following hydrolysis of the ester to the acid, the Curtius rearrangement was again 
employed. In the case of cyclobutyl 157a, tetrahydropyranyl 157d, and N-Cbz-piperidinyl 157e 
substrates, the addition of Cs2CO3 alongside the benzyl alcohol led to better yields of the Cbz 
amine product. The metathesis proceeded well for most substrates, with especially high yields 




Scheme 47. Synthesis of 2,2-disubstituted precursors 
For the 2,2-diphenyl ester 155f, LiHMDS was used for the deprotonation for convenience, and 
upon alkylation yielded the alkenyl ester 156f in 42% yield. Hydrolysis of the ester followed 
the same procedure as for the other substrates and gave the carboxylic acid 157f in 54% yield. 
For the Curtius rearrangement, Cs2CO3 was also included with the benzyl alcohol, which 
generated the Cbz amine 158f in a good yield of 65%. The metathesis conditions also worked 





Scheme 48. Synthesis of 2,2-diphenyl precursor 
These newly synthesised precursors were then subjected to the cyclisation conditions 
previously stated (cyclohexane (R)-TRIP, 80 °C) (Figure 11).   
 
Figure 11. Asymmetric cyclisation to form 2,2- spirocyclic pyrrolidines. 
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In the case of the 2,2-disubstituted pyrrolidines the cycloalkyl substituents (160a, 160b, and 
160c) gave good to high yields, while maintaining high enantioselectivity. This reflected the 
results seen for the 2,2-dimethyl pyrrolidine (Table 1, Entry 5) which gave an er of 96:4 and a 
yield of 77%. Gratifyingly, the introduction of the tetrahydropyranyl spirocycle 160d gave a 
good yield of 61% whilst maintaining high enantioselectivity (96:4 er). The N-Cbz-piperidinyl 
160e saw a larger drop in yield to 37% and a substantial drop in er to 70:30. This reduction in 
selectivity and yield was also seen for the 2,2-diphenyl pyrrolidine 160f, with a very poor yield 
of 14% and an er of 76:24 attained which was only attained after an extended reaction time 
of 48 hours. 
The lower yields and enantioselectivity observed for the diphenyl 160f and N-Cbz-piperidinyl 
160e pyrrolidines could be due to the increased steric bulk in the transition state of the 
reaction. Our hopes had been that increasing steric bulk would lead to an increase in 
selectivity by creating a larger energy gap between the transition states of the reaction which 
lead to either the (R) or (S) enantiomer. However, it appears that larger substituents disfavour 
cyclisation as well as selectivity. The 2,2-diphenyl-pyrroldine 160f gave particularly poor 
results, which could be a combination of both steric and electronic factors, although it is 
unclear as to the degree these different factors affect the reaction. However, the high yields 
and enantioselectivity observed when synthesising the cycloalkyl and tetrahydropyranyl 
spiropyrrolidines, was gratifying.  
This result coupled with the positive results gained for the 3,3-disubstituted spiropyrrolidines 
gave us a robust methodology to move forward with. One substrate that had not been tested 
was that of the unsubstituted pyrrolidine, and this seemed the most obvious compound to 
try next. 
2.4. Synthesis of an unsubstituted pyrrolidine 
The formation of the unsubstituted precursor was achieved through protection of 4-penten-
1-amine 161 with benzyl chloroformate to give the Cbz amine 162 in 64% yield. Metathesis 





Scheme 49. Synthesis of the unsubstituted precursor 
As before the precursor 163 was subjected to the cyclisation conditions of (R)-TRIP at 80 °C in 
cyclohexane. Under these conditions, the substrate cyclised well giving a high yield of 87%, 
but the selectivity dropped significantly to 90:10 (Scheme 50). Despite the screening for the 
2,2-dimethyl substrate resulting in the initial conditions proving to be the best, the lower 
selectivity observed for the unsubstituted pyrrolidine merited another screen of the 
conditions.  
 
Scheme 50. Cyclisation of the unsubstituted precursor with (R)-TRIP 
Increasing the steric bulk through substitution was theorised to favour certain catalyst 
transition states, as well as providing a Thorpe-Ingold effect to increase the rate of reaction. 
Without that substitution, both rates and enantioselectivity could be affected. Certainly, we 
can see that the enantioselectivity dropped when using the previously optimised conditions, 
so to ensure a thorough screen, the conditions selected for the screen mirrored those seen in 
Table 1. The screen for the unsubstituted pyrrolidine synthesis is shown in Table 3. 
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Table 3. Conditions screen for p-tolyl, unsubstituted pyrrolidine 
 
Entry CPA Solvent T / °C Time / hrs Yield % er 
1 (R)-TRIP cyclohexane 80 24 87 90:10 
2 (R)-TRIP cyclohexane 50 24 88 91:9 
3 (R)-TRIP cyclohexane 50 48 43 89:11 
4 (R)-TRIP toluene 50 24 42 90:10 
5 (R)-TRIP 1,2-DCE 50 24 44 88:12 
6 (R)-TiPSY cyclohexane 80 24 87 94:6 
7 (R)-phen cyclohexane 80 24 73 81:19 
8 (R)-anth cyclohexane 80 24 97 78:22 
Reducing the temperature of the reaction to 50 °C (Table 3, entry 2) showed almost no change 
to the reaction conducted at 80 °C, both gave comparable yields and a slight increase in 
enantioselectivity. Interestingly, when the reaction was conducted for 48 hours (Table 3, 
Entry 3), instead of increasing the yield, there was a significant drop from 87 % for the 24 hour 
reaction, to 43%. It was theorised that while extending the reaction time may lead to an 
increase in the amount of product formed for a more sluggish reaction, extending the time 
also leads to competing decomposition pathways, possibly through hydrolysis of the 
thioester. For both toluene and 1,2-DCE, yields were approximately half of that obtained with 
cyclohexane (Table 3, entries 4 and 5). Likewise, enantioselectivity was only marginally 
affected, with 1,2-DCE performing slightly poorer than toluene and cyclohexane.  
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In screening the catalysts, (R)-TiPSY (Table 3, entry 6) achieved a yield of 87% to match that 
of (R)-TRIP (Table 3, entry 1), but with an increased er of 94:6. (R)-phen gave a slightly lower 
yield of 73%, but showed a significant decrease in er to 81:19 (Table 3, entry 7). (R)-anth 
showed a near quantitative yield for but also led to a lower er of 78:22 (Table 3, entry 8). The 
increase in enantioselectivity and high yields for (R)-TiPSY suggest that for unsubstituted 
compounds it is a better catalyst than (R)-TRIP 
With the discovery that (R)-TiPSY gave better results in the case of the p-tolyl unsubstituted 
pyrrolidine, the utility in screening conditions had been demonstrated. One other aspect that 
warranted investigation was modification of the thioester. While the use of a mesityl 
thioester did not improve on the p-tolyl results for the 2,2-dimethyl pyrrolidine, it was 
deemed appropriate to test the effect of the thioester substitution on the cyclisation of the 
unsubstituted pyrrolidine.  
To do this, the unsubstituted Cbz amine 162 was once again submitted to the metathesis 
conditions, this time with the mesityl thioacrylate. This gave the cyclisation precursor 165 in 
a high yield of 87% (Scheme 51). 
 
Scheme 51. Synthesis of unsubstituted mesityl thioester precursor 
As the effect of solvent had again been shown to be minimal on yield and selectivity, 
cyclohexane was carried forward for the screen, with toluene and 1,2-DCE not tested. 
However, temperature, time and catalyst were screened, as shown in Table 4. 
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Table 4. Conditions screen for mesityl, unsubstituted pyrrolidine 
 
Entry CPA Solvent T / °C Time / hrs Yield % er 
1 (R)-TRIP cyclohexane 80 24 91 85:15 
2 (R)-TRIP cyclohexane 50 24 62 85:15 
3 (R)-TRIP cyclohexane 50 48 91 85:15 
4 (R)-TiPSY cyclohexane 80 24 36 93:7 
5 (R)-phen cyclohexane 80 24 10 67:33 
6 (R)-anth cyclohexane 80 24 89 72:28 
When the reaction was performed with (R)-TRIP at 80 °C for 24 hours, a high yield of 91% was 
obtained, but an er of only 85:15 was achieved (Table 4, entry 1). Reduction of the reaction 
temperature to 50 °C did also reduce the yield to 62%, but the enantioselectivity was 
unchanged, achieving an er of 85:15 (Table 4, entry 2). Extending the reaction time to 48 hours 
at 50 °C did increase the yield to 91% but again, no increase in enantioselectivity was observed 
(Table 4, entry 3).  
The use of (R)-phen and (R)-anth (Table 4, Entries 5 and 6) saw a decrease in both yield and 
enantioselectivity when compared to (R)-TRIP , but (R)-TiPSY (Table 4, Entry 4) showed a 
dramatic increase in er to 93:7. This reflects the results seen for the unsubstituted p-tolyl 
where (R)-TiPSY led to a higher enantioselectivity when compared to (R)-TRIP (Table 3, Entries 
1 and 6). Unfortunately, the yield of the mesityl thioester (36%) was lower when (R)-TiPSY 




It is also worth noting that when extended reaction times were used for the unsubstituted p-
tolyl thioesters, the yield dropped significantly (Table 3, Entry 3), possibly due to hydrolysis of 
the thioester. In the case of the mesityl thioester, extending the reaction time not only 
increased the yield (Table 4, Entry 3), it also matched the results seen for the higher 
temperature reaction (Table 4, Entry 1). This suggests that, while less effective at providing 
enantioselectivity, the mesityl thioester does seem to be more stable to hydrolysis or 
decomposition than the p-tolyl. By varying the thioester, it was clear that the cyclisation itself 
was significantly affected, but the stability of the resultant thioester to hydrolysis or 
decomposition under the reaction conditions was a result worth considering. 
2.5. Functionalisation of pyrrolidines 
The pyrrolidine substructure offers two main handles that could be used to introduce 
functionalisation; the thioester and the nitrogen atom. The thioester can be modified in 
similar ways to an oxoester, such as reduction, hydrolysis or transesterification. The 
transesterification was of interest as a method for determining the stereochemistry of the 
stereogenic centre formed in the cyclisation 167 (Figure 12). The simplest modification of the 
nitrogen was deprotection of the Cbz group to reveal the secondary amine 168, which could 
then go undergo further reactions such as reductive aminations or Buchwald Hartwig 
coupling.90 
 
Figure 12. Potential transesterification and deprotection products 
2.5.1. Transesterification and confirmation of stereochemistry 
One of the aspects of the thioester which made it especially useful for asymmetric synthesis 
of pyrrolidines, was its comparatively higher reactivity than the ester. While the ester gave 
lower yields and enantioselectivity than the thioester in the aza-Michael reaction, conversion 
of the thioester into an ester would enable access to analogues of L-β-homoproline. They 
could also serve as a linker unit to attach the pyrrolidine subunit onto a larger molecule. 
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Fortunately, methods have been reported in the literature to produce esters from 
corresponding thioesters. A report by Hanessian et. al. demonstrates a process using AgOTf 
in MeOH/CH2Cl2 to convert a thiophenyl ester into a methyl ester.91 Using these conditions, 
the pyrrolidine 164 was converted smoothly into the methyl ester 169 in 67% yield and with 
minimal change in enantiomeric ratio (Scheme 52). 
 
Scheme 52. Transesterification using silver triflate and methanol 
The synthesis of the pyrrolidine methyl ester 169 was performed for two main reasons; firstly, 
to demonstrate the transesterification procedure, but also to allow for determination of the 
absolute stereochemistry of the product. In a publication by the Clayden group, they 
synthesised (S,S)-clemastine 172 from ʟ-proline 170 through an Arndt-Eistert extension of the 
amino acid.4 They formed the Cbz-methyl ester-protected-β-amino acid 169 as part of the 
synthesis which matches the structure of the product of the transesterification procedure. 
(Scheme 53). 
 
Scheme 53. Synthesis of (S,S)-clemastine with β-amino acid intermediate 
76 
 
As this intermediate in the synthesis was derived from an enantiomerically pure source (ʟ-
proline), the value for the optical rotation of the molecule would enable the determination of 
configuration in the (R)-TRIP catalysed cyclisation. By discovering the configuration of the 
stereogenic centre formed in the cyclisation, alternate catalysts could be used, e.g. (S)-TRIP, 
depending on which enantiomer is required in further syntheses. It can also allow for analysis 
of the transition state and mechanism of the reaction through computational studies. 
The optical rotation of the methyl ester synthesised from the cyclised thioester was recorded 
to be [α]D25 -25.4 (c 0.55, CHCl3), with the value for the literature compound as [α]D25 -42.7 (c 
1.33, CHCl3).4 Comparison of the sign of optical rotation with the literature value led to the 
conclusion that the configurtion of the pyrrolidine methyl ester 169 was (S) and therefore the 
thioester 164 must also be (S)- as there appeared to be no racemisation of the stereocentre.  
2.5.2. Cbz de-protection 
One of the most obvious points of functionalisation on the pyrrolidine ring is that of the 
nitrogen atom. For functionalisation to take place, the nitrogen must first be deprotected, 
and the usual methods for the removal of a Cbz group is through hydrogenation. Cbz had 
been used since the start of the methodology in preference to Boc, mainly due to its stability 
under acidic conditions as the cyclisation procedures were performed using acid catalysts. 
However, this stability of the Cbz offers more challenges in its removal. Standard deprotection 
methods used within the group were the use of 10 mol% Pd/C in methanol under an 
atmosphere of hydrogen. When tested on the cyclised pyrrolidine 164, no reaction was 
observed, and only starting material was recovered (Table 5, entry 1). Replacing the solvent 
with one of higher polarity has been a variation employed for particularly difficult 
substrates.92 However, when acetic acid was used in place of methanol, the results of the 
reaction were much the same with only starting material recovered and no deprotection 
observed (Table 5, entry 2). Using an excess of palladium also proved fruitless when 1.1 
equivalents of Pd(OH)2 were used in methanol (Table 5, entry 3). Under this set of conditions, 
no product or starting material was recovered, with only decomposition products observed 
by NMR. Another method for the removal of Cbz groups is through transfer hydrogenation. 
This replaces gaseous hydrogen with a chemical source, in this case ammonium formate, as 
the hydrogen donor. This procedure has shown utility in peptide synthesis and has been 
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demonstrated in the deprotection of Cbz proline.93 To test this reaction, a catalytic amount 
of Pd(OH)2/C with an excess of ammonium formate was refluxed with the pyrrolidine 164 in 
ethanol. Unfortunately, this was not productive in yielding the deprotected product, and only 
decomposition was observed (Table 5, entry 4). 
Table 5. Hydrogenation conditions tested for the removal of the Cbz protecting group. 
 
Entry Pd catalyst (loading) Solvent/temp Hydrogen source Result 
1 Pd/C (10 mol%) MeOH, rt H2 No reaction 
2 Pd/C (10 mol%) AcOH, rt H2 No reaction 
3 Pd(OH)2/C (1.1 eq) MeOH, rt H2 Decomposition  
4 Pd(OH)2/C (10 mol%) EtOH, reflux NH4CO2H (10 eq.) Decomposition 
It was theorised that the some of the decomposition observed may have been due to 
hydrolysis of the thioester in alcoholic solvents. The liberated sulfur may have then gone on 
to poison the palladium on charcoal, rendering it unable to perform the hydrogenation.94 As 
none of the palladium catalysed hydrogenation gave viable methods for deprotection, 
alternate procedures were investigated. 
One procedure proposed, was the use of boron trichloride-dimethyl sulphide complex as a 
debenzylating reagent.95 Both boron tribromide and boron trichloride have been used to 
remove benzyl groups from benzyl protected alcohols and amines. It was reasoned that the 
benzyl group of the Cbz may undergo deprotection under these conditions to give the 
resultant carbamic acid, which could then break down releasing CO2 to generate the 
deprotected amine. Due to material availability, this process was tested on a racemic 3,3-
cyclopentyl pyrrolidine (±)-144b. Gratifyingly, when treated with BCl3.DMS the Cbz was 
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removed smoothly to generate the HCl salt of the pyrrolidine (±)-173 in a very high 96% yield 
(Scheme 54).  
 
Scheme 54. Cbz deprotection using BCl3.DMS 
2.6. Summary of results 
The use of α,β-unsaturated thioesters as Michael acceptors in an intramolecular asymmetric 
aza-Michael reaction has been demonstrated. Initial comparisons between oxo-esters and 
ketones showed that the thioester gave better yields and higher enantioselectivity than the 
other substrates. When using (R)-TRIP in the synthesis of 3,3-disubstituted and spirocyclic 
pyrrolidines, high yields and enantiomeric ratio could be achieved. After a series of 
optimisations, it was also shown that these same conditions led to the formation of 2,2-
disubstituted pyrrolidines as well, although with an overall slightly reduced selectivity when 
compared with 3,3-disubstituted pyrrolidines. It is unclear as to the exact reason for the 
difference in selectivity, but the proximity of the substitution, and thus steric bulk, to the 
nucleophile could be a factor. Screening of the reaction did reveal that the use of (R)-TiPSY in 
the synthesis of unsubstituted pyrrolidines was beneficial, and led to higher 
enantioselectivity, with only a small loss in yield.  
Screening of the reaction conditions showed the extent to which each variable affected the 
yield and selectivity of the reaction. Solvent choice affected the yield of the reactions, with 
cyclohexane performing best in all cases, but had little effect on enantioselectivity. Generally, 
raised temperatures (80 °C instead of 50 °C) increased yield but did not greatly affect the 
enantioselectivity.  Increasing the reaction times from 24 to 48 hours at 50 °C increased yields 
in the case of the mesityl thioester but not the p-tolyl, possibly due to competing hydrolysis 
or decomposition reactions. However, when higher temperatures were used (80 °C) the p-
tolyl thioesters gave higher yields and enantioselectivities than when using mesityl thioesters. 
79 
 
The main factor in determining the enantioselectivity of the reaction was in the catalyst 
choice, with (R)-TiPSY giving the best selectivity for unsubstituted pyrrolidines, and (R)-TRIP 
giving the best selectivity for substituted pyrrolidines.  
Through this process of optimisation, we were able to decide upon a general set of conditions 
for the asymmetric synthesis of spiropyrrolidines; (R)-TRIP, cyclohexane, 80 °C for 24 h. These 
conditions proved to be productive for synthesising a range of spirocyclic and di-substituted 
pyrrolidines. 
Functionalisation of the cyclised products was achieved through a transesterification 
procedure and deprotection. The transesterification procedure allowed for easy modification 
of the thioester into the corresponding methyl ester in 67% yield with no appreciable 
racemisation of the stereocentre observed.  Comparison of the specific rotation of the methyl 
ester allowed for the determination of the absolute configuration of the compound, and thus 
the stereochemistry of the product of cyclisation, as being the (S)-enantiomer. Deprotection 
of the Cbz group was not possible using traditional hydrogenation conditions, but the use of 
BCl3.DMS gave the HCl salt of the pyrrolidine in a very high 96% yield.  
80 
 
3.  Expanding the methodology 
With a wide substrate scope demonstrated for the asymmetric synthesis of substituted 
pyrrolidines, further attempts to expand the methodology were investigated. The initial scope 
gave access to a range of spirocyclic pyrrolidines, a structural motif which can increase the 
three-dimensionality of a compound. When developing drugs or drug-like compounds, 
changing the shape or form of a molecule is one way in which the pharmacokinetics can be 
tuned.96 Further modification of potential drug-like compounds, such as introduction of 
heteroatoms or diastereotopic centres, can also help in the tuning of a drugs properties. 
One area of interest in synthetic and medicinal chemistry is the incorporation of fluorine 
atoms into drug molecules. Fluorination of organic molecules is non-trivial and the possibility 
of introducing fluorine into the pyrrolidine structures 174 and 175 provided an interesting 
synthetic challenge (Figure 13). Another point of functionalisation was the double bond 
where introduction of an R group, such as a methyl, could lead to new enantioenriched 
pyrrolidines 176 or new diastereomeric pyrrolidines 177. These variations could affect the 
lipophilicity of the pyrrolidine scaffolds in the case of fluorine, or the branching and steric 
interactions with the double bond substitution. Both approaches would lead to a greater 
scope for the methodology, adding complexity to the pyrrolidine scaffolds available using the 
cyclisation procedure. 
 
Figure 13. Potential new pyrrolidines using existing procedures 
3.1. Di-fluorinated pyrrolidines 
Fluorine and its properties are of interest to medicinal chemistry for the pharmacokinetic 
properties it provides to drugs, and its introduction into organic molecules can be non-
trivial.97,98 The size of the fluorine atom is relatively small (Van der Waal radius of 1.47 Å) 
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considering the size of a hydrogen atom (1.20 Å),99 while its electronegativity is 3.98 on the 
Pauling scale.100 Replacement of hydrogen in a drug molecule with fluorine has been shown 
to mimic the steric interactions of hydrogen when binding to a receptor or enzyme.101 This, 
coupled with the stability of the C-F bond in comparison to C-H, can lead to an increase in 
chemical and metabolic stability and enhanced biological activity.101 While the steric 
interactions may be small, the electrostatic interaction of the fluorine can also induce a 
conformational bias in both ring and aliphatic systems, as well as affecting the pKa of 
functional groups both proximal and distal to the fluorine.98,102 The presence of fluorine can 
also increase the lipophilicity of a compound, a property that can affect the solubility and 
membrane permeability of a drug.98 For these reasons, it seems clear that the introduction of 
fluorine to a molecule warrants investigation.  
3.1.1. Previous route 
In order to synthesise the appropriate precursor, the initial plan was to follow the previous 
syntheses used for producing the disubstituted pyrrolidines. To begin with 
difluoroacetonitrile 179 was selected as a starting material for the synthesis of the 3,3-
difluoro pyrrolidines (Scheme 55). First, the alkylation procedure of difluoroacetonitrile was 
tested using LDA to deprotonate the nitrile, followed by addition of allyl bromide. 
Unfortunately, no product was observed in the reaction (Scheme 55). It was hypothesised, 
that the nitrile anion may be stabilised by the adjacent fluorine atoms making it less reactive 
towards nucleophilic addition. Whether this reactivity would be observed when using other 




Scheme 55. Retrosynthetic analysis and forward synthesis of 3,3-difluorinated pyrrolidine 
While the nitrile proved unsuccessful, there was hope that the use of ethyl difluoroacetate 
182 may be more fruitful in synthesising the 2,2-difluorinated precursor 181 (Scheme 56). Use 
of the nitrile was non-trivial due to its low boiling point and high volatility. Consequently, a 
new synthesis for the 3,3-difluorinated precursor 178 was conceived, also from ethyl 
difluoroacetate 182 giving a common starting material to derive both 2,2- and 3,3-difluoro 
compounds (Scheme 56).  
 
Scheme 56. Retrosynthetic analysis of 2,2- and 3,3-difluorinated pyrrolidines 
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As a forward synthesis, the first conditions tested were those previously used when 
synthesising 2,2-disubstituted pyrrolidines; LDA in THF at -78 °C followed by addition of 4-
bromobut-1-ene (Table 6, entry 1). Under these conditions, no product was isolated, and 
analysis of the crude material did not discern any identifiable compounds. When LDA was 
replaced with LiHMDS as an alternative non-nucleophilic amine base, the only product 
observed was the hydrolysed starting material (Table 6, entry 2).  Another base commonly 
used for deprotonation in the formation of enolates is sodium hydride. Under reflux in dry 
benzene (Table 6, entry 3), the only product recovered was difluoroacetic acid with no 
alkylated product seen. It was hypothesised that small amounts of water may have entered 
the reaction and, coupled with high temperatures, resulted in the hydrolysis of the starting 
material. To try and combat hydrolysis, NaH deprotonation was attempted at -78 °C in dry 
THF (Table 6, entry 4). Unfortunately this method also resulted in hydrolysis. It was therefore 
concluded that quenching the reaction with water led to the formation of NaOH during 
workup which would be the most likely explain the hydrolysis observed. 
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Table 6. Enolate formation and alkylation with 4-bromobut-1-ene 
 
Entry Base Solvent Temp / 
°C  
Additive Result Yield 
%  
1 LDA THF -78 - Decomposition - 
2 LiHMDS THF -78 - difluoroacetic 
acid 
62 
3 NaH benzene 80 - difluoroacetic 
acid 
63 
4 NaH THF -78 - difluoroacetic 
acid 
76 
5 KHMDS Toluene -40 18-crown-6 
(premixed) 
Decomposition - 
6 KHMDS Toluene -40  18-crown-6 (after 
halide) 
Decomposition - 
The lack of product formation may also be due to the stability of the metal enolate, as even 
at elevated temperatures, no product was observed. To try and counter this, KHMDS was 
used as a base with 18-crown-6 added as a potassium ionophore. When KHMDS was premixed 
with the crown ether (Table 6, entry 5), decomposition was observed. The crown ether was 
also added after the addition of the bromide to the reaction (Table 6, entry 6) to try and break 
up the potassium enolate in the presence of the bromide. Regrettably, decomposition still 
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occurred, possibly from side-reactions such as self-condensation or condensation with 
products.   
The results for the reaction with 4-bromobut-1-ene were disappointing and seemed to 
suggest it may not be possible to synthesise the desired product via this route.  However, we 
hypothesised replacement of the 4-bromobut-1-ene with allyl bromide for the synthesis of 
the 3,3- substrate may provide different results. This was reasoned as allyl halides undergo 
an SN2' reaction as opposed to direct 1,2-nucleophilic substitution, which may be more 
amenable with this enolate. 
Table 7. Enolate formation and allylation with allyl bromide 
 
Entry Base Solvent Temp / 
°C  
Additive Result Yield 
% 
1 LDA THF -78 - Decomposition - 
2 LiHMDS THF -78 - difluoroacetic 
acid 
77 
3 NaH benzene 80 - difluoroacetic 
acid 
72 
4 NaH THF -78 - difluoroacetic 
acid 
75 
5 KHMDS Toluene -40 18-crown-6 (premixed) Decomposition - 





When the conditions for the reaction with 4-bromobut-1-ene were mirrored with allyl 
bromide (Table 7), very similar results were observed. When using LDA or KHMDS with 18-
crown-6 (Table 7, entries 1,5 and 6) decomposition occurred again, and when LiHMDS or NaH 
was used, the only observable product was hydrolysed starting material. Overall, this suggests 
the major difficult in performing this reaction is less to do with the electrophile, but more to 
do with the formation and stability of the enolate. Therefore, other methods would be 
required in order to synthesise the difluorinated compounds required. 
3.1.2. Synthesis of 2,2-difluoro precursors 
Upon investigation of the literature, a report by Fustero et al. showed the synthesis of 2,2-
difluoro-5-hexenoic acid with the keys step being a difluorination of an α-keto ester.103 This 
acid is the same intermediate we were intending to make as a precursor to the Curtius 
rearrangement, making this procedure much more synthetically viable than the initial plan of 
direct alkylation of ethyl difluoroacetate. This route would have an additional step but there 
was clear precedent for the synthesis of the desired compound. 
Following the same procedures as Fustero, we were able to obtain the α-keto ester 187 in 
41% yield from diethyl oxalate (Scheme 57). The product of the Grignard addition 184 could 
potentially undergo further addition reactions explaining the lower yield. 
 
Scheme 57. Synthesis of difluorinated ester 
With the α-keto ester in hand, the fluorination step could be performed. This involved the use 
of the nucleophilic fluorinating agent bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-
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Fluor®). The reactivity of this reagent is such that it can convert α-ketones and aldehydes into 
the corresponding geminal difluoride but leave the ester functionality intact. Gratifyingly, 
when the α-keto ester was subjected to the fluorination conditions, the difluoroester 184 was 
revealed in a 57% yield with an overall yield of 23% over the two steps (Scheme 57). While 
this gave sufficient material to work with, as the α-keto ester was prone to decomposition 
over time, it was imperative to perform the fluorination soon after isolation. To try and 
circumvent this instability, the reaction was telescoped to remove the column 
chromatography step used to purify the α-keto ester. Instead, the Grignard reaction was only 
treated with an aqueous work-up and the crude material then subjected to fluorination 
conditions. By performing the reaction over two steps, the yield of the difluorinated ester 184 
was marginally increased to 26% from 23% and eliminated the need for chromatography after 
the first step (Scheme 58).  
 
Scheme 58. Telescoped reaction for the synthesis if the difluorinated ester 
With the ester in hand, the next step was a hydrolysis to give the 2,2-difluoro-5-hexenoic acid. 
This was readily accessible from the ester through the use of LiOH in THF/H2O, with the acid 
obtained in a very high 89% yield. 
 
Scheme 59. Synthesis of 2,2-difluoro-5-hexenoic acid 
The acid 188 could then be subjected to Curtius rearrangement conditions that had been 
previously optimised, with DPPA followed by BnOH addition (Scheme 60). However, when 
using these conditions, no identifiable product could be observed. To try and simplify the 
reaction, the procedure was performed without the benzyl alcohol allowing for isolation of 
88 
 
the isocyanate product, which could then be subjected to either hydrolysis or benzyl alcohol 
conditions in a separate step. When the reaction was tested, the only product that was 
isolated was the difluorinated phenyl ester 189 with no isocyanate observed. It is believed 
that the DPPA formed the acyl azide as expected, but the intermediate does not undergo 
decomposition and rearrangement. Instead, the acyl azide is likely intercepted with phenol to 
give the phenyl ester 189 in 34% yield (Scheme 60). The sources of phenol are most likely 
from either the DPPA or phosphoryl by-products which may have liberated phenol at the 
elevated temperatures.  
 
Scheme 60. Attempts at the Curtius rearrangement 
To try and prevent the formation of the phenyl ester and to allow for isolation of the 
isocyanate, the reaction was modified to remove the DPPA. Instead the acyl azide was formed 
through the synthesis of acyl chloride 190 from acid 188 through the use of oxalyl 
chloride/DMF followed by sodium azide addition to the crude acyl chloride to give a crude 
acyl azide 191 (Scheme 61). Further purification of the acyl chloride or the acyl azide was not 
performed to try and prevent hydrolysis back to the starting carboxylic acid. Formation of the 
acyl azide was confirmed by infra-red (IR) spectroscopy with a distinctive azide stretch 
observed at 2148 cm-1. The crude acyl azide was then heated in dry toluene to 100 °C to try 
and effect the Curtius rearrangement and isolate the isocyanate. This reaction was monitored 
by taking aliquots for IR analysis at 1, 13 and 20 hours, with an expected isocyanate stretch 




Scheme 61. Alternative procedure for the Curtius rearrangement 
After 20 hours of reaction, the azide peak had completely disappeared, but over the course 
of the reaction no isocyanate was observed by IR and no free amine was recovered on 
workup. This suggests that the C-C bond which would normally insert into the nitrene is not 
nucleophilic enough, most likely because of the electrophilicity of the difluoro group. Due to 
this, a Curtius rearrangement approach will therefore likely be unfruitful for synthesising the 
2,2-difluoroamine. Despite investigation of the literature, no alternative procedures were 
found that may enable the synthesis of a 2,2-difluoroamine, so further attempts at isolating 
the 2,2-difluoropyrroldine were not pursued. 
3.1.3. Synthesis of 3,3-difluoro precursors 
While this approach was not feasible for the 2,2-difluoroamine, there remained the possibility 
of using the Deoxo-Fluor® procedure in the synthesis of the 3,3-difluoroamine. To do this, the 
synthesis would need to be modified to use allylmagnesium bromide instead of forming the 
Grignard reagent from 4-bromobut-1-ene. Unfortunately, addition of allyl Grignard into 
diethyl oxalate was not successful despite multiple attempts, with only decomposition or 
multiple side products observed in the reaction (Scheme 62). It was reasoned that the allyl 
group may undergo a rearrangement to form the conjugated ketone which could then lead 




Scheme 62. Attempted addition of allylmagnesium bromide to diethyl oxalate 
After searching the literature, an alternative procedure was found for the synthesis of the 
desired difluoroester from ethyl bromodifluoroacetate 193. The method involved the use of 
copper powder and allyltributylstannane, with the authors suggesting the formation of a 
tributyl tin radical abstracting the bromide from ethyl bromodifluoroacetate.104 This radical 
could then react further with the allyltributylstannane to form the desired product. However, 
the report gave no procedure or quantities for the synthesis. Fortunately, further literature 
investigation found a patent with a very similar method to produce the desired ester.105 The 
method employed ethyl iododifluoroacetate and allyl bromide as the coupling reagents, 
which was much more appealing as it avoided the use of toxic stannanes. Due to availability 
of materials, ethyl iododifluoroacetate was replaced with ethyl bromodifluoroacetate 193 
and the reaction tested. Gratifyingly, the reaction proceeded and the product was obtained 
in 26% yield (Scheme 63).  
 
Scheme 63. Allylation of ethyl bromodifluoroacetate 
The main difficulty with this reaction was the isolation of the product. The difluorinated ester 
185 was volatile and could only be isolated through bulb-to-bulb distillation.105 The following 
step in this reaction was the formation of the amide 183 by treatment of the ester with 
ammonium hydroxide in THF. To try and prevent loss of the ester, the reaction was telescoped 
to include the amidation of the crude ester after an aqueous workup (Scheme 64). Despite an 
additional step, the formation of the amide 183 was achieved in 40% yield over two steps, a 




Scheme 64. Telescoped allylation and amidation 
To obtain the desired Cbz protected amine, the amide was reduced using LiAlH4 and the 
resultant amine trapped as the HCl salt. The amine hydrochloride was then ‘cracked’ with 
K2CO3 and subjected to benzyl chloroformate to give the Cbz protected amine 178 in 42% 
yield over the 3 steps. The Cbz amine 178 could then be subjected to the metathesis 
procedure, as had been done for other 3,3-disubstituted substrates, which yielded the 
metathesis product in a moderate yield of 45% (Scheme 65).  
 
Scheme 65. Reduction and Cbz protection of 2,2-difluoroamide with subsequent metathesis  
With the metathesis product in hand, the cyclisation procedure could then be tested. To 
obtain a racemate of the product for HPLC analysis, the 3,3-difluoro precursor was treated 
with rac-CSA in DCE at 50 °C. Unfortunately, no reaction was observed, with no product 
observed in the crude NMR. The reaction was also repeated with both (R)-TRIP and (R)-TiPSY 
catalysts in cyclohexane at 80 °C to test the optimised procedure for the asymmetric 
cyclisation. This also gave no observable product when analysing the crude NMR, with only 




Scheme 66. Attempted cyclisation of 3,3-difluoro pyrrolidine  
The difficulty in trying to cyclise the precursor 194 was disappointing and it was reasoned that 
this poor reactivity was from electronic effects over steric effects. As stated earlier the relative 
size of the fluorine atom is small, and considering the propensity for sterically bulky 
substrates, such as the cyclohexyl-spiropyrrolidine to cyclise, steric effects were ruled out as 
the reason for this lack of reactivity. However, the high electrophilicity of fluorine may have 
reduced the effective nucleophilicity of the nitrogen atom. From this we can also infer that 
the 2,2-difluoro pyrrolidine would also be difficult to cyclise as the effects of the fluorine 
would be even more pronounced when α to the amine. Therefore, it was concluded that the 
synthesis of difluoro pyrrolidines using this methodology would not be possible. 
3.2. Methyl substitution on Michael acceptor 
Another avenue of interest was the introduction of a methyl group to the double bond of the 
Michael acceptor before cyclisation. Methyl substitution at the 5-position of the pyrrolidine 
would create a tetrasubstituted pyrrolidine giving access to novel enantiomers as well as  a 
new quaternary centre. Introduction of an R group at the position alpha to the carbonyl would 
result in new diastereomers as analogues of pharmaceutically relevant compounds. A series 
of patents for kinase inhibitors show several drug molecules that use pyrrolidines as a 
terminal substructure in the active compounds.106–109 Typically, the pyrrolidine is synthesised 
as an analogue of L-β-homoproline which is then coupled to the core of the drug through the 




Figure 14. Intermediates in the synthesis of kinase inhibitors 
While these examples demonstrate an aryl substitution at the α-position, using methyl as an 
initial substituent would serve as a benchmark for reaction feasibility and the possibility of 
further substitution.  
To introduce the methyl group, the procedure for the synthesis would have to be modified. 
To ensure both good conversion and enantioselectivity, it was decided to begin by testing the 
3,3-dimethyl precursor, as this had given some of the best results in the initial cyclisation 
procedure. In order to produce a tetrasubstituted pyrrolidine 200, the allyl bromide used in 
the alkylation of isobutyronitrile 128 would have to be replaced with 3-bromo-2-
methylpropene. This could then be subjected to the metathesis conditions with the p-tolyl 
thioacrylate to give the double bond with methyl substitution at the β-position to the 
carbonyl. Introduction of the methyl at the α-position of the carbonyl would be done through 
modification of the thioester. Replacing acryloyl chloride with methacryloyl chloride would 
enable the synthesis of the p-tolyl 2-methyl-thioacrylate 203 to give the correct substitution 




Scheme 67. Retrosynthetic analysis for the introduction of a methyl group onto cyclisation precursors 
For the forward synthesis, the modified allylation of isobutyronitrile with 3-bromo-2-
methylpropene gave a moderate yield of 50% for the nitrile 204 (Scheme 68). Subsequent 
reduction with lithium aluminium hydride and protection with benzyl chloroformate gave the 
Cbz protected amine 201 in 57% yield over the 2 steps. 
 
Scheme 68. Forward synthesis of methyl substituted Cbz amine 
Similarly, the modification of the thioacrylate synthesis proved fruitful, giving the 2-methyl-
thioacrylate 203 in a high yield of 86% (Scheme 69). The yield of this product was noticeably 
higher than that of the unsubstituted thioacrylate (68%), possibly due to less side reactions 
of the thioacrylate product. The unsubstituted thioacrylate shows a certain amount of 1,4-
addition by-product from attack of the p-thiocresol during the reaction, but this is not 




Scheme 69. Forward synthesis of methyl substituted thioacrylate 
With the methyl substituted precursors in hand, the next step was to monitor how each 
compound performed under the optimised metathesis conditions. Unfortunately, neither 
metathesis reaction yielded any of the desired product (Scheme 70). 
 
Scheme 70. Attempted metathesis of methyl substituted precursors 
This result was disappointing but perhaps unsurprising. 1,1-disubstituted olefins are known 
to be less reactive than other monosubstituted olefins, as are α,β-unsaturated olefins, both 
of which are present in the precursors.84 No further attempts were made to obtain the methyl 
substituted precursors using this method as the metathesis did not seem feasible with these 
substrates. Other synthetic routes for introduction of a methyl group may be possible but 




3.3. Summary of results 
Attempts at introducing fluorine around the pyrrolidine ring were not successful. The 
synthesis of the 2,2-difluoro precursor was not possible with the methods attempted, but the 
3,3-difluoro precursor was synthesised after extensive testing of conditions and literature 
research. However, when attempting cyclisation under racemic or asymmetric conditions, no 
product was observed. This lack of reactivity was reasoned to be due to the high 
electronegativity of the fluorine atom affecting the nucleophilicity of the nitrogen atom, 
rendering cyclisation difficult. Introduction of methyl groups to the double bond was also met 
with limited success. Both the methyl substituted thioester and methyl substituted Cbz amine 
were synthesised readily using previously developed methods, however both compounds 
failed to undergo the necessary metathesis reaction to produce the cyclisation precursor.  
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4. Total Synthesis of Natural Products 
The presence of pyrrolidine structures in pharmaceuticals has been documented and, 
according to one study, the pyrrolidine was the most prevalent 5-membered N-heterocycle 
in FDA approved small molecule drugs.1  Pyrrolidines also feature prominently in many 
alkaloids which have been the target of total syntheses.17,110,111 To demonstrate the utility of 
the pyrrolidine thioesters that have been synthesised, total synthesis of a natural product 
seemed a good demonstration. After literature examination, two candidates for total 
synthesis were targeted: (R)-bgugaine 207 and (R)-irnidine 208 (Figure 15). 
  
Figure 15. Natural products (R)-bgugaine and (R)-irnidine 
Both (R)-bgugaine and (R)-irnidine were isolated from the tubers of Arisarum vulgare, a plant 
widespread in Morocco.112–114 In the initial isolation, these compounds were shown to be 
toxic in the brine shrimp bioassay (LC50 of 1.0 and 1.5 µg/ml respectively), with (R)-bgugaine 
demonstrating both antibacterial and antifungal properties.112,113 Subsequently, (R)-bgugaine 
was shown to have affinity for binding to DNA as well as being a strong hepatotoxin in both 
rat liver cells and the human hepatoblastoma cell line HepG2. 115,116 The cytotoxicity effects of 
bgugaine have also been demonstrated in the mouse mastocytoma cell line P815, and the 
human laryngeal carcinoma cell line Hep for both the (R)- and the (S)- enantiomer.117 The IC50 
values were recorded for the mastocytoma P815 as 10 and 5 µml-1 for (R) and (S) respectively, 
with carcinoma Hep requiring 5 and 100 µml-1 for (R) and (S) respectively. It should be noted 
that the (R)-isomer is the natural occurring isomer of bgugaine, and the (S)-enantiomer used 
in this study was acquired through enantioselective synthesis. This makes investigation into 
methods for asymmetric synthesis particularly useful due to the lack of natural source for the 
(S)-enantiomer, which has also been investigated separately for its cytotoxic effects on MRC-
5 fibroblasts.118 While a few racemic and asymmetric syntheses have been developed for the 
synthesis of bgugaine, there are no reports of the asymmetric synthesis of irnidine.  
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The racemic synthesis of bgugaine was achieved by Naito through a radical addition and ionic 
cyclisation of oxime ethers 209 (Scheme 71).119  The reaction utilised triethyl borane as a 
radical initiator to generate an alkyl radical from the alkyl iodide. This radical was then able 
to add to the oxime to produce a nitrogen centred radical which was quenched by triethyl 
borane. The nitrogen-borane ionic adduct could then cyclise by displacing the tosylate group 
with loss of the borane. One of the limitations of the reaction is it uses a large excess of 
reagents to achieve cyclisation, with 20 equivalents of the alkyl iodide required for only 30% 
yield.  
 
Scheme 71. Radical oxime route to the racemic synthesis of bgugaine 
Another synthesis was reported by Huang starting from the lactam 211 (Scheme 72). 
Activation of the amide was achieved using triflic anhydride and 2,6-di-tert-butyl-4-
methylpyridine (DTBMP). This led to an O-sulfonated iminium intermediate 212 that enabled 
addition of the Grignard reagent. After the addition, the intermediate triflate 213 was then 
reduced with lithium aluminium hydride to yield the natural product in 75% yield as a one pot 
procedure.120  
 
Scheme 72. One-pot reductive alkylation of lactams as a method for the synthesis of racemic bgugaine 
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For an asymmetric synthesis of bgugaine there have been 3 main methods of introducing the 
desired stereocentre: using a chiral starting material, a chiral auxiliary, or a chiral ligand during 
a synthetic step. The use of chiral starting material was demonstrated by Tilve et.al. through 
the use of (S)-N-carboethoxy prolinal 214, a derivative of ʟ-proline (Scheme 73).121 Through a 
Wittig condensation, the alkyl chain required for (R)-bgugaine was installed in a 50% yield 
with subsequent transformations yielding the natural product. While this method is useful in 
providing the (R)-enantiomer of bgugaine, the (S) enantiomer could be more difficult to 
obtain in larger quantities using this strategy as it would require starting from ᴅ-proline. This 
can add extra costs as the ‘unnatural’ enantiomer can be up to twenty times more expensive 
than ʟ-proline. 
 
Scheme 73. Asymmetric approach to the synthesis of (R)-bgugaine from chiral starting material 
Another method for the introduction of the desired stereocentre, is the use of a chiral 
auxiliary during the synthesis which is then later removed. One of the main advantages of this 
method is that the option for synthesizing opposite enantiomers can be more readily available 
than when using chiral starting materials. The earliest example of the synthesis of (R)-
bgugaine was reported by Jossang et.al. where 4-oxooctadecanoic acid 216 underwent a 
condensation reaction with (R)-phenylglycinol to form the bicyclic lactam 217 in 89% yield 
(Scheme 74).122 Treatment of LiAlH4/AlCl3 simultaneously reduced the lactam carbonyl and 
selectively ring-opened the oxazole to afford pyrrolidine 218 in 75% yield. Removal of the 
auxiliary and N-methylation led to (R)-bgugaine. This methodology has also been employed 





Scheme 74. Asymmetric approaches to the synthesis of (R)-bgugaine using a chiral auxiliary 
An alternative approach has been to form chiral amines through nucleophilic addition to 
chiral imines. One example by Enders and Thiebes utilized the (S)-1-amino-2-
methoxymethylpyrrolidine (SAMP) chiral auxiliary to form hydrazone 219 (Scheme 75).123 
Tetradecyl lithium was then used as a nucleophile to give the hydrazide 220 in high 
diastereoselectivity (≥96% de) and yield (85%). Successive manipulations led to the natural 
product while maintaining the selectivity in the addition, with (R)-bgugaine synthesised with 
≥96% ee.  The same synthetic steps were used to synthesise (S)-bgugaine with an ee of 92% 
by using the opposite enantiomer of the chiral auxiliary, RAMP. 
 
Scheme 75. SAMP approach to asymmetric synthesis of (R)-bgugaine 
Another auxiliary used in the synthesis of chiral amines is the ‘Ellman’ (R)-tert-
butylsulfinamide auxiliary. This approach was exploited by Shu et.al. with an asymmetric 
Grignard addition to the aldimine 221, to isolate sulfinamide 222 in 84% yield as a single 
diastereomer (Scheme 76).124,125 Removal of the auxiliary and replacement with a tosyl 
protecting group gave the chiral homopropargyl amide 223 in 78% yield over the two steps. 
This product could then undergo a gold catalyzed oxidative cyclisation to yield the lactam 224 





Scheme 76. Ellman auxiliary route to the asymmetric synthesis of (R)-bgugaine 
The only other asymmetric synthesis of (R)-bgugaine was reported by Takahata et.al. and 
employed a Sharpless asymmetric dihydroxylation and epoxidation to give the epoxide 225. 
This could then undergo selective ring-opening with tridecanylmagnesium bromide to give 
the hydroxy phthalimide 226 in 75% yield, which was subsequently deprotected and 
reprotected to give the Cbz amine 227 in 79% yield. Further transformations led to the 
isolation of the natural product and, by modification of the Sharpless asymmetric 
dihydroxylation catalyst system, (S)-bgugaine was also isolated.  
 
Scheme 77. Asymmetric approach to the synthesis of (R)-bgugaine through ring opening of a chiral epoxide 
As stated earlier, the asymmetric synthesis of irnidine has not been achieved, but a racemic 
synthesis has been reported Zhang et.al. 126,127 The key step in the formation of the pyrrolidine 
ring was a base catalysed intramolecular hydroamination of conjugated enyne 228 to give 
allene 229 in 95% yield (Scheme 78). An alkyne zipper reaction was then used to give the 
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terminal alkyne 230 in good yield. Sonogashira coupling of 2-iodoanisole and reduction of the 
alkyne led to the formation of racemic irnidine in reasonable yields.  
 
Scheme 78. Racemic synthesis of irnidine 
While there are a few examples for the asymmetric synthesis of bgugaine, most introduce the 
stereocentre with chiral auxiliaries, and the only catalytic system still required stoichiometric 
quantities of oxidant. The chiral phosphoric acid catalysed cyclisation reported in this thesis 
offers the opportunity to create a novel catalytic method for the asymmetric synthesis of (R)-
bgugaine and the first asymmetric synthesis of (R)-irnidine from a common intermediate. In 
order to achieve the highest possible enantiomeric ratio, the unsubstituted pyrrolidine was 
synthesised using (R)-TiPSY as the chiral catalyst to give an er of 94:6 for all starting 
pyrrolidines in this section.   
4.1. Wittig route 
The pyrrolidine thioester 164 can supply the core of both bgugaine 207 and irnidine 208. 
Therefore, the main transformations required in the synthesis are the introduction of the alkyl 
chain to the 2-position and the conversion of Cbz to an N-methyl group. Access to the N-
methyl should be simple, as Cbz can be converted directly into a methyl via reduction with 
LiAlH4. Another process can be the removal of the Cbz followed by reductive amination with 
formaldehyde. The more problematic part of the synthesis is the installation of the sidechain. 
Initially, it was hoped that the molecule could be synthesised via a Wittig reaction (Scheme 
79).  Reduction of the thioester 164 to the corresponding aldehyde 234 could then allow for 
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a Wittig reaction to give alkenes 232 and 233. Further reductions of the alkene and Cbz could 
then lead to the natural products.  
 
Scheme 79. Retrosynthetic analysis via aldehyde formation and Wittig reaction 
The transformation of thioesters into aldehydes offer a few synthetic challenges, mainly 
controlling the level of reduction, as it can be possible to over reduce the more reactive 
aldehyde and obtain an alcohol. To try and counter this, methods of reduction have been 
investigated to reduce thioesters which stop at the aldehyde without over reduction. One of 
the earliest methods  reported is the Fukuyama reduction using triethylsilane as the reducing 
agent, and was developed as an approach for accessing aldehydes from carboxylic acids 
without reduction to the alcohol and subsequent oxidation.128 In the presence of catalytic 
palladium in acetone, triethylsilane was able to reduce ethyl thioesters to the aldehyde in 
good to excellent yields. However, when this procedure was attempted on thioester 164, no 
aldehyde was formed and only decomposition was observed (Scheme 80). Another similar 
method was developed shortly after by Sonoda to reduce aryl thioesters in the presence of 
thioalkenes using tributyltin hydride and a palladium catalyst.129 Again the conditions were 
tested on thioester 164 but failed to yield any product with 86% of starting material recovered 




Scheme 80. Attempts at palladium catalysed reduction of thioester 
As the palladium reactions were unsuccessful, an alternative approach was considered. The 
use of DIBAL-H to reduce esters to aldehydes is well practiced in organic synthesis, and there 
have also been reports of this approach being applied to thioesters.130 The main difficulty in 
using this reagent is DIBAL-H can also be used to reduce esters to alcohols if conditions are 
not controlled.  However, by maintaining cryogenic temperatures and using controlled 
addition of the reducing agent, DIBAL-H was able to reduce the thioester 164 to the aldehyde 
234 in 33% yield which matched literature data.131 While the reduction was successful, the 
low yield for this reaction was not encouraging and this route was not investigated further.  
 
Scheme 81. Reduction of thioester to aldehyde with DIBAL-H 
4.2 Liebeskind-Srogl coupling route 
As the Wittig route had been abandoned, other methods for the introduction of the sidechain 
were researched. One such reaction is the Liebeskind-Srogl coupling, a cross coupling reaction 
between thioesters and aryl boronic acids to synthesise ketones.132 The reaction has also been 
modified to introduce alkyl chains by replacing the boronic acid with a B-alkyl-9-BBN 
derivative.133 By using the modified procedure it should be possible to couple the correct side 
chains for the natural products, and then remove the ketone through a deoxygenation 





Scheme 82. Retrosynthetic analysis via Liebeskind-Srogl coupling and deoxygenation 
The alkyl boron reagent can be synthesised readily via the hydroboration of the relevant 
alkene using 9-BBN under inert conditions to prevent oxidation to the alcohol. To install the 
sidechain of bgugaine, the alkene required is commercially available 1-dodecene, but the 
alkene required for irnidine needed to be synthesised. This was achieved through lithiation of 
2-bromoanisole 237 with s-BuLi followed by alkylation with 1,4-dibromobutane to give 
bromide 238 in 33% yield (Scheme 83).134 This low yield is likely due to overreaction with the 
lithiated anisole, giving a double addition product, as well as difficulties in separating the 
starting material and product with chromatography. The low yield was offset by the reaction 
being performed on a multigram scale to give good quantities of material for further 
reactions. The bromide 238 the underwent nucleophilic substitution with allylmagnesium 
bromide to give the alkene 239 in 47% yield. 
 
Scheme 83. Alkene synthesis for irnidine sidechain 
With the alkene in hand, the Liebeskind-Srogl coupling could be tested. As mentioned earlier, 
the alkenes could be converted easily into the B-alkyl-9-BBN derivative through addition of 9-
BBN. This solution of the boron reagent was then added to a degassed solution of the 
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thioester with CuTC, Cs2CO3 and the palladium catalyst. The reaction proceeded smoothly for 
both reagents, with the dodecyl product 235 isolated in 77% yield and the (2-
methoxyphenyl)alkyl product 236 isolated in 73% yield. 
 
Scheme 84. Liebeskind-Srogl coupling to install the alkyl sidechains of bgugaine and irnidine 
4.2.1 Alcohol deoxygenation 
Once the ketones were synthesised, the next step was deoxygenation, for which multiple 
methods exist in the literature. The first of these that was investigated was a Barton-
McCombie deoxygenation of a xanthate ester.135 The deoxygenation occurs when tributyltin 
hydride and AIBN are used to effect a homolytic cleavage of the C-O bond of a xanthate ester. 
Quenching of the carbon radical by hydrogen atom transfer then leads to the overall 
replacement of a C-O bond with C-H. In the case of the Liebeskind-Srogl coupled products, 
the ketone must be reduced to the secondary alcohol in order to then form the required 
xanthate ester.  
As the natural product had an N-methyl group, the global reduction using lithium aluminium 
hydride would allow for the synthesis of both the secondary alcohol and the reduction of the 
Cbz. This was done with a large excess of reducing agent and the product used without further 
purification. The secondary alcohol was deprotonated using sodium hydride/imidazole and 
intercepted with carbon disulfide to form the xanthate sodium salt, which was then alkylated 
using methyl iodide to form the xanthate ester. However, the excess of methyl iodide also 
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produced the quaternary ammonium salts 240 and 241 through over alkylation of the 
nitrogen in low to moderate yields (Scheme 85).   
 
Scheme 85. Formation of xanthate esters 
While this reaction was unforeseen, it did indicate that a global reduction strategy would not 
be useful. Therefore, separate reduction steps would be required, and the ketone was 
reduced using sodium borohydride. This preceded smoothly giving near quantitative yields 
for both substrates 242 (98%) and 243 (100%) (Scheme 86). 
 
Scheme 86. Reduction of ketone with sodium borohydride 
With the secondary alcohols in hand, the formation of the xanthate was tested using the same 
conditions as before (deprotonation with NaH, trapping with CS2, and methylation with MeI). 
While formation of a quaternary ammonium was not observed, another product was formed 
instead of the xanthate ester. During deprotonation of the secondary alcohols, a cyclization 
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of the alkoxide onto the Cbz protecting group occurred to form the cyclic carbamates 244 and 
245 (Scheme 87). The location of the alcohols meant that a 6-exo-trig ring closure could occur 
preferentially to an intermolecular reaction with carbon disulfide.  
 
Scheme 87. Attempted formation of xanthate ester and resultant carbamate cyclisation 
The cyclisation of alcohols onto a Cbz group has been reported before by Cossy and Pardo as 
a method of determining the relative stereochemistry of trifluoromethyl pyrrolidines.136 The 
use of DAST and pyridine in dichloromethane led to the formation of a bicyclic system from 
trifluoromethyl pyrrolidines 246 and 248 (Scheme 88). NOE studies allowed the group to 
determine the relative stereochemistry of the trifluoromethyl group to the proton of the 
pyrrolidine. 
 
Scheme 88. Studies by Cossy and Pardo into the relative stereochemistry of trifluoromethyl pyrrolidines.  
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Comparison of the 1H NMR data for the bicyclic products 247 and 249 reported by Cossy and 
Pardo enabled easier assignment of the bicyclic carbamates synthesised in Scheme 87. 
Attempted formation of xanthate ester and resultant carbamate cyclisation. Figure 16 shows 
a section of the 1H NMR of product 244 with the key C-H peaks for the bicyclic product 
highlighted. The protons assigned as H-7 allow for a determination of the diastereomeric ratio 
of the sodium borohydride reduction as 6:1, although further NOE studies to determine the 
relative stereochemistry were not performed, as this was deemed unnecessary for the 
purposes of the total synthesis.  
 
Figure 16. 1H NMR spectrum of bicyclic carbamate 244 showing key identifying peaks 
This result meant that any steps involving the deprotonation of an alcohol would likely be 
unproductive when trying to remove the alcohol. To try and counter this, an alternative 
approach was tested through the tosylation of alcohol 242 and 243. As pyridine is used in this 
reaction, it does not deprotonate the alcohol but acts as a base to sequester HCl as a by-
product. Unfortunately, no product was isolated from this reaction and starting material was 




Scheme 89. Attempted tosylation of alcohol 
As the alcohols had proved resistant to deoxygenation, efforts were instead focused on the 
manipulation of the ketone for a more direct removal of the oxygen.  
4.2.2 Dithiolane synthesis 
One method that can be used to reduce ketones to an alkane is through a desulfurization 
reaction, which proceeds via the formation of a dithioacetal, followed by reduction with 
Raney®-Nickel under a hydrogen atmosphere.137 The desulfurization is seen as a milder 
version to other related reductions such as the Clemmensen or Wolff-Kishner reductions 
which generally require more forcing conditions (strong acids or bases, and heat). The 
desulfurization conditions (Raney®-Nickel/H2) may also lead to deprotection of the Cbz group, 
but as there are methods for introduction of the N-methyl, this reaction would not affect the 
overall step count.  
The formation of the thioacetal of ketones 235 and 236 was performed using 1,2-
ethanedithiol with boron trifluoride diethyl etherate as the Lewis acid.138 Dithiolanes 250 and 
251 were isolated in 30% and 33% yield respectively (Scheme 90). It was theorised that the 
low yields were due to side reactions of the BF3·Et2O with the Cbz group, as BCl3 had been 
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previously shown to deprotect the pyrrolidine. As the yields were particularly low, this route 
was not investigated further. 
 
Scheme 90. Synthesis of dithiolanes 
4.2.3 Wolff-Kishner reduction 
An alternative to the desulfurization reaction that can be used to reduce a ketone to an alkane 
is the Wolff-Kishner reduction.139 This reaction is generally performed through the in situ 
generation of a hydrazone from a ketone or an aldehyde using hydrazine hydrate. The 
hydrazone is then heated in the presence of a strong base to generate the alkane through loss 
of N2. While this can be effective in deoxygenating the relevant compound, the forcing 
conditions can be unsuitable for certain substrates, and functional group tolerance can be 
low. To circumvent this, a number of modifications have been developed that can use lower 
temperatures or milder reagents to effect the same result. One such procedure is the Caglioti 
modification, which uses p-tosyl hydrazide in place of hydrazine hydrate and replaces the base 
with a hydride source.140 The original conditions tested the deoxygenation of various steroids 
by forming the tosylhydrazone which was then refluxed in THF (66 °C) in the presence of 
lithium aluminium hydride to afford the alkane. These conditions were appealing for the 
synthesis of bgugaine and irnidine, as the use of LiAlH4 would provide a telescoped reaction 
where both the ketone could be removed and the Cbz group could be converted into the N-
methyl group required in the product.  
To test this, the tosylhydrazone of ketone 235 was formed through addition of p-tosyl 
hydrazide in MeOH with a catalytic amount of acetic acid. The formation of the hydrazone 
was monitored by TLC and, once all the ketone had been consumed, the reaction was 
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quenched. After an aqueous work up the crude hydrazone was passed through a silica pad 
filtration to remove excess hydrazide and the tosyl hydrazone was used without purification. 
Subjecting the hydrazone to LiAlH4 conditions resulted in multiple decomposition products, 
with no isolatable quantity of product (Scheme 91). This reaction was only tested on the 
dodecyl ketone 235 due to availability of material. 
 
Scheme 91. Attempted Wolff-Kishner reduction using lithium aluminium hydride for global reduction 
As the LiAlH4 had not been successful, it was deemed prudent to test the reaction in a 
sequential manner by performing the Wolff-Kishner reduction with a milder reducing agent 
first, and then convert the Cbz to the N-methyl in a separate step. The reaction was tested on 
both the dodecyl 235 and (2-methoxy-phenyl)-heptanyl 236 ketones with sodium 
borohydride used as the reducing agent in THF/H2O. While the reaction failed to yield product 
for the dodecyl ketone, the irnidine precursor 253 was isolated in 33% yield (Scheme 92).  
 
Scheme 92. Wolf-Kishner reduction using sodium borohydride in THF/H2O 
It is unclear as to why this reaction did not work for the dodecyl substrate, but the results for 
the irnidine precursor were promising. Upon literature investigation, a report by Kim showed 
the use of zinc-modified cyanoborohydride as a selective reducing agent that could be applied 
to the deoxygenation of aldehydes and ketones via tosylhydrazones.141 This reducing agent 
has also been applied to the construction of Iboga alkaloids by Sames for the deoxygenation 
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of sterically hindered tosylhydrazones.142 Application of this method on dodecyl ketone 235 
resulted in a very good yield of 81% for bgugaine precursor 252, while ketone 236 gave a 
minor improvement over the sodium borohydride reduction with a yield of 40% the irnidine 
precursor 253 (Scheme 93). While the improvement for the irnidine precursor was not 
substantial, the ability to isolate the bgugaine precursor in a high yield using this reaction 
procedure gives more synthetic viability to this route than the other approaches tested.  
 
Scheme 93. Wolff-Kishner reduction using sodium cyanoborohydride 
Reduction of the Cbz group with LiAlH4 had already been demonstrated when attempting the 
Barton-McCombie deoxygenation previously. Following the same method with an excess of 
LiAlH4 in THF, revealed (R)-bgugaine 207 in 68% yield and (R)-irnidine 208 in 88% yield with 
both compounds matching spectroscopically to the literature (Scheme 94).112,113  
 
Scheme 94. Cbz reduction to reveal the natural products 
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Optical rotations can be used as a measure for the enantiomeric purity of a synthesised 
compound through calculation of the enantiomeric ratio. The natural products were 
synthesised from the starting pyrrolidine 164 cyclised by the (R)-TiPSY with an enantiomeric 
ratio of 94:6. Racemisation of the chiral centre of the pyrrolidine was not expected in any of 
the synthetic steps, but comparison of the optical rotation with the literature reported values 
would provide a good confirmation. The values measured for each product are listed in Table 
8 along with the literature values and form these the enantiomeric ratio calculated. For (R)-
bgugaine, the er had apparently dropped from 94:6 to 92:8 (entry 1), while for (R)-irnidine 
the er had increased to 95:5 (entry 2). While the calculated values do not exactly match those 
expected, the difference is not great, and error in either measuring the optical rotation or the 
concentration of the product being analysed could account for those errors. Importantly, both 
compounds rotated the plane of polarised light in an l-rotary direction, indicated by the 
negative sign. Both the measured and literature values demonstrate a negative sign, which 
shows that the synthesised compounds were both the (R) enantiomers. 
Table 8. Optical rotations of the natural products compared to literature values 
Entry Compound Measured [α]D20 Lit. [α]D20 Calculated er Expected er 
1 (R)-bgugaine -35.9° MeOH -42.5° MeOH 143 92:8 94:6 
2 (R)-irnidine -18.2° CHCl3 -20.0° CHCl3 113 95:5 94:6 
NMR analysis confirmed the synthesis of the natural products. In the case of (R)-bgugaine the 
1H NMR showed an integration of 39 protons corresponding to the number of protons in the 
natural product (Figure 17). A triplet with an integration of 3H was observed at 0.84 ppm, 
alongside a large peak at 1.34 – 1.06 ppm which integrated to 25H. Both of these peaks are 
indicative of a long aliphatic chain, as seen in (R)-bgugaine. The N-Me group is also distinctly 
visible at 2.29 ppm integrating to 3H, while the CH2 protons in the pyrrolidine ring α- to the 
nitrogen are indicated by the peaks at 3.05 and 2.10 ppm. These assignments are supported 





Figure 17. 1H NMR spectrum of (R)-bgugaine 
For (R)-irnidine assignments of the 1H NMR were performed in a similar way to (R)-bgugaine 
and the 1H NMR spectra for (R)-irnidine is shown in Figure 18. Upon integration of the peaks, 
the total number of protons was calculated as 35, equal to the number of protons in (R)-
irnidine. The N-Me peak was observed at 2.29 ppm, analogous to that of (R)-bgugaine, and 
the additional CH3 peak for the O-Me was assigned as the singlet at 3.81 integrating to 3H. 
The aromatic protons are shown as a zoomed in region in Figure 18, and splitting pattern 
analysis supports the assignment of an ortho substitution pattern on the aromatic. The CH2 
protons in the pyrrolidine ring α- to the nitrogen are indicated by the peaks at 3.05 and 2.13 
ppm, again analogous to those seen in (R)-bgugaine. Another indicative peak of the side chain 
is the triplet at 2.58 integrated to 2H, which corresponds to the CH2 adjacent to the aromatic. 
Comparison with the literature supports these assignments and indicates successful synthesis 




Figure 18. 1H NMR spectrum of (R)-irnidine 
4.3. Summary of results  
(R)-Bgugaine 207 was synthesized in a 33% overall yield in 6 steps from a simple Cbz protected 
amine 162 while (R)-irnidine 208 was synthesized for the first time in an overall yield of 18% 
over 6 steps. After research into routes via a Wittig olefination, a Barton McCombie 
deoxygenation, and a desulfurization reaction proved unproductive, the asymmetric total 
synthesis of (R)-bgugaine 207 and (R)-irnidine 208 was achieved via a metathesis and 
asymmetric cyclisation reaction to give a pyrrolidine core for both molecules. A Liebeskind-
Srogl coupling allowed for the selective installation of the side chain required for each natural 
product.  Fine tuning of a Wolf-Kishner reaction enabled and deoxygenation in moderate to 
high yields and subsequent LiAlH4 reduction allowed access to the natural products in high 
yields. Analysis of the products and comparison with literature data confirmed the 
enantioselective synthesis of the natural products, for both natural enantiomers. 
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5. Desymmetrisation of Prochiral Amines 
The total synthesis of (R)-bgugaine and (R)-irnidine demonstrated a viable synthetic pathway 
to produce pyrrolidine alkaloids using our methodology. While this is useful for synthesising 
alkaloids that contain a single pyrrolidine core, there remained the possibility of synthesising 
another class of alkaloids containing a pyrrolizidine core using this methodology. Pyrrolizidine 
alkaloids are widely found in nature in plants, microorganisms and animals.144 They have a 
range of biological activity and often show toxicity in humans and this activity has been 
exploited in the development of pharmaceuticals, which will be discussed later.144 Some 
general motifs observed for pyrrolizidine alkaloids are shown in Figure 19, and the general 
atomic numbering shown on compound 254.145 Substitution around the pyrrolizidine can vary 
but the 1,2-unsaturated 255 structures show a general trend of enhanced toxicity from 
cytochrome P450 3A4 mediated metabolic pathways.146 The metabolites of various 
pyrrolizidine alkaloids were shown to induce toxicity in human, pig, rat, and mouse liver 
microsomes, with humans being particularly susceptible to hepatotoxicity.147  
 
Figure 19. Structural motifs of pyrrolizidine alkaloids 
Despite the toxicity of pyrrolizidine alkaloids, there are a number of examples that show 
pharmacological properties, including anti-microbial, anti-inflammatory, anti-cancer and anti-
HIV activity.144  Usaramine 258 (Figure 20) is a pyrrolizidine alkaloid isolated from Crotalaria 
retusa seeds and its activity against biofilm formation of Staphylococcus epidermidis was 
studied.148 While the usaramine did not significantly impact the growth of the bacteria, the 
formation of biofilm was inhibited by 50% with a dosage of 1 mg/ml.148 In the same study, 
another related alkaloid monocrotaline 259 (Figure 20) was extracted from C. retusa seeds 
which showed activity against the parasitic protozoan Trichomonas vaginalis. Treatment of 
the protozoan with monocrotaline 259 at a dosage of 1 mg/ml killed 74% of the parasitic cells 
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whilst showing no cytotoxicity to vaginal epithelial cells, making it a potential topical 
treatment for the disease.148  
 
Figure 20. Pyrrolizidine alkaloids with pharmacological applications.   
 
A potential anti-cancer compound that has attracted interest in the treatment of leukaemia 
is indicine N-oxide 260 (Figure 20).149,150 In one study of 22 patients with acute and chronic 
leukaemia, the use of indicine N-oxide 260  with a dosage between 3.0-3.75 g/m2 over 5 days 
resulted in complete remission for 3 patients and partial remission for 2 patients.149 However, 
one patient of the 22 suffered liver failure and higher doses were shown to increase the 
incidence of severe hepatotoxicity. In a phase II clinical trial of 46 patients, lower doses of 2.0-
2.5 g/m2 were given over a 5 day period but showed a reduced response against the cancer 
when compared to the 3.0 g/m2 dosage.150 The trial concluded that, while indicine N-oxide 
260 is active in the treatment of acute lymphoblastic leukaemia in children, the hepatotoxicity 
and narrow therapeutic index mean long term administration of the drug may be unsafe. The 
researchers also suggested that the development of new pyrrolizidine alkaloids, that 
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demonstrate antileukemic effects whilst reducing hepatotoxicity, would be required before 
they could be incorporated into treatments for leukaemia.150  
A series of pyrrolizidine alkaloids extracted from Liparis nervosa were screened for their 
ability to inhibit nitric oxide production in macrophages, which plays a role in the immune 
response.151 While all the compounds screened showed some level of inhibition to nitric oxide 
production, alkaloid 261 (Figure 20) showed the strongest inhibitory effect with an IC50 of 2.16 
± 0.57 µM, whilst showing no cytotoxicity towards the macrophage. The range of alkaloids 
was also tested for potential anti-cancer activity, but no inhibition was observed.151 
It is apparent that having synthetic tools that can enable the formation of novel pyrrolizidine 
alkaloids can be very useful from a medicinal chemistry perspective. The synthesis of 
pyrrolizidine alkaloids has been of interest to chemists for a number of years, with several 
reviews published on recent methodologies.145,152,153 One possible method for synthesising 
pyrrolizidines is through intramolecular aza-Michael reactions and this method was 
demonstrated by the Stockman group in the synthesis of 3,5-disubstituted pyrrolizidines 
(Scheme 95).154 Through a one-pot reductive amination of ketone 262 and subsequent double 
Michael addition, pyrrolizidine 266 was synthesised in 71% yield over 3 steps (Scheme 95).154 
 
Scheme 95. Tandem reductive amination-double Michael addition synthesis of pyrrolizidines 
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While the initial approach demonstrated the use of α,β-unsaturated ethyl esters as Michael 
acceptors, the group also showed an alternative procedure utilising α,β-unsaturated ketone 
(enone) functionality. The use of the enone meant that the previous reductive amination 
strategy was not feasible, so amine functionality was introduced before the formation of the 
enone through the synthesis of Boc amine 267 (Scheme 96). Through a one-pot metathesis 
with enone 268 and TFA mediated double cyclisation, the pyrrolizidine 269 was synthesised 
in 72% yield. The choice of 1-penten-3-one as the metathesis coupling partner was important, 
as the number of carbons on the side chains of pyrrolizidine 269 formed the core of the 
natural product alkaloid cis-223B 271.155,156 Through formation of dithiolane 270 and 
subsequent reduction with Raney® Nickel, the natural product 271 was isolated in excellent 
yields (Scheme 96).154 
 
Scheme 96. Double Michael addition and synthesis of alkaloid cis-223B 
One distinction to note about Stockman’s methodology, is that the procedure forms a meso 
compound. If chirality was introduced during the first cyclisation, it would then be lost during 
the second cyclisation. While this is not detrimental to the synthesis of alkaloid cis-223B 271, 
there are some cases where enantio-enrichment may be beneficial. A later paper published 
by the group shows an adaptation of the reductive amination strategy to synthesise another 
alkaloid (±)-xenovenine 274 as well as alkaloid cis-223B 271 (Scheme 97).157 This procedure 
features a triple reductive amination which allowed for the isolation of (±) xenovenine 274 in 
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24% yield as a single diastereomer. The natural product is not a meso compound (there is no 
plane of symmetry) so an asymmetric reaction could theoretically produce a single 
enantiomer. However, the conditions used do not allow for this as there is no chiral catalyst 
or auxiliary that could give the desired stereochemistry. 
 
Scheme 97. Reductive amination strategy for synthesising alkaloid cis-223B and (±) xenovenine 
While these strategies were unable to produce single enantiomers, the possibility for the 
asymmetric synthesis of bicyclic amines has been demonstrated by the Fustero group in the 
total synthesis of (-)-hippodamine 278 through a desymmetrisation reaction (Scheme 98).158 
The use of a chiral sulfinamide enabled the asymmetric intramolecular aza-Michael reaction 
of amine 275 to give 2,6-substituted piperidine 276 in 89% yield with a 3:1 cis/trans ratio. 
Removal of the chiral auxiliary with HCl/dioxane and treatment of the salt with K2CO3 led to 
a second cyclisation to give quinolizidine 277 in 85% yield and >99% ee. The use of the t-Bu 
ester was essential in achieving high enantioselectivity, as when the corresponding ethyl ester 





Scheme 98. Asymmetric synthesis of (-)- hippodamine 
The formation of a single enantiomer of quinolizidine 277 shows the asymmetric synthesis of 
bicyclic amines through a desymmetrisation procedure to be possible. In the synthesis of (-)-
hippodamine the enantioselectivity was induced through the use of a chiral auxiliary.158 The 
work from Stockman showed that the use of enones as Michael acceptors could be used in a 
metathesis/Michael reaction to effect the synthesis of the racemic pyrrolizidines.154,157 It was 
hypothesised that by replacing the enone with a thioacrylate and application of a chiral 
catalyst would be effective in the asymmetric synthesis of pyrrolizidines. 
5.1. Synthesis of Precursors 
In the work of Stockman, the metathesis reaction of Boc-amine 267  with 1-penten-3-one 
gave a mix of uncyclised and cyclised products, and so was taken through as a mixture to the 
deprotection/second cyclisation step to obtain the pyrrolizidine 269 (Scheme 96).154 In order 
to perform an asymmetric desymmetrisation reaction with (R)-TRIP, the cyclisation precursor 
280 needed to be isolated (Scheme 99). The use of a thioacrylate in a metathesis reaction 
with alkenyl amines without cyclisation has been shown to give high yields in this thesis, and 
it was decided to use this procedure in the desymmetrisation reaction. To employ the 
methodology in line with previous reactions, the Cbz protected amine 281 was required 




Scheme 99. Retrosynthetic analysis for the desymmetrisation reaction 
Amine 282 was prepared using literature procedures and protected with benzyl 
chloroformate to give Cbz amine 281 in 86% yield (Scheme 100).159 Using an excess of 
thioacrylate 134, the metathesis reaction was performed using Hoveyda-Grubbs second 
generation catalyst and copper iodide to give the cyclisation precursor 280 in 77% yield 
(Scheme 100).  
 
Scheme 100. Synthesis of achiral pyrrolizidine precursor 
5.2.  Asymmetric Cyclisation 
With the prochiral amine 280 in hand, the cyclisation was tested with both rac-CSA and (R)-
TRIP to give racemic and enantioenriched pyrrolidines and allow for HPLC analysis. Under the 
racemic conditions A, pyrrolidine 279 was isolated in 60% yield as a mixture of diastereomers 
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(92:8 dr), while asymmetric conditions B gave a slightly higher 77% yield and a dr of 92:8 
(Scheme 101). 
 
Scheme 101. Cyclisation and desymmetrisation reaction to give 2,5-disubstituted-pyrroldine 
To determine both the diastereomeric ratio and enantiomer ratios achieved in the reaction, 
the mixture was analysed by chiral HPLC. Initial screening for the HPLC conditions was 
performed using the racemic substrate, as each diastereomer should have a 50:50 
enantiomeric ratio, which allows for easier determination of product peaks. After screening 
several HPLC conditions, the CHIRALPAK® IG column gave good separation of both 
diastereomers, as well as separating each diastereomer into individual enantiomers (Figure 
21). In the chromatogram, the two peaks for the minor diastereomer are indicated as peaks 
1 and 2 while the major diastereomer peaks shown as peaks 3 and 4. From this the 
diastereomeric ratio was calculated as being 92:8, based on the assumption that both 









































































































































































































































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 29.01 510349.719 4.152 1.611
2 31.41 530868.500 4.319 1.745
3 57.62 5641569.000 45.899 3.349
4 62.46 5608441.500 45.630 3.531  
Figure 21. HPLC chromatogram for cyclisation of pyrrolidine (±)-279 with rac-CSA 
As a secondary confirmation of the diastereomeric ratio, the NMR spectrum of the 
diastereomeric mixture was analysed for key peaks. The complexity of the NMR analysis was 
increased due to the presence of rotamers from the Cbz group. For example, the proton H-14 
is expected to have a splitting pattern of a doublet after coupling to the only adjacent proton 
H-13 (Figure 22). However, the alkene signal at 6.3-6.0 ppm which corresponds to H-14 
showed two large doublets, each with a J value of 15.5 Hz, a magnitude indicative of a trans 
alkene. The presence of these two doublets is expected for a mixture of diastereomers and 
the two larger doublets might be assigned as a 50:50 dr for the mixture. However, the 
presence of smaller overlapping peaks at 6.1-6.0 ppm suggest that these smaller peaks 
correspond to the minor diastereomer (assigned as H-14b), and the larger doublets 




Figure 22. NMR spectrum of the mixture of diastereomers of cyclised pyrrolidine 279 
The assignments for the alkene proton H-13 showed even greater evidence for the presence 
of rotamers and diastereomers. The signal at 7.0-6.8 ppm, can be split into two doublet of 
triplet signals, a splitting pattern that corresponds with the H-13a proton. Like the H-14a 
proton, these two signals correspond to a 50:50 mixture of rotamers, but the peaks for the 
minor diastereomer H-13b were not visible in this region. COSY analysis revealed a minor peak 
at 5.9-5.8 ppm which showed a coupling to the H-14b proton and was assigned to the alkene 




Figure 23. COSY NMR spectrum of the mixture of diastereomers of cyclised pyrrolidine 279 
With two distinct peaks for the H-13 protons, the diastereomeric ratio could be confirmed. 
Integration of all the peaks between 6.3-6.0 ppm and normalisation of the integration value 
to 100 was used to encompass all the rotameric and diastereomeric signals for H-14 (Figure 
22). Integration of the H-13a and H-13b peak gave a ratio of 92.0:6.28 which aligned with the 
value for the diastereomeric ratio of 92:8 dr measured by HPLC. 
Confirmation that the peak H-13b corresponded to the minor diastereomer and that the 
minor diastereomer peaks were overlapping peak H-14 was achieved by isolating the major 
diastereomer through flash column chromatography. In the initial analysis, the mixture of 
diastereomers was isolated as a single fraction during chromatography and was compared to 
the NMR spectrum of the crude reaction mixture to ensure no loss of either diastereomer. 
Repeating the chromatography allowed for isolation of the major diastereomer in order to 
compare peak data. The peaks at 5.9-5.8 ppm for proton H-13b  and at 6.1-6.0 ppm for proton 
H-14b are no longer observed in the NMR spectrum of the major diastereomer  (Figure 24) 
confirming the assignment of the major and minor diastereomers. It also confirms that the 
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two doublets observed for H-14 correspond to rotamers and not to diastereomers (Figure 
24).  
 
Figure 24. NMR spectrum of the major diastereomer of cyclised pyrrolidine 279 
With the HPLC conditions decided upon and diastereomeric ratio confirmed for the racemic 
reaction, the product of the (R)-TRIP reaction could be analysed for enantioselectivity. 
Integration of the chromatogram (Figure 25) showed a diastereomeric ratio of 92:8, the same 
as the racemic reaction. Calculation of enantioselectivity showed the major diastereomer 
having a high enantiomeric ratio of 93:7, with the minor diastereomer being less selective 
with a 56:44 er. This result was very gratifying and demonstrated the potential for this 









































































































































































































































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 29.02 444878.438 3.280 1.600
2 31.34 574038.750 4.232 1.736
3 57.64 834827.313 6.155 3.106
4 61.86 11709307.000 86.332 3.516  
Figure 25. HPLC chromatogram for cyclisation of pyrrolidine 279 with (R)-TRIP 
5.2.1 Determination of stereochemistry 
With high diastereo- and enantioselectivity achieved, the relative stereochemistry of the 
reaction needed to be determined. To do this, NOE studies were performed on the molecule 
to see if there was any through space interaction between protons H-10 and H-7 (Figure 26). 
In the case of a trans configuration (279-trans), no NOE would be observed between H-10 and 
H-7, whereas a cis configuration (279-cis) should show an NOE signal due to the closer 




Figure 26. 3D structures and expected NOE resonance for cis and trans diastereomers 
This method has been used in literature reports to assign the relative stereochemistry for 
structurally similar 2,5-disubstituted pyrrolidines 283-trans and 283-cis (Figure 27).160 In the 
case of pyrrolidine 283-trans no NOE was observed, while an NOE was measured between H-
2 and H-5 for pyrrolidine 283-cis, although no value was reported. 
 
Figure 27. Literature examples of 2,5-disubstituted pyrrolidines. 
The peaks in the NMR spectrum associated with H-7 and H-10 are seen at 4.32 ppm and 3.87 
ppm respectively (Figure 28). When each signal is individually excited, no NOE was seen 
between the two CH protons as indicated in Figure 28. H-10 showed an NOE with the CH2 
protons at the α-position to the thioester (3.4-3.0 and 2.7-2.6 ppm) as well as NOEs to the 
CH2 protons in the pyrrolidine ring (2.3-1.8 ppm). H-7 showed NOEs to the CH2 protons in the 
pyrrolidine and to the CH2 protons in the alkenyl side chain (2.3-1.4 ppm). Due to the 
overlapping multiplets in the CH2 region, the individual signals were not assigned to specific 




Figure 28. NMR spectrum and NOE studies of major diastereomer of pyrrolidine 279  
The lack of an NOE between H-7 and H-10 suggest that the major diastereomer formed was 
the 2,5-trans pyrrolidine. It was also assumed that the stereochemistry for H-7 (which was 
formed from the intramolecular Michael addition of the Cbz amine was (S). This was the same 
stereochemistry as that observed for the unsubstituted pyrrolidine 164, as both reactions 
used (R)-TRIP as the chiral catalyst. Due to time constraints, the deprotection and cyclisation 
to form the pyrrolizidine was not attempted. 
 




A novel asymmetric synthesis of spirocyclic pyrrolidines has been presented through an 
intramolecular aza-Michael reaction catalysed by a chiral phosphoric acid, (R)-TRIP. The use 
of an α,β-unsaturated thioester as a Michael acceptor provided higher yields than the ester 
analogue, and better enantioselectivity than the enone analogue. The scope of the cyclisation 
was demonstrated through the synthesis of a range of 2,2- and 3,3-spirocyclic and 
disubstituted pyrrolidines. Generally high yields and enantioselectivities were observed for 
cycloalkyl substituents, with heterocyclic and diphenyl substituents giving poorer yields and 
selectivity. Deprotection and transesterification conditions were found for the pyrrolidines, 
and formation of the methyl ester enabled the absolute stereochemistry to be assigned as 
(S). 
Adaptation of the synthesis of the cyclisation precursors enabled the introduction of 3,3-
difluoro functionality, although cyclisation of the fluorinated precursor was ultimately 
unsuccessful. This was hypothesized to be due to the high electronegativity of the fluorine 
atoms reducing the nucleophilicity of the nitrogen. Attempts at introducing a methyl group 
onto the double bond of the Michael acceptor were unsuccessful during the metathesis 
reaction used to make the cyclisation precursors. Alternative approaches to install a methyl 
group were not attempted due to time constraints and this avenue of research was 
considered a lower priority. 
The formation of an unsubstituted pyrrolidine was achieved using (R)-TiPSY as a catalyst. This 
unsubstituted pyrrolidine was an analogue of β-homo-proline and could form the core 
structure of several pyrrolidine alkaloids. To that end, the total synthesis of (R)-bgugaine and 
(R)-irnidine was accomplished over 6 steps in 33% and 18% yield respectively. This was 
achieved through a Liebeskind-Srogl coupling to install the relevant side-chain of the natural 
product followed by Wolff-Kishner reduction and LiAlH4 reduction to yield both natural 
products. This marks only the second catalytic asymmetric synthesis of (R)-bgugaine and the 
first asymmetric synthesis of (R)-irnidine. 
The application of the methodology towards the synthesis of natural products was extended 
to a desymmetrisation reaction for the asymmetric synthesis of pyrrolizidines. Initial work 
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demonstrated that the asymmetric cyclisation could be applied to an prochiral amine and 
resulted in isolation of the pyrrolidine in high yields, diastereoselectivity and 
enantioselectivity. The relative stereochemistry was determined through NMR and NOE 
analysis of the major diastereomer which indicated a trans relationship between the CH 
protons at the 2,5 positions of the pyrrolidine. 
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7. Future work 
With promising initial work having been completed with the desymmetrisation procedure, 
the next step would be to investigate the deprotection and second cyclisation to form the 
pyrrolizidine 285. Deprotection could be performed with BCl3 as this was shown to be 
effective in removal of the Cbz group for the spirocyclic pyrrolidines. Alternatively, 
replacement of the Cbz with Boc may allow for a milder deprotection and second cyclisation 
(Scheme 102). 
 
Scheme 102. Possible deprotection/cyclisation conditions to form pyrrolizidines 
The key to this synthesis will be the determination of the stereochemistry of the final 
pyrrolizidine. If the pyrrolizidine formed is a meso compound, then any chirality installed in 
the first cyclisation will be lost. This may be prevented by using a chiral catalyst in the second 
cyclisation to force a specific chirality at the cyclisation position, but this may be a kinetically 
disfavoured reaction. An alternative would be to functionalise the pyrrolidine before the 
second cyclisation on one of the thioester groups (Scheme 103). This should be possible 
through exploitation of the thioester vs α,β-unsaturated thioester reactivity. A report by 
Fujioka that utilises PPh3 and TMSOTf to form an in situ protecting group for an enone whilst 
reducing a ketone on the same molecule.161 The similar reactivity of thioesters to ketones 
should allow for a similar strategy to selectively reduce the saturated thioester. Following 
deprotection and second cyclisation, there would be no plane of symmetry in the molecule, 




Scheme 103. Functionalisation through selective thioester reduction 
Attempts to install a methyl group onto the double bond or fluorine around the pyrrolidine 
ring were not met with success. However, the possibility of introducing further substitution, 
especially fluorine, into the pyrrolidine is still of interest from a medicinal chemistry 
perspective. This could be potentially be done before or after cyclisation (Scheme 104). 
 
Scheme 104. Installation of a heteroatom onto the pyrroldine 
Another area of interest is the application of the α,β-unsaturated thioester as a Michael 
acceptor in the cyclisation of piperidines (Scheme 105). The selectivity observed in the 
pyrrolidine cyclisation have the potential to form enantioenriched piperidines, although 
modifications may be required to the procedure. Changing the substitution of the thioester 
may be necessary in order to improve yields or selectivity, but this tuning ability is what makes 
the thioester an appealing motif. 
 





Unless otherwise noted all compounds were bought from commercial suppliers and used 
without further purification. Where a solvent is described as “dry” it was purified by PureSolv 
alumina columns from Innovative Technologies.  Melting points were determined using a 
Stuart SMP3 apparatus. Infra-red spectra were acquired on a ThermoNicolet Avatar 370 FT-
IR spectrometer. Nuclear magnetic resonance spectra were recorded on a Jeol ECS-400, a Jeol 
500 Avance III HD 500 or a Jeol AV500 at ambient temperature. Coupling constants (J) are 
quoted in Hertz. Mass spectrometry was performed by the University of York mass 
spectrometry service using electron spray ionisation (ESI) technique. Thin layer 
chromatography was performed on glass-backed plates coated with Merck Silica gel 60 F254. 
The plates were developed using ultraviolet light, acidic aqueous ceric ammonium molybdate 
or basic aqueous potassium permanganate. Liquid chromatography was performed using 
forced flow (flash column) with the solvent systems indicated. The stationary phase was silica 
gel 60 (220–240 mesh) supplied by Fluorochem or silica gel Merck TLC grade 11695 supplied 
by Sigma-Aldrich. NMR assignments were made using 2D NMR including COSY, HMBC, HSQC 
techniques which can be accessed at DOI: 10.15124/a01fe9be-9b9e-43ac-8a21-
20a9075784c5. All numbering on the structures below is for the benefit of characterisation 
and does not necessarily conform to IUPAC rules.  
Screening of Michael acceptors in the intramolecular aza-Michael reaction 
2,2-dimethyl-pent-4-enenitrile (129) 
 
To a solution of diisopropylamine (8.59 ml, 61.3 mmol) in dry THF (25 ml) at -78 °C under N2 
was added n-BuLi (2.5 M in hexanes, 66.8 mmol) and the solution stirred for 45 mins. A 
solution of isobutyronitrile (5 ml, 55.7 mmol) in THF (25 ml) was added over 5 mins at -78 °C 
and reaction stirred for 45 mins. Allyl bromide (5.30 ml, 61.3 mmol) was added over 2 min at 
-78 °C and the reaction warmed to room temperature. The reaction was stirred overnight and 
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quenched with 1 M HCl (40 ml). The reaction was partitioned with diethyl ether (30 ml) and 
aqueous phase extracted with diethyl ether (3 x 50 ml), Organic fractions were combined, 
washed with saturated brine solution (2 x 50 ml), dried with MgSO4, filtered and concentrated 
in vacuo. Crude product was purified by bulb to bulb vacuum distillation (25 °C, 0.2 mbar) to 
give 129 as a pale yellow oil (2.93 g, 26.9 mmol, 48% yield). 1H NMR (400 MHz, Chloroform-d) 
δ 5.88 (ddt, J = 16.8, 10.1, 7.3 Hz, 1 H, H-5), 5.23 (dq, J = 10.1, 1.5 Hz, 1 H, H-6), 5.19 (dq, J = 
16.8, 1.5 Hz, 1 H, H-6), 2.28 (dd, J = 7.3, 1.5 Hz, 2 H, H-4), 1.35 (s, 6 H, H-3) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 132.2 (C-5), 124.7 (C-1), 119.9 (C-6), 45.0 (C-4), 32.1 (C-2), 26.2 (C-3) 
ppm; IR (ATR): νmax 3082, 2980, 2937, 2235, 1643, 1469, 1418, 1391, 1370, 1279, 1254, 1192, 
1122, 1083, 1048, 996, 932, 888, 874, 718, 633, 613, 565 cm-1; HRMS (APCI) 110.0961 (M + 
H+. C7H12N requires 110.0964) 
 
(2,2-dimethyl-pent-4-enyl)-carbamic acid benzyl ester (130) 
 
To a suspension of LiAlH4 (484 mg, 12.75 mmol) in dry diethyl ether (25 ml) at 0 °C under N2 
was added nitrile 129 (928 mg, 8.50 mmol) in dry diethyl ether (25 ml) over 5 mins and the 
reaction stirred at 0 °C for 30 mins. The reaction was then warmed to room temperature and 
stirred overnight. The reaction was cooled to 0 °C and quenched with H2O (0.5 ml), followed 
by NaOH solution (15% w/w aq, 0.5 ml), followed by H2O (1.5 ml) and the reaction warmed 
to rt. MgSO4 was added and the suspension was filtered through Celite®, followed by washings 
with diethyl ether (50 ml). The filtrate was concentrated in vacuo to give the amine as a 
colourless oil (641 mg, 5.66 mmol, 67% yield) which was used without further purification. 
Amine (430 mg, 3.78 mmol) was dissolved in dioxane (10 ml) to which was added K2CO3 
solution (50% w/w aq, 1.20 g, 4.53 mmol) followed by benzyl chloroformate (0.65 ml, 4.53 
mmol) and the reaction stirred at room temperature for 4 hours. The reaction was quenched 
with H2O (10 ml) and portioned with CH2Cl2 (10 ml). The aqueous phase was extracted with 
CH2Cl2 (2 x 10 ml) and organic fractions combined. The combined organics were washed with 
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saturated brine solution (10 ml), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude residue was purified by flash column chromatography (10% EtOAc/hexane) to afford 
130 as a pale brown oil (801 mg, 3.24 mmol, 86% yield). 1H NMR (400 MHz, Chloroform-d) δ 
7.29 - 7.41 (m, 5 H, Ar-H), 5.82 (ddt, J = 16.9, 10.1, 7.3 Hz, 1 H, H-11), 5.11 (s, 2 H, H-5), 5.06 
(dq, J = 10.1, 1.5 Hz, 1 H, H-12), 5.03 (dq, J = 16.9, 1.5 Hz, 1 H, H-12), 4.80 (br. s., 1 H, NH), 3.04 
(d, J = 6.4 Hz, 2 H, H-7), 1.98 (d, J = 7.3 Hz, 2 H, H-10), 0.89 (s, 6 H, H-9) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 156.7 (C-6), 136.6 (C-4), 134.7 (C-11), 128.5 (Ar-CH), 128.2 (Ar-CH), 
128.1 (Ar-CH), 117.6 (C-12), 66.7 (C-5), 50.8 (C-7), 44.3 (C-10), 34.7 (C-8), 24.7 (C-9) ppm; IR 
(ATR): νmax 3340, 3071, 3033, 2960, 2929, 1703, 1639, 1520, 1468, 1455, 1410, 1389, 1367, 
1323, 1242, 1137, 1090, 1039, 1028, 997, 914, 775, 751, 735, 696, 623, 574, 509, 462 cm-1; 





To a solution of 4’-methylacetophenone (2.0 ml, 15.0 mmol) and paraformaldehyde (0.9 g, 30 
mmol) in THF (15 ml) was added diisopropylammonium trifluoroacetate (3.23 g, 15 mmol) 
and trifluoroacetic acid (0.12 ml, 1.5 mmol). The reaction was heated to reflux for 2 hours, 
cooled to room temperature and a second portion of paraformaldehyde (0.9 g, 30 mmol) was 
added. The reaction was heated to reflux for a further 8 hours, then cooled to room 
temperature and solvent was removed in vacuo. The reaction was partitioned between 
diethyl ether (20 ml) and 1M HCl (aq) (20 ml). The organic fraction was washed with 1M NaOH 
(20 ml) and saturated brine solution (20 ml), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude residue was purified by flash column chromatography (5% EtOAc/hexane) 
to afford 132 as a colourless oil (493 mg, 3.37 mmol, 22% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.87 (d, J = 7.8 Hz, 2 H, H-5), 7.29 (d, J = 7.8 Hz, 2 H, H-6), 7.17 (dd, J = 17.2, 
10.7 Hz, 1 H, H-2), 6.44 (dd, J = 17.2, 1.5 Hz, 1 H, H-1), 5.91 (dd, J = 10.7, 1.5 Hz, 1 H, H-1), 2.43 
(s, 3 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 190.6 (C-3), 144.0 (C-7), 134.8 (C-4), 
132.4 (C-2), 129.8 (C-1), 129.4 (C-6), 128.9 (C-5), 21.8 (C-8) ppm; IR (ATR): νmax 3031, 2922 
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1666, 1603, 1570, 1409, 1398, 1311, 1289, 1235, 1211, 1180, 1120, 1038, 1021, 1001, 980, 
966, 844, 768, 726, 700, 637, 599, 526 cm-1; HRMS (APCI) 147.0806 (M + H+. C10H11O requires 
147.0804). 
 
Thioacrylic acid S-p-tolyl ester (134) 
 
To a solution of NaOH (15% w/w aq. 20 ml) was added NaBH4 (0.05 g, 1.32 mmol) and p-
thiocresol (5.46 g, 44 mmol) which was then stirred for 3 hours. A solution of butylated 
hydroxytoluene (0.145g, 0.66 mmol) and acryloyl chloride (5.36 ml, 66 mmol) in cyclohexane 
(30 ml) was cooled to 0 °C. The aqueous solution of p-thiocresol was added dropwise to the 
acyrolyol chloride solution and the reaction warmed to room temperature. The reaction was 
then heated to 55 °C for 2.5 hours. After this time the reaction was cooled to room 
temperature and extracted with Et2O (80 ml). The combined organics were washed with 
saturated NaHCO3 solution (100 ml) and saturated brine solution (100 ml), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude material was purified by column 
chromatography (2% Et2O/hexane) to afford 134 as a pale yellow oil (5.37 g, 30.1 mmol, 68 % 
yield). 1H NMR (400 MHz, Chloroform-d) δ 7.36 (d, J = 8.4 Hz, 2H, H-5), 7.26 (d, J = 8.4 Hz, 2H, 
H-6), 6.48 (dd, J = 17.5, 10.0 Hz, 1H, H-2), 6.40 (dd, J = 17.5, 1.5 Hz, 1H, H-1), 5.78 (dd, J = 10.0, 
1.5 Hz, 1H, H-1), 2.41 (s, 3H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.9 (C-3), 139.7 
(C-7), 134.5 (C-5), 134.3 (C-2), 130.0 (C-6), 127.2 (C-1), 123.5 (C-4), 21.3 (C-8) ppm; IR (ATR): 
νmax 3023, 2921, 1681, 1611, 1597, 1493, 1447, 1393, 1304, 1276, 1160, 986, 940, 803, 722, 
704, 627, 528, 470 cm-1; HRMS (ESI) 179.0536 (M + H+. C10H11OS requires 179.0536). 
 
Acrylic acid p-tolyl ester (136) 
 
To a solution of NaOH (15% w/w aq. 22.4 ml) was added NaBH4 (0.048 g, 1.26 mmol) and p-
cresol (4.4 ml, 42 mmol) which was then stirred for 3 hours. A solution of butylated 
hydroxytoluene (0.139 g, 0.63 mmol) and acryloyl chloride (5.12 ml, 63 mmol) in cyclohexane 
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(30 ml) was cooled to 0 °C. The aqueous solution of p-cresol was added dropwise to the 
acyrolyl chloride solution and the reaction warmed to room temperature. The reaction was 
then heated to 55 °C for 2.5 hours. After this time the reaction was cooled to room 
temperature and extracted with Et2O (80 ml). The combined organics were washed with 
saturated NaHCO3 solution (100 ml) and saturated brine solution (100 ml), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude material was purified by column 
chromatography (10 % Et2O/hexane) to afford 136 as a colourless oil (6.07 g, 37.4 mmol, 89% 
yield) 1H NMR (400 MHz, Chloroform-d) δ 7.20 (d, J = 8.4 Hz, 2 H, H-6), 7.03 (d, J = 8.4 Hz, 2 H, 
H-5), 6.61 (dd, J = 17.5, 1.5 Hz, 1 H, H-1), 6.33 (dd, J = 17.5, 10.7 Hz, 1 H, H-2), 6.01 (dd, J = 
10.7, 1.5 Hz, 1 H, H-1), 2.37 (s, 3 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 164.8 (C-
3), 148.3 (C-4), 135.5 (C-7), 132.4 (C-1), 129.9 (C-6), 128.0 (C-2), 121.2 (C-5), 20.9 (C-8) ppm; 
IR (ATR): νmax 3035, 2924, 1739, 1634, 1506, 1402, 1293, 1251, 1196, 1165, 1146, 1104, 1068, 
1018, 981, 938, 897, 845, 801, 755, 703, 671, 614, 501 cm-1; HRMS (APCI) 163.0748 (M + H+. 
C10H11O2 requires 163.0754). 
 
6-Cbz-amino-5,5-dimethyl-hex-2-enethioic acid S-p-tolyl ester (126b) 
 
A solution of thioester 134 (165 mg, 0.924 mmol) in 1,2-DCE (7.5 ml) was added under N2 to 
a dry flask containing Hoveyda-Grubbs Catalyst™ 2nd generation (19.3 mg, 0.0308 mmol) and 
copper iodide (58.7 mg, 0.308 mmol) while stirring. A solution of Cbz-amine 130 (76.2 mg, 
0.308 mmol) in 1,2-DCE (7.5 ml) was added under N2 and the reaction heated to 50 °C for 16 
hours. The reaction was then cooled to room temperature, exposed to air and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (8% EtOAc/hexane) 
to afford 126b as a colourless residue (92.2 mg, 0.232 mmol, 75% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.35 - 7.43 (m, 5 H, Ar-H), 7.33 (d, J = 8.1 Hz, 2 H, H-15), 7.24 (d, J = 8.1 Hz, 2 
H, H-16), 6.98 (dt, J = 15.2, 8.2 Hz, 1 H, H-11), 6.20 (d, J = 15.2 Hz, 1 H, H-12), 5.12 (s, 2 H, H-
5), 4.85 (t, J = 6.7 Hz, 1 H, NH), 3.08 (d, J = 6.7 Hz, 2 H, H-7), 2.39 (s, 3 H, H-18), 2.15 (d, J = 8.2 
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Hz, 2 H, H-10), 0.95 (s, 6 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.2 (C-13), 156.7 
(C-6), 142.5 (C-11), 139.6 (C-17), 136.4 (C-4), 134.5 (C-15), 130.3 (C-12), 130.0 (C-16), 128.5 
(Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 123.9 (C-14), 66.8 (C-5), 51.2 (C-7), 42.4 (C-10), 35.8 (C-
8), 24.7 (C-9), 21.3 (C-18) ppm; IR (ATR): νmax  3346, 3063, 3031, 2959, 2926, 2871, 1698, 1630, 
1523, 1494, 1467, 1455, 1392,1368, 1336, 1238, 1181, 1163, 1135, 1117, 1081, 1042, 1016, 
888, 808, 775, 736, 697, 647, 619, 575, 534, 475 cm-1; HRMS (ESI) 398.1792 (M + H+. 
C23H28NO3S requires 398.1784), 420.1609 (M + Na+. C23H27NNaO3S requires 420.1604). 
 
6-Cbz-amino-5,5-dimethyl-hex-2-enoic acid p-tolyl ester (126c) 
 
A solution of ester 136 (238 mg, 1.465 mmol) in 1,2-DCE (7.5 ml) was added under N2 to a dry 
flask containing Hoveyda-Grubbs Catalyst™ 2nd generation (30.6 mg, 0.0488 mmol) and 
copper iodide (92.9 mg, 0.488 mmol) while stirring. A solution of Cbz-amine 130 (121 mg, 
0.488 mmol) in 1,2-DCE (7.5 ml) was added under N2 and the reaction heated to 50 °C for 16 
hours. The reaction was then cooled to room temperature, exposed to air and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (12% 
EtOAc/hexane) to afford 126c as a brown oil (161 mg, 0.422 mmol, 86% yield). 1H NMR (400 
MHz, Chloroform-d) δ 7.29 - 7.43 (m, 5 H, Ar-H), 7.18 (d, J = 8.4 Hz, 2 H, H-16), 7.16 (dt, J = 
15.3, 7.6 Hz, 1 H, H-11), 7.00 (d, J = 8.4 Hz, 2 H,H-15), 6.04 (d, J = 15.3 Hz, 1 H, H-12), 5.12 (s, 
2 H, H-5), 4.83 (t, J = 6.7 Hz, 1 H, NH), 3.10 (d, J = 6.7 Hz, 2 H, H-7), 2.36 (s, 3 H, H-18), 2.21 (d, 
J = 7.6 Hz, 2 H, H-10), 0.97 (s, 6 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 164.9 (C-
13), 156.8 (C-6), 148.6 (C-14), 147.6 (C-11), 136.6 (C-4), 135.5 (C-17), 130.1 (C-16), 128.7 (Ar-
CH), 128.4 (Ar-CH), 128.4 (Ar-CH), 123.5 (C-12), 121.4 (C-15), 67.0 (C-5), 51.3 (C-7), 42.7 (C-
10), 35.8 (C-8), 24.9 (C-9), 21.0 (C-18) ppm; IR (ATR): νmax 3356, 3033, 2960, 1721, 1650, 1531, 
1507, 1455, 1391, 1369, 1313, 1241, 1198, 1167, 1132, 1075, 1040, 1018, 982, 821, 775, 736, 
697, 510 cm-1; HRMS (ESI) 382.2010 (M + H+. C23H28NO4 requires 382.2013), 399.2273 (M + 





A solution of enone 132 (206 mg, 1.407 mmol) in 1,2-DCE (7.5 ml) was added under N2 to a 
dry flask containing Hoveyda-Grubbs Catalyst™ 2nd generation (29.4 mg, 0.0469 mmol) and 
copper iodide (89.3 mg, 0.469 mmol) while stirring. A solution of Cbz-amine 130 (116 mg, 
0.469 mmol) in 1,2-DCE (7.5 ml) was added under N2 and the reaction heated to 50 °C for 16 
hours. The reaction was then cooled to room temperature, exposed to air and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (10% 
EtOAc/hexane) to afford (±)-127a as a pale brown oil (147 mg, 0.402 mmol, 86% yield). 1H 
NMR (400 MHz, Chloroform-d) δ 7.90 (d, J = 7.8 Hz, 1.2H, H-15, rotamer 1), 7.70 (d, J = 7.8 Hz, 
0.8H, H-15, rotamer 2), 7.39-7.27 (m, 5H, Ar-H), 7.24 (d, J = 7.8 Hz, 1.2H, H-16, rotamer 1), 
7.14 (d, J = 7.8 Hz, 0.8H, H-16, rotamer 2), 5.21 – 5.06 (m, 2H, H-5), 4.41 – 4.26 (m, 1H, H-11), 
4.07 (dd, J = 15.4, 3.6 Hz, 0.6H H-12, rotamer 1), 3.73 (dd, J = 15.4, 3.6 Hz, 0.4H, H-12, rotamer 
2), 3.49 (d, J = 10.6 Hz, 0.4H, H-7, rotamer 2), 3.38 (d, J = 10.6 Hz, 0.6H, H-7, rotamer 1), 3.06 
(d, J = 10.6 Hz, 1H, H-7’), 2.90 – 2.75 (m, 1H, H-12’), 2.39 (s, 3H, H-18), 2.11 – 1.99 (m, 1H, H-
10), 1.54 – 1.42 (m, 1H, H-10’), 1.07 (s, 3H, H-9), 0.99 (s, 3H, H-9’) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 198.6(198.2) (C-13), 155.2 (C-6), 144.1(144.0) (C-17), 137.0(136.7) (C-4), 
134.5(134.3) (C-14), 129.4 (C-16), 128.7(128.6) (C-15), 128.5(128.3) (Ar-CH), 128.3(128.2) (Ar-
CH), 128.0(127.8) (Ar-CH),67.1(66.7) (C-5), 59.4(59.3) (C-7), 54.9(54.2) (C-11), 46.9(45.9) (C-
10), 45.1(43.8) (C-12), 37.6(37.3) (C-8), 26.5(26.4) (C-9), 26.2(26.1) (C-9’), 21.7 (C-18) ppm; IR 
(ATR): νmax 3033, 2957, 2870, 1698, 1681, 1607, 1573, 1498, 1449, 1412, 1356, 1302, 1204, 
1178, 1100, 1038, 1001, 810, 770, 752, 698, 584, 462 cm-1; HRMS (ESI) 366.2060 (M + H+. 










A solution of amino-ester 126c (19.9 mg, 0.052 mmol) in 1,2-DCE (5 ml) was added to rac-CSA 
(36.3 mg, 0.156 mmol) under N2 and the reaction heated to 50 °C for 24 hours. The reaction 
was cooled to room temperature, quenched with Et3N (0.2 ml) and concentrated in vacuo. 
The crude material was analysed by NMR to show 8% conversion. 
Asymmetric 
A solution of amino-ester 126c (22.1 mg, 0.0579 mmol) in cyclohexane (2.9 ml, 0.02M) was 
added to (R)-TRIP (8.72 mg, 0.0116 mmol) under N2 and the reaction heated to 80 °C for 24 
hours. The reaction was then cooled to room temperature and concentrated in vacuo. The 
crude material was purified by column chromatography (2% Et2O/hexane) to afford 127c as a 
colourless oil (4.5 mg, 0.0118 mmol, 20% yield, 95:5 er). 
1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.26 (m, 5H, Ar-H), 7.14 (d, J = 8.1 Hz, 2H, H-16), 
6.94 (d, J = 8.1 Hz, 1.2H, H-15, rotamer 1), 6.89 (d, J = 8.1 Hz, 0.8H, H-15, rotamer 2), 5.24 – 
5.07 (m, 2H, H-5), 4.36 – 4.17 (m, 1H, H-11), 3.50 (d, J = 10.7 Hz, 0.4H, H-7, rotamer 2), 3.40 
(d, J = 10.7 Hz, 0.6H, H-7, rotamer 1), 3.33 (dd, J = 15.7, 4.0 Hz, 0.6H, H-12, rotamer 1), 3.15 
(dd, J = 15.7, 4.0 Hz, 0.4H, H-12, rotamer 2), 3.09 (d, J = 10.7 Hz, 0.6H, H-7’, rotamer 1), 3.08 
(d, J = 10.7 Hz, 0.4H, H-7’, rotamer 2), 2.74 (dd, J = 15.7, 8.4 Hz, 0.6H, H-12’, rotamer 1), 2.68 
(dd, J = 15.7, 8.4 Hz, 0.4H, H-12’, rotamer 2), 2.32 (s, 3H, H-18), 2.06 (dd, J = 12.8, 7.4 Hz, 1H, 
H-10), 1.69 (dd, J = 12.8, 8.8 Hz, 0.4H, H-10’, rotamer 2), 1.63 (dd, J = 12.8, 8.8 Hz, 0.6H, H-10’, 
rotamer 1), 1.11 (s, 1.2H, H-9, rotamer 2), 1.09 (s, 1.8H, H-9, rotamer 1), 1.01 (s, 3H, H-9’) 
ppm; 13C NMR (101 MHz, Chloroform-d) δ 170.3 (C-13), 155.2 (C-6), 148.4 (C-14), 137.1 (C-
4)135.5 (C-17), 130.0 (C-16), 128.6(128.5) (Ar-CH), 128.0 (Ar-CH), 127.9(127.8) (Ar-CH), 
121.3(121.2) (C-15), 67.1(66.8) (C-5), 59.4 (C-7), 54.4(53.8) (C-11), 46.3(45.5) (C-10), 
40.1(38.9) (C-12), 37.5 (C-8), 26.4(26.1) (C-9), 21.0 (C-18) ppm; IR (ATR): νmax 3034, 2957, 
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2923, 2870, 1756, 1701, 1507, 1433, 1413, 1357, 1303, 1198, 1166, 1137, 1101, 1041, 1019, 
1003, 946, 914, 827, 769, 752, 698, 613, 505 cm-1; HRMS (ESI) 382.2019 (M + H+. C23H28NO4 
requires 382.2013), 404.1837 (M + Na+. C23H27NNaO4 requires 404.1832), 420.1575 (M + K+. 





A solution of amino-thioester 126b (19.2 mg, 0.048 mmol) in 1,2-DCE (5 ml) was added to rac-
CSA (33.7 mg, 0.145 mmol) under N2 and the reaction heated to 50 °C for 24 hours. The 
reaction was cooled to room temperature and extracted with DCM (10 ml). The organic 
fraction was washed with saturated NaHCO3 solution (10 ml), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by column chromatography (8% 
EtOAc/hexane) to afford 127b as a yellow oil (17.2 mg, 0.043 mmol, 90% yield). 
Asymmetric 
A solution of amino-thioester 126b (19.5 mg, 0.049 mmol) in cyclohexane (0.02M) was added 
to (R)-TRIP (7.4 mg, 0.098 mmol) under N2 and the reaction heated to 80 °C for 24 hours. The 
reaction was then cooled to room temperature, quenched with Et3N (0.2 ml) and 
concentrated in vacuo. The crude material was purified by column chromatography (8% 
EtOAc/hexane) to afford 127b as a yellow oil (16.2 mg, 0.041 mmol, 83% yield, 98:2 er). 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.29 (m, 5H, Ar-H), 7.24 (m, 4H, H-15, H-16), 5.27 
– 5.12 (m, 2H, H-5), 4.25 (m, 1H, H-11), 3.54 (dd, J = 15.2, 3.7 Hz, 0.6H, H-12, rotamer 1), 3.49 
(d, J = 10.7 Hz, 0.4H, H-7, rotamer 2), 3.38 (d, J = 10.7 Hz, 0.6H, H-7, rotamer 1), 3.28 (dd, J = 
15.2, 3.7Hz, 0.4H, H-12, rotamer 2), 3.06 (d, J = 10.7 Hz, 0.4H, H-7’, rotamer 2), 3.05 (d, J = 
10.7 Hz, 0.6H, H-7’, rotamer 1), 2.87 (dd, J = 15.2, 8.7 Hz, 0.6H, H-12’, rotamer 1), 2.78 (dd, J 
= 15.2, 8.7 Hz, 0.4H, H-12’, rotamer 2), 2.38 (s, 3H, 18), 2.01 (dd, J = 12.9, 7.5 Hz, 1H, H-10), 
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1.64 (m, 1H, H-10’), 1.11 (s, 1.2 H, H-9, rotamer 2), 1.11 (s, 1.8 H, H-9, rotamer 1), 1.00 (s, 3H, 
H-9’) ppm; 13C NMR (101 MHz, Chloroform-d) δ 196.0(195.9) (C-13), 155.1 (C-6), 139.9(139.7) 
(C-17), 137.0 (C-4), 134.5(134.5) (C-15), 130.2(130.1) (C-16), 128.7(128.6) (Ar-CH), 
128.1(128.0) (Ar-CH), 127.8 (Ar-CH), 124.2(124.0) (C-14), 67.1(66.8) (C-5), 59.5(59.3) (C-7), 
54.8(54.3) (C-11), 48.7(47.3) (C-12), 46.2(45.2) (C-10), 37.5(37.2) (C-8), 26.4(26.3) (C-9), 
26.1(26.0) (C-9’), 21.4 (C-18) ppm; IR (ATR): νmax 3032, 2956, 2925, 2869, 1698, 1598, 1494, 
1454, 1410, 1355, 1328, 1285, 1210, 1179, 1101, 1039, 984, 807, 769, 697, 610, 533, 474 cm-
1; HRMS (ESI) 398.1785 (M + H+. C23H28NO3S requires 398.1784); 420.1602 (M + Na+. 
C23H27NNaO3S requires 420.1604); [α]D20 -66.3° (c 0.81, CHCl3). 
Synthesis of 3,3-disubstituted precursors 
General procedure A 
To a solution of diisopropylamine (61.3 mmol) in dry THF (25 ml) at -78 °C under N2 was added 
n-BuLi (2.5 M in hexanes, 66.8 mmol) and the solution stirred for 45 mins. A solution of nitrile 
(55.7 mmol) in THF (25 ml) was added over 5 mins at -78 °C and reaction stirred for 45 mins. 
Allyl bromide (61.3 mmol) was added over 2 min at -78 °C and the reaction warmed to room 
temperature. The reaction was stirred overnight and quenched with 1 M HCl (40 ml). The 
reaction was partitioned with diethyl ether (30 ml) and aqueous phase extracted with diethyl 
ether (3 x 50 ml), Organic fractions were combined, washed with saturated brine solution (2 
x 50 ml), dried with MgSO4, filtered and concentrated in vacuo. Crude product was purified 
by column chromatography to yield the nitrile product.  
1-Allyl-cyclobutanecarbonitrile (141a) 
 
141a was synthesised using general procedure A with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 12 mmol), cyclobutanecarbonitrile (0.93 ml, 10 mmol) and allyl 
bromide (1.73 ml, 20 mmol). 141a yielded as a colourless oil (737 mg, 6.08 mmol, 61% yield) 
after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 5.82 
(ddt, J = 16.9, 10.1, 7.3 Hz, 1 H, H-6), 5.22 (m, 2 H, H-7), 2.43 - 2.57 (m, 4 H, H-3, H-5), 1.96 - 
2.23 (m, 4 H, H-3, H-4) ppm; 13C NMR (101 MHz, Chloroform-d) δ 131.9 (C-6), 124.3 (C-1), 
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119.4 (C-7), 41.8, (C-5), 35.0, (C-2), 31.3 (C-3), 16.5 (C-4) ppm; IR (ATR): νmax 3081, 2982, 2947, 
2230, 1642, 1432, 1293, 1245, 1175, 992, 921, 719, 569 cm-1; HRMS (APCI) 122.0966 (M + H+. 




141b was synthesised using general procedure A with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 12 mmol), cyclopentanecarbonitrile (1.04 ml, 10 mmol) and allyl 
bromide (1.73 ml, 20 mmol). 141b yielded as a colourless oil (1.05 g, 7.73 mmol, 77% yield) 
after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 5.81 - 
6.01 (m, 1 H, H-6), 5.15 - 5.26 (m, 2 H, H-7), 2.34 (d, J = 7.6 Hz, 2 H, H-5), 2.06 - 2.15 (m, 2 H, 
H-3), 1.79 - 1.91 (m, 2 H, H-4), 1.72 - 1.80 (m, 2 H, H-4), 1.62 - 1.71 (m, 2 H, H-3) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 132.9 (C-6), 125.1 (C-1), 119.2 (C-7), 42.5 (C-2), 42.4 (C-5), 37.5 (C-
3), 24.2 (C-4) ppm; IR (ATR): νmax 3081, 2965, 2875, 2231, 1643, 1453, 1417, 1323, 994, 922, 




141c was synthesised using general procedure A with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 12 mmol), cyclohexanecarbonitrile (1.19 ml, 10 mmol) and allyl 
bromide (1.73 ml, 20 mmol). 141c yielded as a colourless oil (1.20 g, 8.04 mmol, 80% yield) 
after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 5.89 
(ddt, J = 17.1, 10.0, 7.3 Hz, 1 H, H-7), 5.18 (dq, J = 17.1, 1.5 Hz, 1 H, H-8), 5.21 (dq, J = 10.0, 0.9 
Hz, 1 H, H-8), 2.29 (d, J = 7.3 Hz, 2 H, H-6), 1.96 (m, 2 H, H-3), 1.54 - 1.81 (m, 5 H, H-4, H-5), 
1.15 - 1.30 (m, 3 H, H-3, H-5) ppm; 13C NMR (101 MHz, Chloroform-d) δ 131.9 (C-7), 123.4 (C-
1), 119.6 (C-8), 44.6 (C-6), 38.8 (C-2), 35.3 (C-3), 25.3 (C-5), 23.0 (C-4) ppm; IR (ATR): νmax 3080, 
2933, 2859, 2230, 1642, 1451, 1417, 1351, 1306, 1265, 1141, 1114, 1083, 996, 974, 920, 847, 






LiHMDS (1M in THF, 12.4 ml, 12.4 mmol) was diluted in dry THF (20 ml) under N2 and cooled 
to -78 °C. A solution of diphenyl acetonitrile (2 g, 10.3 mmol) in THF (20 ml) was added at -78 
°C over 5 mins and the reaction stirred for 45 mins. Allyl bromide (0.99 ml, 11.4 mmol) was 
added over 1 min at -78 °C and the reaction warmed to room temperature. The reaction was 
stirred overnight and quenched with 1 M HCl (40 ml). The reaction was partitioned with 
diethyl ether (40 ml) and aqueous phase extracted with diethyl ether (2 x 40 ml), Organic 
fractions were combined, washed with saturated brine solution (40 ml), dried with MgSO4, 
filtered and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (4% EtOAc/hexane) to afford 141d as a colourless oil (2.17 g, 9.31 mmol, 
90% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.19 - 7.39 (m, 10 H, Ar-H), 5.67 (ddt, J = 17.5, 
10.0, 6.9Hz, 1 H, H-8), 5.17 (d, J = 17.5 Hz, 1 H, H-9), 5.13 (d, J = 10.0 Hz, 1 H, H-9), 3.10 (d, J = 
6.9 Hz, 2 H, H-7) ppm; 13C NMR (101 MHz, Chloroform-d) δ 139.7 (C-3), 131.8 (C-8), 128.8 (Ar-
CH), 127.9 (Ar-CH), 127.0 (Ar-CH), 121.9 (C-1), 120.4 (C-9), 51.7 (C-2), 43.9 (C-7) ppm; IR (ATR): 
νmax 3063, 2237, 1642, 1598, 1494, 1449, 1189, 1087, 1033, 991, 753, 697, 668, 636, 539 cm-
1; HRMS (ESI) 256.1108 (M + Na+. C17H15NNa requires 256.1097). 
 
General procedure B 
To a suspension of LiAlH4 (12.75 mmol) in dry diethyl ether (25 ml) at 0 °C under N2 was added 
nitrile (8.50 mmol) in dry diethyl ether (25 ml) over 5 mins and the reaction stirred at 0 °C for 
30 mins. The reaction was then warmed to room temperature and stirred overnight. The 
reaction was cooled to 0 °C and quenched with H2O (0.5 ml), followed by NaOH solution (15% 
w/w aq, 0.5 ml), followed by H2O (1.5 ml) and the reaction warmed to rt. MgSO4 was added 
and the suspension was filtered through Celite®, followed by washings with diethyl ether (50 
ml). The filtrate was concentrated in vacuo to give the amine purification (5.66 mmol, 67% 
yield) which was used without further purification. Amine (4.78 mmol) was dissolved in 
dioxane (10 ml) to which was added K2CO3 solution (50% w/w aq, 4.53 mmol) followed by 
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benzyl chloroformate (4.53 mmol) and the reaction stirred at room temperature for 4 hours. 
The reaction was quenched with H2O (10 ml) and portioned with CH2Cl2 (10 ml). The aqueous 
phase was extracted with CH2Cl2 (2 x 10 ml) and organic fractions combined. The combined 
organics were washed with saturated brine solution (10 ml), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash column chromatography (3.24 
mmol, 86% yield). 
 
(1-Allyl-cyclobutylmethyl)-carbamic acid benzyl ester (142a) 
 
Nitrile 141a (209 mg, 1.72 mmol) was reduced using general procedure B with LiAlH4 (98 mg, 
2.59 mmol) to give the amine as a pale yellow oil (201 mg, 1.61 mmol, 93% yield). Amine (97 
mg, 0.78 mmol) was Cbz protected with K2CO3 solution (50% w/w aq, 258 mg, 0.94 mmol) and 
benzyl chloroformate (0.13 ml, 0.94 mmol). 142a yielded as a colourless oil (127 mg, 0.49 
mmol, 63% yield) after column chromatography (10% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 - 7.43 (m, 5 H, Ar-H), 5.81 (ddt, J = 17.0, 10.0, 7.3 Hz, 1 H, H-12), 5.11 (s, 
2 H, H-5), 5.03 - 5.10 (m, 2 H, H-13), 4.78 (br. s., 1 H, NH), 3.26 (d, J = 6.5 Hz, 2 H, H-7), 2.20 (d, 
J = 7.3 Hz, 2 H, H-11), 1.83 - 1.95 (m, 2 H, H-10), 1.73 - 1.82 (m, 4 H, H-9) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 156.8 (C-6), 136.6 (C-4), 134.5 (C-12), 128.5 (Ar-CH), 128.2 (Ar-CH), 
128.1 (Ar-CH), 117.4 (C-13), 66.7 (C-5), 47.8 (C-7), 42.1 (C-11), 41.7 (C-8), 28.6 (C-9), 14.9 (C-
10) ppm; IR (ATR): νmax 3338, 3070, 3033, 2975, 2930, 1697, 1639, 1536, 1454, 1412, 1359, 
1307, 1246, 1135, 997, 913, 774, 735, 696, 612, 486 cm-1; HRMS (ESI) 282.1454 (M + Na+. 
C16H21NNaO2 requires 282.1464) 
 
(1-Allyl-cyclopentylmethyl)-carbamic acid benzyl ester (142b) 
 
Nitrile 141b (264 mg, 1.95 mmol) was reduced using general procedure B with LiAlH4 (111 
mg, 2.93 mmol) to give the amine as a pale yellow oil (266 mg, 1.91 mmol, 98% yield). Amine 
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(124 mg, 0.88 mmol) was Cbz protected with K2CO3 solution (50% w/w aq, 294 mg, 1.06 mmol) 
and benzyl chloroformate (0.15 ml, 1.06 mmol). 142b yielded as a colourless oil (158 mg, 0.58 
mmol, 66% yield) after column chromatography (10% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 - 7.47 (m, 5 H, Ar-H), 5.74 - 5.90 (m, 1 H, H-12), 5.11 (s, 2 H, H-5), 5.02 - 
5.09 (m, 2 H, H-13), 4.81 (br. s., 1 H, NH), 3.13 (d, J = 6.4 Hz, 2 H, H-7), 2.09 (d, J = 7.3 Hz, 2 H, 
H-11), 1.55 - 1.70 (m, 4 H, H-10), 1.33 - 1.48 (m, 4 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-
d) δ 156.7 (C-6), 136.6 (C-4), 135.5 (C-12), 128.5 (Ar-CH), 128.2 (Ar-CH), 128.1 (Ar-CH), 117.4 
(C-13), 66.7 (C-5), 48.0 (C-7), 46.2 (C-8), 42.4 (C-11), 35.0 (C-9), 24.8 (C-10) ppm; IR (ATR): νmax 
3339, 3070, 3033, 2950, 2867, 1701, 1638, 1521, 1454, 1411, 1332, 1239, 1137, 913, 774, 735, 
696 cm-1; HRMS (ESI) 296.1612 (M + Na+. C17H23NNaO2 requires 296.1621). 
 
(1-Allyl-cyclohexylmethyl)-carbamic acid benzyl ester (142c) 
 
Nitrile 141c (252mg, 1.69 mmol) was reduced using general procedure B with LiAlH4 (96 mg, 
2.53 mmol) to give the amine as a pale yellow oil (249 mg, 1.62 mmol, 96% yield). Amine (119 
mg, 0.78 mmol) was Cbz protected with K2CO3 solution (50% w/w aq, 258 mg, 0.93 mmol) and 
benzyl chloroformate (0.13 ml, 0.93 mmol). 142c yielded as a colourless oil (182 mg, 0.633 
mmol, 81% yield) after column chromatography (10% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 - 7.44 (m, 5 H, Ar-H), 5.83 (ddt, J = 15.6, 11.0, 7.3 Hz, 1 H, H-13), 5.10 - 
5.14 (m, 2 H, H-5), 5.01 - 5.09 (m, 2 H, H-13), 4.76 (br. s., 1 H, NH), 3.13 (d, J = 6.4 Hz, 2 H, H-
7), 2.05 (d, J = 7.3 Hz, 2 H, H-12), 1.44 - 1.59 (m, 4 H, H-10), 1.36 - 1.44 (m, 2 H, H-11), 1.23 - 
1.35 (m, 4 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 156.7 (C-6), 136.6 (C-4), 134.5 
(C-13), 128.5 (Ar-CH), 128.2 (Ar-CH), 128.1 (Ar-CH), 117.5 (C-14), 66.7 (C-5), 47.4 (C-7), 40.6 
(C-12), 36.9 (C-8), 33.2 (C-9), 26.1 (C-11), 21.4 (C-10) ppm; IR (ATR): νmax 3341, 3069, 3033, 
2924, 2852, 1703, 1638, 1518, 1454, 1412, 1239, 1130, 1077, 1077, 1019, 1000, 912, 847, 824, 






(2,2-diphenyl-pent-4-enyl)-carbamic acid benzyl ester (142d) 
 
Nitrile 141d (1.64 g, 7.03 mmol) was reduced using general procedure B with LiAlH4 (400 mg, 
10.5 mmol) to give the amine as a pale yellow oil (1.66 g, 6.99 mmol, 99% yield).  Amine (1.20 
g, 5.03 mmol) was Cbz protected with K2CO3 solution (50% w/w aq, 1.60 g, 6.04 mmol) and 
benzyl chloroformate (0.86 ml, 6.04 mmol). 142d yielded as a colourless oil (1.47 g, 3.97 
mmol, 79% yield) after column chromatography (5% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.11 - 7.43 (m, 15 H, Ar-H), 5.44 (ddt, J = 16.9, 10.1, 7.3 Hz, 1 H, H-14), 5.06 
(s, 2 H, H-5), 4.93 - 5.02 (m, 2 H, H-15), 4.35 (t, J = 6.0 Hz, 1 H, NH), 3.95 (d, J = 6.0 Hz, 2 H, H-
7), 2.88 (d, J = 7.3 Hz, 2 H, H-13) ppm; 13C NMR (101 MHz, Chloroform-d) δ 156.2 (C-6), 145.2 
(C-9), 136.4 (C-4), 133.7 (C-14), 128.5 (Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 
128.0 (Ar-CH), 126.5 (Ar-CH), 118.6 (C-15), 66.7 (C-5), 50.2 (C-8), 47.6 (C-7), 41.6 (C-13) ppm; 
IR (ATR): νmax 3433, 3060, 3030, 2936, 1721, 1639, 1598, 1510, 1496, 1405, 1358, 1219, 1142, 
1100, 1071, 1030, 1000, 971, 916, 843, 754, 735, 695, 655, 578, 529, 491, 464 cm-1; HRMS 
(ESI) 372.1969 (M + H+. C25H26NO2 requires 372.1958), 394.1784 (M + Na+. C25H26NNaO2 
requires 394.1784) 
 
General procedure C 
A solution of thioester 134 (0.924 mmol) in 1,2-DCE (7.5 ml) was added under N2 to a dry flask 
containing Hoveyda-Grubbs Catalyst™ 2nd generation (0.0308 mmol) and copper iodide 
(0.308 mmol) while stirring. A solution of Cbz-amine (0.308 mmol) in 1,2-DCE (7.5 ml) was 
added under N2 and the reaction heated to 50 °C for 16 hours. The reaction was then cooled 
to room temperature, exposed to air and concentrated in vacuo. The crude residue was 




6-Cbz-amino-5,5-cyclobutyl-hex-2-enethioic acid S-p-tolyl ester (143a) 
 
 
143a was synthesised using general procedure C with thioester 134 (118 mg, 0.66 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (13.8 mg, 0.022 mmol), copper iodide (41.9 mg, 
0.22 mmol) and Cbz-amine 142a (57 mg, 0.22 mmol). 143a yielded as a green oil (76 mg, 0.19 
mmol, 84% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.33 - 7.40 (m, 5 H, Ar-H), 7.32 (d, J = 7.6 Hz, 2 H, H-16), 7.23 (d, J = 7.6 Hz, 2 
H, H-17), 6.96 (dt, J = 15.3, 7.6 Hz, 1 H, H-12), 6.23 (d, J = 16.0 Hz, 1 H, H-13), 5.12 (s, 2 H, H-
5), 4.79 (br. s, 1 H, NH), 3.28 (d, J = 6.1 Hz, 2 H, H-7), 2.39 (s, 3 H, H-19), 2.36 (d, J = 7.6 Hz, 2 
H, H-11), 1.87 - 1.98 (m, 2 H, H-10), 1.78 - 1.87 (m, 4 H, H-9) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 188.3 (C-14), 156.7 (C-6), 142.3 (C-12), 139.6 (C-18), 136.4 (C-4), 134.6 (C-
16), 130.1 (C-13), 130.0 (C-17), 128.6 (Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 123.9 (C-15), 66.9 
(C-5), 48.0 (C-7), 42.3 (C-8), 40.3 (C-11), 28.6 (C-9), 21.4 (C-19), 14.9 (C-10) ppm; IR (ATR): νmax 
3349, 3032, 2930, 1695, 1629, 1532, 1494, 1454, 1335, 1243, 1134, 1045, 1003, 979, 808, 774, 













6-Cbz-amino-5,5-cyclopentyl-hex-2-enethioic acid S-p-tolyl ester (143b) 
 
 
143b was synthesised using general procedure C with thioester 134 (118 mg, 0.66 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (13.8 mg, 0.022 mmol), copper iodide (41.9 mg, 
0.22 mmol) and Cbz-amine 142b (60 mg, 0.22 mmol). 143b yielded as a green oil (81 mg, 0.19 
mmol, 86% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.33 - 7.42 (m, 5 H, Ar-H), 7.32 (d, J = 7.8 Hz, 2 H, H-16), 7.23 (d, J = 7.8 Hz, 2 
H, H-17), 6.97 (dt, J = 15.3, 7.6 Hz, 1 H, H-12), 6.21 (d, J = 15.3 Hz, 1 H, H-13), 5.12 (s, 2 H, H-
5), 4.79 (br. s, 1 H, NH), 3.15 (d, J = 6.1 Hz, 2 H, H-7), 2.39 (s, 3 H, H-19), 2.25 (d, J = 7.6 Hz, 2 
H, H-11), 1.60 - 1.70 (m, 4 H, H-10), 1.36 - 1.54 (m, 4 H, H-9) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 188.3 (C-14), 156.7 (C-6), 143.2 (C-12), 139.6 (C-18),136.4 (C-4), 134.6 (C-16), 
130.1 (C-13), 130.0 (C-17), 128.6 (Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 123.9 (C-15), 66.9 (C-
5), 48.3 (C-7), 47.0 (C-8), 40.6 (C-11), 35.0 (C-9), 24.8 (C-10), 21.4 (C-19) ppm; IR (ATR): νmax 
3345, 3032, 2950, 2867, 1695, 1629, 1534, 1494, 1239, 1140, 1005, 889, 807, 774, 735, 697, 
617, 447 cm-1; HRMS (ESI) 446.1774 (M + Na+. C25H29NNaO3S requires 446.1760). 
 




143c was synthesised using general procedure C with thioester 134 (120 mg, 0.68 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (14.1 mg, 0.023 mmol), copper iodide (42.9 mg, 
0.23 mmol) and Cbz-amine 142c (65 mg, 0.23 mmol). 143c yielded as a colourless oil (66.2 
mg, 0.15 mmol, 66% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 
MHz, Chloroform-d) δ 7.29 - 7.42 (m, 5 H, Ar-H), 7.32 (d, J = 7.6 Hz, 2 H, H-17), 7.23 (d, J = 7.6 
Hz, 2 H, H-18), 7.00 (dt, J = 15.3, 7.6 Hz, 1 H, H-13), 6.21 (d, J = 15.3 Hz, 1 H, H-14), 5.12 (s, 2 
H, H-5), 4.75 (t, J = 6.4 Hz, 1 H, NH), 3.16 (d, J = 6.4 Hz, 2 H, H-7), 2.39 (s, 3 H, H-20), 2.21 (d, J 
= 7.6 Hz, 2 H, H-12), 1.40 - 1.60 (m, 6 H, H-10, H-11), 1.24 - 1.39 (m, 4 H, H-9) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 188.2 (C-15), 156.6 (C-6), 142.6 (C-13), 139.6 (C-19), 136.4 (C-4), 
134.6 (C-17), 130.0 (C-14), 130.0 (C-18), 128.5 (Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 123.9 (C-
16), 66.9 (C-5), 47.6 (C-7), 39.0 (C-12), 38.2 (C-8), 33.2 (C-9), 25.9 (C-11), 21.3 (C-10), 21.3 (C-
20) ppm; IR (ATR): νmax 3346, 3063, 3031, 2924, 2853, 1692, 1627, 1598, 1529, 1494, 1454, 
1401, 1361, 1336, 1303, 1238, 1147, 1132, 1105, 1091, 1061, 1015, 981, 918, 882, 848, 835, 
807, 774, 752, 734, 697, 646, 617, 597, 576, 533, 475 cm-1; HRMS (ESI) 438.2105 (M + H+. 
C26H32NO3S requires 438.2097), 460.1925 (M + Na+. C26H31NNaO3S requires 460.1917). 
 
6-Cbz-amino-5,5-diphenyl-hex-2-enethioic acid S-p-tolyl ester (143d) 
 
143d was synthesised using general procedure C with thioester 134 (276 mg, 1.55 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (32.4 mg, 0.0517 mmol), copper iodide (98.5 mg, 
0.517 mmol) and Cbz-amine 142d (192 mg, 0.517 mmol). 143d yielded as a pale brown oil 
(146 mg, 0.280 mmol, 54% yield) after column chromatography (8% EtOAc/hexane). 1H NMR 
(400 MHz, Chloroform-d) δ 7.13 - 7.38 (m, 19 H, Ar-H), 6.60 (dt, J = 16.0, 7.6 Hz, 1 H, H-14), 
6.07 (d, J = 16.0 Hz, 1 H, H-15), 5.06 (s, 2 H, H-5), 4.34 (t, J = 6.1 Hz, 1 H, NH), 3.94 (d, J = 6.1 
Hz, 2 H, H-7), 2.98 (d, J = 7.6 Hz, 2 H, H-13), 2.35 (s, 3 H, H-21) ppm; 13C NMR (101 MHz, 
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Chloroform-d) δ 188.1 (C-16), 156.2 (C-6), 144.18 (C-9), 141.5 (C-14), 139.5 (C-20), 136.2 (C-
4), 134.5 (C-18), 130.9 (C-15), 129.9 (C-19), 128.6 (Ar-CH), 128.6 (Ar-CH), 128.3 (Ar-CH), 128.2 
(Ar-CH), 127.8 (Ar-CH), 126.9 (Ar-CH), 124.0 (C-17), 66.9 (C-5), 50.9 (C-8), 48.3 (C-7), 40.2 (C-
13), 21.3 (C-21) ppm; IR (ATR): νmax 3432, 3030, 2924, 1722, 1685, 1630, 1513, 1495, 1445, 
1224, 1139, 1072, 1017, 910, 808, 755, 734, 699, 476 cm-1; HRMS (ESI) 522.2091 (M + H+. 
C33H32NO3S requires 522.2097), 544.1913 (M + Na+. C33H31NNaO3S requires 544.1917) 
Synthesis of 2,2-disubstituted precursors 
General procedure D 
To a solution of diisopropylamine (10.8 mmol) in dry THF (5 ml) at -78 °C under N2 was added 
n-BuLi (2.5 M in hexanes, 10.8 mmol) and the solution stirred for 45 mins. A solution of ester 
(9.9 mmol) in THF (5 ml) was added over 5 mins at -78 °C and the reaction stirred for 45 mins. 
4-bromo-1-butene (1.00 ml, 9.9 mmol) was added over 1 min at -78 °C and the reaction 
warmed to room temperature. The reaction was stirred overnight and quenched with 1 M 
HCl (10 ml). The reaction was partitioned with diethyl ether (30 ml) and aqueous phase 
extracted with diethyl ether (2 x 30 ml), organic fractions were combined, washed with 
saturated brine solution (30 ml), dried with MgSO4, filtered and concentrated in vacuo. The 
crude residue was purified by flash column chromatography to afford the product (6.93 
mmol, 70% yield) 
2,2-dimethyl-hex-5-enoic acid ethyl ester (146) 
 
146 was synthesised using general procedure D with diisopropylamine (1.51 ml, 10.8 mmol), 
n-BuLi (2.5 M in hexanes, 10.8 mmol), ethyl isobutyrate (1.33 ml, 9.9 mmol) and 4-bromo-1-
butene (1.00 ml, 9.9 mmol). 146 yielded as a colourless oil (1.18 g, 6.93 mmol, 70% yield) after 
column chromatography (5% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 5.80 (ddt, J 
=16.8, 9.9, 6.9 Hz, 1 H, H-8), 5.01 (dq, J = 16.8, 1.5 Hz, 1 H, H-9), 4.94 (dq, J = 9.9, 1.5 Hz, 1 H, 
H-9), 4.12 (q, J = 7.6 Hz, 2 H, H-2), 1.95 - 2.04 (m, 2 H, H-7), 1.59 - 1.66 (m, 2 H, H-6), 1.25 (t, J 
= 7.6 Hz, 3 H, H-1), 1.18 (s, 6 H, H-5) ppm; 13C NMR (101 MHz, Chloroform-d) δ 177.8 (C-3), 
138.5 (C-8), 114.4 (C-9), 60.2 (C-2), 42.0 (C-4), 39.8 (C-6), 29.3 (C-7), 25.1 (C-5), 14.2 (C-1) ppm; 
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IR (ATR): νmax 2978, 2938, 1726, 1641, 1473, 1450, 1473, 1386, 1365, 1319, 1280, 1199, 1143, 
1094, 1027, 996, 909, 863, 774, 646, 580, 556, 503 cm-1; HRMS (APCI) 171.1373 (M + H+. 
C10H19O2 requires 171.1380). 
 
1-But-3-enyl-cyclobutanecarboxylic acid methyl ester (156a) 
 
156a was synthesised using general procedure D with diisopropylamine (0.68 ml, 4.82 mmol), 
n-BuLi (2.5 M in hexanes, 4.82 mmol), methyl cyclobutane carboxylate (0.5 ml, 4.38 mmol) 
and 4-bromo-1-butene (0.45 ml, 4.38 mmol). 156a yielded as a colourless oil (285 mg, 1.69 
mmol, 39% yield) after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 5.80 (ddt, J = 16.8, 9.9, 6.1 Hz, 1 H, H-8), 5.01 (dq, J = 16.8, 1.5 Hz, 1 H, H-9), 
4.94 (dq, J = 9.9, 1.5 Hz, 1 H, H-9), 3.69 (s, 3 H, H-1), 2.37 - 2.49 (m, 2 H, H-4), 1.83 - 1.99 (m, 8 
H, H-4, H-5, H-6, H-7) ppm; 13C NMR (101 MHz, Chloroform-d) δ 177.5 (C-2), 138.2 (C-8), 114.6 
(C-9), 51.6 (C-1), 47.4 (C-3), 37.2 (C-6), 30.0 (C-4), 29.3 (C-7), 15.6 (C-5) ppm; IR (ATR): νmax 
3077, 2948, 2869, 1731, 1693, 1641, 1434, 1329, 1283, 1244, 1201, 1142, 1112, 994, 911, 806, 
692, 637, 458 cm-1; 
 
1-But-3-enyl-cyclopentanecarboxylic acid methyl ester (156b) 
 
156b was synthesised using general procedure D with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 11 mmol), methyl cyclopentane carboxylate (1.28 g, 10 mmol) and 
4-bromo-1-butene (1.00 ml, 10 mmol). 156b yielded as a colourless oil (1.44 g, 7.89 mmol, 
79% yield) after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-
d) δ 5.78 (ddt, J = 16.9, 10.5, 6.9 Hz, 1 H, H-8), 5.00 (dq, J = 16.9, 1.5 Hz, 1 H, H-9), 4.93 (dq, J 
= 10.5, 1.5 Hz, 1 H, H-9), 3.67 (s, 3 H, H-1), 2.07 - 2.19 (m, 2 H, H-4), 1.92 - 2.01 (m, 2 H, H-7), 
1.67 - 1.75 (m, 2 H, H-6), 1.58 - 1.67 (m, 4 H, H-5), 1.43 - 1.53 (m, 2 H, H-4) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 178.2 (C-2), 138.4 (C-8), 114.4 (C-9), 53.8 (C-3), 51.7 (C-1), 38.4 (C-6), 
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36.0 (C-4), 30.3 (C-7), 24.9 (C-5); IR (ATR): νmax 3078, 2951, 2871, 1730, 1641, 1452, 1339, 
1255, 1196, 1162, 994, 910 cm-1. 
 
1-But-3-enyl-cyclohexanecarboxylic acid methyl ester (156c) 
 
156c was synthesised using general procedure D with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 11 mmol), methyl cyclohexane carboxylate (1.45 ml, 10 mmol) and 
4-bromo-1butene (1.00 ml, 10 mmol). 156c yielded as a colourless oil (1.56 g, 7.97 mmol, 80% 
yield) after column chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 
5.76 (ddt, J = 16.9, 10.0, 6.3 Hz, 1 H, H-9), 4.99 (dq, J = 16.9, 1.5 Hz, 1 H, H-10), 4.93 (dq, J = 
10.0, 1.5 Hz, 1 H, H-10), 3.68 (s, 3 H, H-1), 2.03 - 2.14 (m, 2 H, H-4), 1.90 - 2.00 (m, 2 H, H-8), 
1.50 - 1.64 (m, 5 H, H-5, H-6, H-7), 1.16 - 1.40 (m, 5 H, H-4, H-5, H-6) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 177.1 (C-2), 138.5 (C-9), 114.4 (C-10), 51.4 (C-1), 46.8 (C-3), 39.7 (C-7), 34.2 
(C-4), 28.5 (C-8), 25.9 (C-6), 23.2 (C-5); IR (ATR): νmax 3078, 2930, 2854, 1727, 1641, 1453, 
1432, 1364, 1330, 1292, 1275, 1194, 1156, 1134, 1040, 995, 959, 909, 891, 850, 800, 765, 
1649, 620, 567, 514 cm-1; HRMS (APCI) 197.1543 (M + H+. C12H21O2 requires 197.1536). 
 
4-But-3-enyl-tetrahydro-pyran-4-carboxylic acid methyl ester (156d) 
 
156d was synthesised using general procedure D with diisopropylamine (1.54 ml, 11 mmol), 
n-BuLi (2.5 M in hexanes, 11 mmol), methyl tetrahydro-2H-pyran-4-carboxylate (1.54 ml, 10 
mmol) and 4-bromo-1-butene (1.00 ml, 10 mmol). 156d yielded as a colourless oil (1.45 g, 
7.32 mmol, 73% yield) after column chromatography (10% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 5.75 (ddt, J = 16.9, 10.5, 6.4 Hz, 1 H, H-8), 5.00 (dq, J = 16.9, 1.5 Hz, 1 H, H-9), 
4.95 (dq, J = 10.5, 1.5 Hz, 1 H, H-9), 3.83 (ddd, J = 11.7, 4.4, 4.1 Hz, 2 H, H-5), 3.72 (s, 3 H, H-
1), 3.43 (ddd, J = 11.7, 2.3 Hz, 2 H, H-5), 2.10 (ddd, J = 13.7, 4.4, 2.3 Hz, 2 H, H-4), 1.91 - 2.02 
(m, 2 H, H-7), 1.59 - 1.67 (m, 2 H, H-6), 1.52 (ddd, J = 13.7, 11.7, 4.1 Hz, 2 H, H-4) ppm; 13C 
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NMR (101 MHz, Chloroform-d) δ 176.1 (C-2), 137.8 (C-8), 114.8 (C-9), 65.4 (C-5), 51.8 (C-1), 
44.8 (C-3), 39.9 (C-6), 34.2 (C-4), 28.1 (C-7); IR (ATR): νmax 3078, 2954, 2852, 1728, 1641, 1452, 
1389, 1337, 1299, 1242, 1210, 1194, 1152, 1108, 1034, 1015, 997, 982, 912, 888, 840, 802, 
775, 600, 561, 491, 462 cm-1; HRMS (ESI) 211.1150 (M + Na+. C11H18NaO3 requires 211.1150). 
 
4-But-3-enyl-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-methyl ester (156e) 
 
LiHMDS (1M in THF, 22.9 ml, 22.9 mmol) was diluted in dry THF (50 ml) under N2 and cooled 
to -78 °C. A solution of N-Cbz-4-piperidinecarboxylic acid methyl ester (5.298 mg, 19.1 mmol) 
in THF (50 ml) was added at -78 °C over 5 mins and the reaction stirred for 45 mins. 4-bromo-
1-butene (2.91 ml, 28.7 mmol) was added over 1 min at -78 °C and the reaction warmed to 
room temperature. The reaction was stirred overnight and quenched with 1 M HCl (100 ml). 
The reaction was partitioned with diethyl ether (100 ml) and aqueous phase extracted with 
diethyl ether (2 x 100 ml), Organic fractions were combined, washed with saturated brine 
solution (100 ml), dried with MgSO4, filtered and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (20% EtOAc/hexane) to afford 156e as a 
colourless oil (1.77 g, 5.33 mmol, 28% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.28 - 7.41 
(m, 5 H, Ar-H), 5.74 (ddt, J = 16.8, 10.7, 6.9 Hz, 1 H, H-8), 5.12 (s, 2 H, H-11), 5.00 (dq, J = 16.8, 
1.5 Hz, 1 H, H-9), 4.95 (dq, J = 10.7, 1.5 Hz, 1 H, H-9), 3.89 - 4.07 (m, 2 H, H-5), 3.71 (s, 3 H, H-
1), 2.80 - 3.05 (m, 2 H, H-5), 2.10 - 2.22 (m, 2 H, H-4), 1.89 - 2.02 (m, 2 H, H-7), 1.55 - 1.65 (m, 
2 H, H-6), 1.30 - 1.47 (m, 2 H, H-4) ppm; 13C NMR (101 MHz, Chloroform-d) δ 175.7 (C-2), 155.2 
(C-10), 137.7 (C-8), 136.8 (C-12), 128.5 (Ar-CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 114.9 (C-9), 67.0 
(C-11), 51.8 (C-1), 45.5 (C-3), 41.5 (C-5), 39.5 (C-6), 33.3 (C-4), 28.2 (C-7) ppm; IR (ATR): νmax 
2948, 1726, 1699, 1641, 1497, 1472, 1430, 1360, 1338, 1278, 1246, 1226, 1145, 1093, 1015, 
912, 767, 603, 556 cm-1; HRMS (ESI) 332.1848 (M + H+. C19H26NO4 requires 332.1856), 




2,2-diphenyl-hex-5-enoic acid methyl ester (156f) 
 
156f was synthesised using the same procedure as 156e with LiHMDS (1M in THF, 10.6 ml, 
10.6 mmol) methyl diphenylacetate (2.0 g, 8.84 mmol) and 4-bromo-1butene (1.00 ml, 10 
mmol). 156f yielded as a colourless oil (1.03 g, 3.67 mmol, 42% yield) after column 
chromatography (2% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ ppm 7.26 - 7.41 (m, 
10 H, Ar-H), 5.81 (ddt, J = 16.8, 9.9, 6.5 Hz, 1 H, H-10), 5.01 (dq, J = 16.8, 1.5 Hz, 1 H, H-11), 
4.96 (dq, J = 9.9, 1.5 Hz, 1 H, H-11), 3.72 (s, 3 H, H-1), 2.45 - 2.57 (m, 2 H, H-8), 1.79 - 1.91 (m, 
2 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 174.7 (C-2), 142.7 (C-4), 138.3 (C-10), 
128.9 (Ar-CH), 127.9 (Ar-CH), 126.8 (Ar-CH), 114.5 (C-11), 60.1 (C-3), 52.3 (C-1), 37.3 (C-8), 
29.6 (C-9) ppm; IR (ATR): νmax 3024, 3060, 2950, 1729, 1640, 1598, 1495, 1445, 1221, 1121, 
1063, 1033, 913, 784, 760, 699, 602, 576, 502, 481 cm-1; HRMS (ESI) 281.1528 (M + H+. 
C19H21O2 requires 281.1536), 303.1356 (M + Na+. C19H20NaO2 requires 303.1356). 
 
General procedure E 
To a solution of alkenyl ester (5.9 mmol) in MeOH (10 ml) was added NaOH (20% w/w, 2.5 ml) 
and reaction heated to reflux while stirring for 3 hours. Reaction was cooled to room 
temperature and diluted with H2O (10 ml) and extracted with diethyl ether (20 ml). The 
aqueous layer was acidified to pH 1 with 3M HCl (8 ml), extracted with diethyl ether (3 x 25 
ml). Combined organics were dried with MgSO4, filtered and concentrated in vacuo, and 
product used without further purification (3.8 mmol, 64% yield). 





147 was synthesised using general procedure E with ester 146 (1.00 g, 5.9 mmol). 147 yielded 
as a colourless oil (539 mg, 3.8 mmol, 64% yield). 1H NMR (400 MHz, Chloroform-d) δ 11.93 
(s, 1 H, COOH), 5.81 (ddt, J = 17.0, 10.7, 6.9 Hz, 1 H, H-6), 5.03 (dq, J = 17.0, 1.5 Hz, 1 H, H-7), 
4.95 (dq, J = 10.7, 1.5 Hz, 1 H, H-7), 2.02 - 2.11 (m, 2 H, H-5), 1.62 - 1.69 (m, 2 H, H-4), 1.22 (s, 
6 H, H-3) ppm; 13C NMR (101 MHz, Chloroform-d) δ 184.8 (C-1), 138.3 (C-6), 114.6 (C-7), 42.0 
(C-2), 39.5 (C-4), 29.2 (C-5), 24.9 (C-3) ppm; IR (ATR): νmax 3078, 2941, 2976, 1696, 1642, 1476, 
1452, 1409, 1367, 1287, 1218, 1177, 994, 909, 788, 644, 549 cm-1; HRMS (ESI) 141.0927 (M - 
H. C8H13O2 requires 141.0921). 
 
1-But-3-enyl-cyclobutanecarboxylic acid (157a) 
 
157a was synthesised using general procedure E with ester 156a (220 mg, 1.31 mmol). 157a 
yielded as a colourless oil (196 mg, 1.27 mmol, 97% yield). 1H NMR (400 MHz, Chloroform-d) 
δ 10.33 (br. s, 1 H, COOH), 5.83 (ddt, J = 16.9, 10.4, 6.2 Hz, 1 H, H-7), 5.05 (dq, J = 16.9, 1.5 Hz, 
1 H, H-8), 4.97 (dq, J = 10.4, 1.5 Hz, 1 H, H-8), 2.39 - 2.56 (m, 2 H, H-3), 1.99 - 2.11 (m, 2 H, H-
6), 1.86 - 1.98 (m, 6 H, H-3, H-4, H-5) ppm; 13C NMR (101 MHz, Chloroform-d) δ 183.6 (C-1), 
138.1 (C-8), 114.7 (C-7), 47.3 (C-2), 36.9 (C-5), 30.0 (C-3), 29.2 (C-6), 15.6 (C-4) ppm; IR (ATR): 
νmax 3078, 2985, 2939, 2869, 1693, 1641, 1450, 1408, 1328, 1286, 1253, 1226, 1153, 1035, 
994, 910, 780, 742, 684, 636, 552 cm-1; HRMS (ESI) 153.0923 (M – H+. C9H13O2 requires 
153.0921). 
 
1-But-3-enyl-cyclopentanecarboxylic acid (157b) 
 
157b was synthesised using general procedure E with ester 156b (1.20 g, 6.58 mmol). 157b 
yielded as a colourless oil (613 mg, 3.64 mmol, 55% yield). 1H NMR (400 MHz, Chloroform-d) 
δ 12.03 (br. s., 1 H, COOH), 5.81 (ddt, J = 17.0, 10.4, 6.5 Hz, 1 H, H-7), 5.03 (dq, J = 17.0, 1.5 
Hz, 1 H, H-8), 4.95 (dq, J = 10.4, 1.5 Hz, 1 H, H-8), 2.11 - 2.22 (m, 2 H, H-3), 2.01 - 2.10 (m, 2 H, 
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H-6), 1.71 - 1.79 (m, 2 H, H-5), 1.61 - 1.70 (m, 4 H, H-4), 1.48 - 1.57 (m, 2 H, H-3) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 184.7 (C-1), 138.3 (C-7), 114.5 (C-8), 53.6 (C-2), 38.1 (C-5), 36.1 (C-
3), 30.2 (C-6), 25.0 (C-4) ppm; IR (ATR): νmax 3078, 2953, 2872, 1693, 1641, 1453, 1406, 1338, 
1281, 1219, 991, 910, 786, 643, 509 cm-1; HRMS (ESI) 167.1077 (M – H+. C10H15O2 requires 
167.1078), 191.1038 (M + Na+. C10H16NaO2 requires 191.1043). 
 
1-But-3-enyl-cyclohexanecarboxylic acid (157c) 
 
157c was synthesised using general procedure E with ester 156c (1.10 g, 5.60 mmol). 157c 
yielded as a white solid (599 mg, 3.29 mmol, 59% yield). 1H NMR (400 MHz, Chloroform-d) δ 
11.61 (br. s., 1 H, COOH), 5.80 (ddt, J = 17.1, 10.2, 6.6 Hz, 1 H, H-8), 5.02 (dq, J = 17.1, 1.8 Hz, 
1 H, H-9), 4.95 (dq, J = 10.2, 1.8 Hz, 1 H, H-9), 1.98 - 2.15 (m, 4 H, H-3,H-7), 1.54 - 1.69 (m, 5 H, 
H-4, H-5, H-6), 1.34 - 1.49 (m, 2 H, H-4), 1.17 - 1.33 (m, 3 H, H-3, H-5) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 182.89 (C-1), 138.3 (C-8), 114.6 (C-9), 46.6 (C-2), 39.3 (C-6), 33.9 (C-3), 28.4 
(C-7), 25.9 (C-5), 23.1 (C-4) ppm; IR (ATR): νmax 3078, 2931, 2856, 1695 1642, 1455, 1407, 1244, 
1214, 1165, 11.39, 995, 910, 850, 751, 570 cm-1; HRMS (ESI) 181.1232 (M - H. C11H17O2 
requires 181.1234); mp. 39.8-41.6 °C. 
 
4-But-3-enyl-tetrahydro-pyran-4-carboxylic acid (157d) 
 
157d was synthesised using general procedure E with ester 156d (1.10 g, 5.60 mmol). 157d 
yielded as a white solid (789 mg, 4.28 mmol, 76% yield). 1H NMR (400 MHz, Chloroform-d) δ 
10.79 (br s, 1 H, COOH), 5.79 (ddt, J = 17.1, 10.4, 6.5 Hz, 1 H, H-7), 5.04 (dq, J = 17.1, 1.8 Hz, 1 
H, H-8), 4.98 (dq, J = 10.4, 1.8 Hz, 1 H, H-8), 3.87 (dt, J = 12.2, 3.8 Hz, 2 H, H-4), 3.52 (ddd, J = 
12.2, 11.6, 1.9 Hz, 2 H, H-4), 2.11 (ddd, J = 13.7, 3.8, 1.9 Hz, 2 H, H-3), 2.01 - 2.08 (m, 2 H, H-
6), 1.65 - 1.74 (m, 2 H, H-5), 1.57 (ddd, J = 13.7, 11.6, 3.8 Hz, 2 H, H-3) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 180.7 (C-1), 137.7 (C-8), 115.1 (C-7), 65.3 (C-4), 44.6 (C-2), 39.6 (C-5), 
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33.9 (C-3), 28.0 (C-6) ppm; IR (ATR): νmax 3072, 2972, 2939, 2910, 2883, 2732, 2598, 1725, 
1641, 1452, 1442, 1425, 1383, 1335, 1301, 12847, 1267, 1240, 1219, 1197, 1159, 1089, 1022, 
975, 910, 891, 782, 746, 596, 558 cm-1; HRMS (ESI) 183.1031 (M - H. C10H15O3 requires 
183.1027); mp. 62.1-63.1°C. 
 
4-But-3-enyl-piperidine-1,4-dicarboxylic acid 1-benzyl ester (157e) 
 
157e was synthesised using general procedure E with ester 156e (1.51 g, 4.56 mmol). 157e 
yielded as a colourless oil (872 mg, 2.75 mmol, 60% yield). 1H NMR (400 MHz, Chloroform-d) 
δ 7.28 - 7.47 (m, 5 H, Ar-H), 5.77 (ddt, J = 17.1, 10.4, 6.5 Hz, 1 H, H-7), 5.13 (s, 2 H, H-10), 5.03 
(dq, J = 17.1, 1.5 Hz, 1 H, H-8), 4.97 (dq, J = 10.4, 1.5 Hz, 1 H, H-8), 3.87 - 4.13 (m, 2 H, H-4), 
2.92 - 3.18 (m, 2 H, H-4), 2.10 - 2.21 (m, 2 H, H-3), 2.00 - 2.08 (m, 2 H, H-6), 1.59 - 1.76 (m, 2 
H, H-5), 1.34 - 1.52 (m, 2 H, H-3) ppm; 13C NMR (101 MHz, Chloroform-d) δ 180.8 (C-1), 155.3 
(C-9), 137.5 (C-7), 136.7 (C-11), 128.5 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 115.1 (C-8), 67.1 
(C-10), 45.3 (C-2), 41.5 (C-4), 39.2 (C-5), 33.0 (C-3), 28.1 (C-6) ppm; IR (ATR): νmax 3072, 2936, 
1727, 1699, 1670, 1477, 1451, 1362, 1279, 1188, 1151, 1107, 1013, 958, 912, 856, 764, 734, 
698, 602, 557, 460 cm-1; HRMS (ESI) 318.1692(M + H+. C18H24NO4 requires 318.1700), 
340.1510 (M + Na+. C18H23NNaO4requires 340.1519). 
 
2,2-diphenyl-hex-5-enoic acid (157f) 
 
157F was synthesised using general procedure E with ester 156f (1.51 g, 4.56 mmol). 157F 
yielded as a white solid (356 mg, 1.34 mmol, 54% yield). 1H NMR (400 MHz, Chloroform-d) δ 
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11.64 (br. s., 1 H, COOH), 7.18 - 7.41 (m, 10 H, Ar-H), 5.76 (ddt, J = 17.2, 10.3, 6.1 Hz, 1 H, H-
9), 4.96 (dq, J = 17.2, 1.5 Hz, 2 H, H-10), 4.92 (dq, J = 10.3, 1.5 Hz, 2 H, H-10), 2.40 - 2.54 (m, 2 
H, H-7), 1.74 - 1.90 (m, 2 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 180.1 (C-1), 142.2 
(C-3), 138.2 (C-9), 129.0 (Ar-CH), 128.0 (Ar-CH), 127.0 (Ar-CH), 114.6 (C-10), 60.0 (C-2), 37.1 
(C-7), 29.6 (C-8) ppm; IR (ATR): νmax 3061, 2975, 1698, 1640, 1600, 1495, 1445, 1398, 1262, 
1217, 1033, 1003, 913, 759, 724, 698, 591, 502 cm-1; HRMS (ESI) 267.1381 (M + H+. C18H19O2 
requires 267.1380), 289.1190 (M + Na+. C18H18NaO2 requires 289.1199), 265.1299 (M - H+. 
C18H17O2 requires 265.1234); mp. 135.0-137.2 °C. 
 
General Procedure F 
To a solution of carboxylic acid (2.10 mmol) in dry toluene (15 ml) under N2 was added Et3N 
(2.52 mmol) and DPPA (2.31 mmol) and the reaction heated to 90 °C for 2 hours. Benzyl 
alcohol (3.15 mmol) was added and reaction stirred at 90 °C for 96 hours. Reaction was 
quenched with H2O (20 ml) and extracted with EtOAc (2 x 30 ml). Combined organics were 
washed with saturated brine solution (2 x 30 ml), dried with Na2SO4, filtered and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (1.40 mmol, 67% 
yield). 
 
(1,1-dimethyl-pent-4-enyl)-carbamic acid benzyl ester (148) 
 
 
148 was synthesised using general procedure F with acid 147 (299 mg, 2.10 mmol), Et3N (0.35 
ml, 2.52 mmol), DPPA (0.50 ml, 2.31 mmol) and benzyl alcohol (0.33 ml, 3.15 mmol). 148 
yielded as a colourless oil (346 mg, 1.40 mmol, 67% yield) after column chromatography (5% 
EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 7.28 - 7.42 (m, 5 H, Ar-H), 5.81 (ddt, J = 
16.8, 10.7, 6.9, Hz, 1 H, H-11), 5.06 (s, 2 H, H-5), 5.02 (dq, J = 17.5, 1.5 Hz, 2 H, H-12), 4.95 (dq, 
J = 10.7, 1.5 Hz, 1 H, H-12), 4.67 (br. s., 1 H, NH), 1.99 - 2.10 (m, 2 H, H-10), 1.70 - 1.82 (m, 2 
H, H-9), 1.31 (s, 6 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 154.5 (C-6), 138.5 (C-11), 
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136.7 (C-4), 128.5 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 114.5 (C-12), 66.0 (C-5), 52.7 (C-7), 
39.4 (C-9), 28.5 (C-10), 27.0 (C-8) ppm; IR (ATR): νmax 3346, 3066, 3033, 2973, 1703, 1640, 
1505, 1453, 1387, 1365, 1314, 1259, 1214, 1071, 1028, 909, 777, 737, 696, 602, 475 cm-1; 
HRMS (ESI) 248.1637 (M + H+. C15H22NO2 requires 248.1645), 270.1455 (M + Na+. C15H21NNaO2 
requires 270.1464). 
 
(1-But-3-enyl-cyclobutyl)-carbamic acid benzyl ester (158a) 
 
158a was synthesised using general procedure F with acid 157a (106 mg, 0.687 mmol), Et3N 
(0.12 ml, 0.824 mmol), DPPA (0.16 ml, 0.756 mmol) and benzyl alcohol (0.11 ml, 1.03 mmol). 
Cs2CO3 (270 mg, 0.824 mmol) was added after 90 hours of stirring. 158a yielded as a colourless 
oil (75 mg, 0.289 mmol, 42% yield) after column chromatography (8% EtOAc/hexane). 1H NMR 
(400 MHz, Chloroform-d) δ ppm 7.29 - 7.44 (m, 5 H, Ar-H), 5.84 (ddt, J = 17.5, 9.9, 6.9, 6.9 Hz, 
1 H, H-12), 5.08 (s, 2 H, H-5), 5.03 (dq, J = 17.5, 1.5 Hz, 3 H, H-13), 4.95 (dq, J = 9.9, 1.5 Hz, 1 
H, H-13), 4.87 (br. s., 1 H, NH), 2.12 - 2.32 (m, 2 H, H-8), 1.99 - 2.09 (m, 4 H, H-8, H-11), 1.86 - 
1.98 (m, 3 H, H-9, H-10), 1.72 - 1.85 (m, 1 H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 
154.4 (C-6), 138.5 (C-12), 136.7 (C-4), 128.5 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 114.5 (C-
13), 66.1 (C-5), 56.7 (C-7), 36.5 (C-10), 32.6 (C-8), 28.3 (C-11), 14.6 (C-9) ppm; IR (ATR): νmax 
3332, 3066, 3032, 2979, 2939, 1697, 1640, 1518, 1498, 1454, 1402, 1372, 1336, 1248, 1234, 
1069, 1027, 995, 909, 775, 736, 696, 631, 595, 489 cm-1; HRMS (ESI) 260.1651 (M + H+. 








(1-But-3-enyl-cyclopentyl)-carbamic acid benzyl ester (158b) 
 
158b was synthesised using general procedure F with acid 157b (313 mg, 1.86 mmol), Et3N 
(0.31 ml, 2.23 mmol), DPPA (0.44 ml, 2.05 mmol) and benzyl alcohol (0.29 ml, 2.79 mmol). 
158b yielded as a colourless oil (314 mg, 1.15 mmol, 62% yield) after column chromatography 
(5% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 7.28 - 7.45 (m, 5 H, Ar-H), 5.82 (ddt, 
J = 17.5, 9.9, 6.1 Hz, 1 H, H-12), 5.06 (s, 2 H, H-5), 5.01 (dq, J = 17.5, 1.8 Hz, 1 H, H-13), 4.93 
(dq, J = 9.9, 1.8 Hz, 1 H, H-13), 4.64 (br. s., 1 H, NH), 2.00 - 2.17 (m, 2 H, H-11), 1.78 - 1.98 (m, 
4 H, H-8, H-10), 1.51 - 1.76 (m, 6 H, H-8, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 154.6 
(C-6), 138.8 (C-12), 136.7 (C-4), 128.5 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 114.3 (C-13), 66.0 
(C-5), 64.0 (C-7), 38.0 (C-10), 36.7 (C-8), 29.5 (C-11), 23.4 (C-9) ppm; IR (ATR): νmax 3343, 3062, 
3032, 2953, 2871, 1697, 1640, 1522, 1499, 1453, 1403, 1372, 1334, 1307, 1251, 1215, 1091, 
1026, 1003, 960, 909, 736, 696, 675, 620, 597, 578, 557, 473, 465 cm-1; HRMS (ESI) 296.1622 
(M + Na+. C17H23NNaO2 requires 296.1621). 
 
(1-But-3-enyl-cyclohexyl)-carbamic acid benzyl ester (158c) 
 
158c was synthesised using general procedure F with acid 157c (287 mg, 1.57 mmol), Et3N 
(0.26 ml, 1.88 mmol), DPPA (0.37 ml, 1.73 mmol) and benzyl alcohol (0.24 ml, 2.36 mmol). 
158c yielded as a colourless oil (353 mg, 1.23 mmol, 78% yield) after column chromatography 
(5% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 7.28 - 7.44 (m, 5 H, Ar-H), 5.81 (ddt, 
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J = 16.8, 10.7, 6.1 Hz, 1 H, H-13), 5.06 (s, 2 H, H-5), 4.99 (dq, J = 16.8, 1.5 Hz, 1 H, H-14), 4.92 
(dq, J = 10.7, 1.5 Hz, 1 H, H-14), 4.52 (br. s., 1 H, NH), 1.89 - 2.09 (m, 4 H, H-8, H-12), 1.75 - 
1.87 (m, 2 H, H-11), 1.16 - 1.59 (m, 8 H, H-8, H-9, H-10) ppm; 13C NMR (101 MHz, Chloroform-
d) δ 154.4 (C-6), 138.9 (C-13), 136.8 (C-4), 128.5 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 114.2 
(C-14), 66.0 (C-5), 54.7 (C-7), 37.5 (C-11), 34.9 (C-8), 27.6 (C-12), 25.7 (C-10), 21.6 (C-9) ppm; 
IR (ATR): νmax 3450, 3347, 3074, 3032, 2980, 2930, 2856, 1706, 1640, 1523, 1505, 1452, 1393, 
1379, 1328, 1282, 1243, 1214, 1090, 1076, 1000, 965, 909, 774, 737, 696, 598, 482, 473, 482 
cm-1; HRMS (ESI) 310.1776 (M + Na+. C18H25NNaO2 requires 310.1777) 
 
(4-But-3-enyl-tetrahydro-pyran-4-yl)-carbamic acid benzyl ester (158d) 
 
158d was synthesised using general procedure F with acid 157d (300 mg, 1.63 mmol), Et3N 
(0.27 ml, 1.96 mmol), DPPA (0.39 ml, 1.79 mmol) and benzyl alcohol (0.253 ml, 2.45 mmol). 
Cs2CO3 (411 mg, 1.26 mmol) was added after 90 hours of stirring. 158d yielded as a white 
solid (354 mg, 1.22 mmol, 75% yield) after column chromatography (10% EtOAc/hexane). 1H 
NMR (400 MHz, Chloroform-d) δ 7.29 - 7.47 (m, 5 H, Ar-H), 5.80 (ddt, J = 16.8, 10.7, 6.7 Hz, 1 
H, H-12), 5.07 (s, 2 H, H-5),  5.01 (dq, J = 16.8, 1.5 Hz, 1 H, H-13), 4.95 (dq, J = 10.7, 1.5 Hz, 1 
H, H-13), 4.57 (br. s., 1 H, NH), 3.76 (ddd, J = 11.8, 4.6, 3.4 Hz, 2 H, H-9), 3.61 (ddd, J = 11.8, 
11.4, 2.3 Hz, 2 H, H-9), 2.01 - 2.10 (m, 2 H, H-11), 1.99 (ddd, J = 13.8, 3.4, 2.3 Hz, 2 H, H-8), 
1.80 - 1.91 (m, 2 H, H-10), 1.66 (ddd, J = 13.8, 11.4, 4.6 Hz, 2 H, H-8) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 154.4 (C-6), 138.3 (C-12), 136.5 (C-4), 128.5 (Ar-CH), 128.2 (Ar-CH), 128.0 (Ar-
CH), 114.7 (C-13), 66.3 (C-5), 63.4 (C-9), 52.6 (C-7), 37.7 (C-10), 35.3 (C-8), 27.3 (C-11) ppm; IR 
(ATR): νmax 3328, 3065, 3034, 2952, 2587, 2139, 1701, 1640, 1529, 1453, 1358, 1332, 1250, 
1235, 1215, 1105, 1073, 1023, 986, 945, 911, 848, 777, 740, 697, 617, 597, 537, 492, 468 cm-




4-Benzyloxycarbonylamino-4-but-3-enyl-piperidine-1-carboxylic acid benzyl ester (158e) 
 
158e was synthesised using general procedure F with acid 157e (610 mg, 1.92 mmol), Et3N 
(0.32 ml, 2.31 mmol), DPPA (0.46 ml, 2.11 mmol) and benzyl alcohol (0.30 ml, 2.88 mmol). 
Cs2CO3 (751 mg, 2.31 mmol) was added after 90 hours of stirring. 158e yielded as a colourless 
oil (270 mg, 0.640 mmol, 33% yield) after column chromatography (20% EtOAc/hexane). 1H 
NMR (400 MHz, Chloroform-d): 7.28 - 7.46 (m, 10 H, Ar-H), 5.78 (ddt, J = 16.8, 10.7, 6.9 Hz, 1 
H, H-18), 5.13 (s, 2 H, H-11), 5.07 (s, 2 H, H-5), 5.00 (dq, J = 16.8, 1.5 Hz, 1 H, H-19), 4.95 (dq, J 
= 10.7, 1.5 Hz, 1 H, H-19), 4.55 (br. s., 1 H, NH), 3.79 - 3.99 (m, 2 H, H-9), 3.00 - 3.22 (m, 2 H, 
H-9’), 1.96 - 2.16 (m, 4 H, H-8, H-17), 1.70 - 1.92 (m, 2 H, H-16), 1.45 - 1.60 (m, 2 H, H-8’) ppm; 
13C NMR (101 MHz, Chloroform-d) δ 155.2 (C-10), 154.5 (C-6), 138.2 (C-18), 136.7 (C-12), 
136.4 (C-4), 128.7 (Ar-CH), 128.6 (Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-CH), 128.1 (Ar-CH), 128.0 
(Ar-CH), 114.8 (C-19), 67.2 (C-11), 66.4 (C-5), 53.3 (C-7), 39.7 (C-9), 37.5 (C-16), 34.4 (C-8), 27.6 
(C-17) ppm; IR (ATR): νmax 3331, 3032, 2931, 1681, 1531, 1497, 1452, 1360, 1333, 1274, 1247, 
1218, 1168, 1088, 1068, 1026, 911, 737, 697, 603, 456 cm-1; HRMS (ESI) 423.2275 (M + H+. 










(1,1-diphenyl-pent-4-enyl)-carbamic acid benzyl ester (158f) 
 
158f was synthesised using general procedure F with acid 157f (244 mg, 0.916 mmol), Et3N 
(0.15 ml, 1.10 mmol), DPPA (0.22 ml, 1.01 mmol) and benzyl alcohol (0.14 ml, 1.37 mmol). 
Cs2CO3 (358 mg, 1.10 mmol) was added after 90 hours of stirring. 158f yielded as a white solid 
(222 mg, 0.598 mmol, 65% yield) after column chromatography (8% EtOAc/hexane). 1H NMR 
(400 MHz, Chloroform-d) δ ppm 7.17 - 7.38 (m, 15 H, Ar-H), 5.80 (ddt, J = 16.8, 10.7, 6.9 Hz, 1 
H, H-14), 5.71 (s, 1 H, NH), 5.03 (s, 2 H, H-5), 4.98 (dq, J = 16.8, 1.5 Hz, 1 H, H-15), 4.94 (dq, J = 
10.7, 1.5 Hz, 1 H, H-15), 2.61 - 2.79 (m, 2 H, H-12), 1.87 - 2.00 (m, 2 H, H-13) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 154.6(C-6), 145.1 (C-8), 138.0 (C-14), 136.5 (C-4), 128.5 (Ar-CH), 
128.2 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 126.9 (Ar-CH), 126.5 (Ar-CH), 114.8 (C-15), 66.5 
(C-5), 64.1 (C-7),37.3 (C-12), 28.6 (C-13) ppm; IR (ATR): νmax 3340, 3061, 3031, 2936, 1735, 
1639, 1584, 1491, 1401, 1332, 1242, 1221, 1086, 1061, 1010, 911, 755, 698, 644, 590, 517 cm-
1; HRMS (ESI) 372.1949 (M + H+. C25H26NO2 requires 372.1958), 394.1769 (M + Na+. 
C25H26NNaO2requires 394.1777); mp. 92.1-94.6 °C 
 
Thioacrylic acid 2,4,6-trimethyl-phenyl ester (152) 
 
152 was synthesised using the same procedure as 134 with a solution of NaOH (15% w/w aq. 
5 ml), NaBH4 (0.010 g, 0.27 mmol), 2,4,6-trimethylthiophenol (1.36 g, 8.93 mmol), butylated 
hydroxytoluene (0.030 g, 0.13 mmol) and acryloyl chloride (1.08 ml, 13.34 mmol). 152 yielded 
as a pale-yellow oil (1.262 g, 6.12 mmol, 69% yield) after column chromatography (2% 
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Et2O/hexane). 1H NMR (400 MHz, Chloroform-d) δ 7.01 (s, 2 H, H-6), 6.50 (dd, J = 17.5, 10.0 
Hz, 1 H, H-2), 6.40 (dd, J = 17.5, 1.2 Hz, 1 H, H-1), 5.76 (dd, J = 10.0, 1.2 Hz, 1 H, H-1), 2.34 (s, 
6 H, H-9), 2.32 (s, 3 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.1 (C-3), 142.6 (C-4), 
134.5 (C-2), 129.2 (C-6), 129.1 (C-7), 126.9 (C-1), 123.0 (C-5), 21.5 (C-9), 21.1 (C-8) ppm; IR 
(ATR): νmax 2952, 2920, 1681, 1612, 1603, 1463, 1375, 1299, 1160, 1031, 994, 940, 850, 726, 
631, 558 cm-1; HRMS (ESI) 207.0838 (M + H+. C12H15OS requires 207.0838) 
6-Cbz-amino-6,6-dimethyl-hex-2-enethioic acid S-p-tolyl ester (149) 
  
149 was synthesised using general procedure C with thioester 134 (214 mg, 1.20 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (25.1 mg, 0.040 mmol), copper iodide (76.2 mg, 
0.40 mmol) and Cbz-amine 148 (100 mg, 0.40 mmol). 149 yielded as a pale green oil (141 mg, 
0.355 mmol, 89% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.28 - 7.40 (m, 5 H, Ar-H), 7.32 (d, J = 8.0 Hz, 2 H, H-15), 7.23 (d, J = 8.0 Hz, 2 
H, H-16), 6.98 (dt, J = 16.0, 6.9 Hz, 1 H, H-11), 6.18 (d, J = 16.0 Hz, 1 H, H-12), 5.06 (s, 2 H, H-
5), 4.64 (br. s., 1 H, NH), 2.39 (s, 3 H, H-18), 2.21 (td, J = 8.4, 6.9 Hz, 2 H, H-10), 1.89 (t, J = 8.4 
Hz, 2 H, H-9), 1.28 - 1.36 (m, 6 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.4 (C-13), 
154.5 (C-6), 146.1 (C-11), 139.6 (C-17), 136.5 (C-4), 134.6 (C-15), 130.0 (C-16), 128.6 (Ar-CH), 
128.1 (Ar-CH), 128.1 (Ar-CH), 127.9 (C-12), 124.0 (C-14), 66.2 (C-5), 52.6 (C-7), 37.8 (C-9), 27.3 
(C-10), 27.3 (C-8), 21.3 (C-18) ppm; IR (ATR): νmax 3358, 3031, 2969, 2925, 1722, 1685, 1631, 
1521, 1495, 1453, 1399, 1388, 1365, 1303, 1262, 1213, 1180, 1089, 1072, 1036, 1017, 1002, 
985, 928, 808, 778, 738, 697, 649, 634, 315, 578, 533, 475 cm-1; HRMS (ESI) 420.1601 (M + 
Na+. C23H27NNaO3S requires 420.1604) 
 





153 was synthesised using general procedure C with thioester 152 (248 mg, 1.20 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (25.1 mg, 0.040 mmol), copper iodide (76.2 mg, 
0.40 mmol) and Cbz-amine 148 (100 mg, 0.40 mmol). 153 yielded as a dark green oil (157 mg, 
0.37 mmol, 92% yield) after column chromatography (5% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 - 7.43 (m, 5 H, Ar-H), 6.99 (s, 2 H, H-16), 6.92 - 7.03 (m, 1 H, H-11), 6.22 
(d, J = 15.3 Hz, 1 H, H-12), 5.06 (s, 2 H, H-5), 4.65 (br. s., 1 H, NH), 2.32 (s, 6 H, H-19), 2.30 (s, 
3 H, J-18), 2.17 - 2.26 (m, 2 H, H-10), 1.85 - 1.95 (m, 2 H, H-9), 1.31 (s, 6 H, H-8) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 187.5 (C-13), 154.5 (C-6), 145.6 (C-11), 142.7 (C-14), 139.8 (C-17), 
136.5 (C-4), 129.2 (C-16), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 128.1 (C-12), 123.4 (C-
15), 66.2 (C-5), 52.6 (C-7), 37.8 (C-9), 27.3 (C-10), 27.2 (C-8), 21.6 (C-19), 21.1 (C-18) ppm; IR 
(ATR): νmax 3358, 3030, 2969, 2924, 1723, 1681, 1631, 1602, 1523, 1454, 1388, 1365, 1299, 
1262, 1213, 1178, 1087, 1072, 1030, 1003, 929, 850, 806, 778, 738, 715, 697, 634, 578, 564 
507, 486, 472 cm-1; HRMS (ESI) 448.1910 (M + Na+. C25H31NNaO3S requires 448.1917 
 
6-Cbz-amino-6,6-cyclobutyl-hex-2-enethioic acid S-p-tolyl ester (159a) 
 
159a was synthesised using general procedure C with thioester 134 (118 mg, 0.66 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (13.8 mg, 0.022 mmol), copper iodide (41.9 mg, 
0.22 mmol) and Cbz-amine 158a (57 mg, 0.22 mmol). 159a yielded as a pale brown oil (83.6 
mg, 0.204 mmol, 93% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 
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MHz, Chloroform-d) δ 7.34 - 7.45 (m, 5 H, Ar-H), 7.32 (d, J = 8.2 Hz, 2 H, H-16), 7.23 (d, J = 8.2 
Hz, 2 H, H-17), 7.00 (dt, J = 15.6, 5.9 Hz, 1 H, H-12), 6.19 (d, J = 15.6 Hz, 1 H, H-13), 5.08 (s, 2 
H, H-5), 4.90 (br. s., 1 H, NH), 2.39 (s, 3 H, H-19), 2.12 - 2.29 (m, 4 H, H-8, H-11), 1.98 - 2.10 (m, 
4 H, H-8, H-10), 1.91 - 1.97 (m, 1 H, H-9), 1.76 - 1.87 (m, 1 H, H-9) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 188.4 (C-14), 154.3 (C-6), 146.1 (C-12), 139.6 (C-18), 136.4 (C-4), 134.6 (C-
16), 130.0 (C-17), 128.5 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 127.9 (C-13), 124.0 (C-15), 66.3 
(C-5), 56.5 (C-7), 35.4 (C-10), 32.8 (C-8), 27.0 (C-11), 21.3 (C-19), 14.7 (C-9) ppm; IR (ATR): νmax 
3346, 3030, 2938, 3854, 1689, 1630, 1598, 1513, 1494, 1453, 1399, 1376, 1303, 1273, 1247, 
1181, 1154, 1084, 1060, 1028, 1016, 982, 807, 737, 697, 649, 618, 535, 475 cm-1; HRMS (ESI) 
410.1770 (M + H+. C24H28NO3S requires 410.1784), 432.1590 (M + Na+. C24H27NNaO3S requires 
432.1604) 
 
6-Cbz-amino-6,6-cyclopentyl-hex-2-enethioic acid S-p-tolyl ester (159b) 
 
159b was synthesised using general procedure C with thioester 134 (126 mg, 0.71 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (14.8 mg, 0.024 mmol), copper iodide (44.9 mg, 
0.24 mmol) and Cbz-amine 158b (65 mg, 0.24 mmol). 159b yielded as a pale green oil (90 mg, 
0.21 mmol, 90% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.33 - 7.47 (m, 5 H, Ar-H), 7.32 (d, J = 8.3 Hz, 2 H, H-16), 7.23 (d, J = 8.3 Hz, 2 
H, H-17), 7.00 (dt, J = 15.6, 6.4 Hz, 1 H, H-12), 6.17 (d, J = 15.6 Hz, 1 H, H-13), 5.07 (s, 2 H, H-
5), 4.65 (br. s., 1 H, NH), 2.35 - 2.43 (m, 3 H, H-19), 2.17 - 2.28 (m, 2 H, H-11), 1.97 - 2.07 (m, 
2 H, H-10), 1.87 - 1.97 (m, 2 H, H-9), 1.65 - 1.79 (m, 4 H, H-8), 1.53 - 1.65 (m, 2 H, H-9) ppm; 
13C NMR (101 MHz, Chloroform-d) δ 188.4 (C-14), 154.6 (C-6), 146.4 (C-12), 139.6 (C-18), 
136.5 (C-4), 134.6 (C-16), 130.0 (C-17), 128.5 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 127.8 (C-
13), 124.0 (C-15), 66.2 (C-5), 63.8 (C-7), 38.1 (C-8), 35.5 (C-10), 28.2 (C-11), 23.3 (C-9), 21.3 (C-
19) ppm; IR (ATR): νmax 3355, 3030, 2953, 2870, 1690, 1630, 1520, 1495, 1453, 1399, 1304, 
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1244, 1181, 1092, 1017, 807, 738, 697, 621, 535, 476 cm-1; HRMS (ESI) 446.1757 (M + Na+. 
C25H29NNaO3S requires 446.1760) 
 
6-Cbz-amino-6,6-cyclohexyl-hex-2-enethioic acid S-p-tolyl ester (159c) 
 
159c was synthesised using general procedure C with thioester 134 (128 mg, 0.72 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (15.0 mg, 0.024 mmol), copper iodide (45.5 mg, 
0.24 mmol) and Cbz-amine 158c (69 mg, 0.24 mmol). 159c yielded as a pale green oil (98 mg, 
0.22 mmol, 94% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.34 - 7.42 (m, 5 H, Ar-H), 7.32 (d, J = 8.2 Hz, 2 H, H-17), 7.23 (d, J = 8.2 Hz, 2 
H, H-18), 6.99 (dt, J = 15.1, 6.9 Hz, 1 H, H-13), 6.16 (d, J = 15.1 Hz, 1 H, H-14), 5.07 (s, 2 H, H-
5), 4.56 (br. s., 1 H, NH), 2.39 (s, 3 H, H-20), 2.13 - 2.26 (m, 2 H, H-12), 1.84 - 2.04 (m, 4 H, H-
8, H-11), 1.50 - 1.68 (m, 3 H, H-9, H-10), 1.20 - 1.49 (m, 5 H, H-8, H-9, H-10) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 188.4 (C-15), 154.3 (C-6), 146.6 (C-13), 139.5 (C-19), 136.6 (C-14), 
134.6 (C-17), 129.9 (C-18), 128.5 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 127.7 (C-14), 124.0 (C-
16), 66.2 (C-5), 54.5 (C-7), 36.4 (C-11), 34.9 (C-8), 26.4 (C-12), 25.6 (C-10), 21.5 (C-9), 21.3 (C-
20) ppm; IR (ATR): νmax 3359, 3030, 2928, 2856, 1720, 1685, 1630, 1495, 1452, 1399, 1328, 
1305, 1281, 1237, 1208, 1168, 1149, 1130, 1091, 1076, 1039, 1029, 1016, 987, 968, 923, 807, 










6-Cbz-amino-6,6-(tetrahydropyran-4-yl)-hex-2-enethioic acid S-p-tolyl ester (159d) 
 
159d was synthesised using general procedure C with thioester 134 (135 mg, 0.76 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (15.7 mg, 0.025 mmol), copper iodide (47.6 mg, 
0.25 mmol) and Cbz-amine 158d (73 mg, 0.25 mmol). 159d yielded as a pale brown oil (74 
mg, 0.17 mmol, 67% yield) after column chromatography (20% EtOAc/hexane). 1H NMR (400 
MHz, Chloroform-d) δ 7.34 - 7.44 (m, 5 H, Ar-H), 7.32 (d, J = 7.6 Hz, 2 H, H-16), 7.23 (d, J = 7.6 
Hz, 2 H, H-17), 6.96 (dt, J = 16.0, 6.1 Hz, 1 H, H-12), 6.16 (d, J = 16.0 Hz, 1 H, H-13), 5.08 (s, 2 
H, H-5), 4.62 (br. s, 1 H, NH), 3.77 (ddd, J = 12.2, 4.6, 3.0 Hz, 2 H, H-9), 3.61 (ddd, J = 12.2, 11.4, 
2.3 Hz, 2 H, H-9), 2.39 (s, 3 H, H-19), 2.14 - 2.24 (m, 2 H, H-11), 1.98 (ddd, J = 14.0, 3.0, 2.3 Hz, 
2 H, H-8), 1.90 - 2.05 (m, 2 H, H-10), 1.66 (ddd, J = 14.0, 11.4, 4.6 Hz, 2 H, H-8) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 188.3 (C-14), 154.4 (C-6), 145.7 (C-12), 139.6 (C-18), 136.3 (C-4), 
134.6 (C-16), 130.0 (C-17), 128.6 (Ar-CH), 128.3 (Ar-CH), 128.1 (Ar-CH), 128.0 (C-13), 123.9 (C-
15), 66.5 (C-5), 63.3 (C-9), 52.4 (C-7), 36.8 (C-10), 35.2 (C-8), 26.0 (C-11), 21.3 (C-19) ppm; IR 
(ATR): νmax 3355, 3031, 2951, 2925, 2856, 1719, 1679, 1630, 1597, 1524, 1494, 1452, 1393, 
1357, 1332, 1303, 1260, 1234, 1212, 1190, 1157, 1104, 1089, 1072, 1018, 992, 935, 911, 847, 
808, 778, 737, 697, 647, 625, 580, 535, 475 cm-1; HRMS (ESI) 440.1886 (M + H+. C25H30NO4S 











6-Cbz-amino-6,6-(N-Cbz-piperidin-4-yl)-hex-2-enethioic acid S-p-tolyl ester (159e) 
 
159e was synthesised using general procedure C with thioester 134 (123.5 mg, 0.69 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (11.9 mg, 0.023 mmol), copper iodide (44.0 mg, 
0.23 mmol) and Cbz-amine 158e (97.6 mg, 0.23 mmol). 159e yielded as a colourless oil (99 
mg, 0.173 mmol, 75% yield) after column chromatography (50% Et2O/hexane). 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.30 (m, 10H, Ar-H), 7.29 (d, J = 8.2 Hz, 2H, H-16), 
7.21 (d, J = 8.2 Hz, 2H, H-17), 6.92 (dt, J = 15.4, 6.6 Hz, 1H, H-12), 6.13 (d, J = 15.4 Hz, 1H, H-
13), 5.11 (s, 2H, H-21), 5.05 (s, 2H, H-5), 4.52 (br. s, 1H, NH), 4.03 – 3.80 (m, 2H, H-9), 3.19 – 
2.93 (m, 2H, H-9’), 2.36 (s, 3H, H-19), 2.22 – 2.12 (m, 2H, H-11), 2.09 – 1.97 (m, 2H, H-10), 1.96 
– 1.80 (m, 2H, H-8), 1.58 – 1.42 (m, 2H, H-8’) ppm;  13C NMR (101 MHz, Chloroform-d) δ 188.4 
(C-14), 155.3 (C-20), 154.6 (C-6), 145.6 (C-12), 139.8 (C-18), 136.8 (C-22), 136.4 (C-4), 134.7 
(C-16), 130.1 (C-17), 128.7 (Ar-CH), 128.6 (Ar-CH), 128.4 (C-13), 128.3 (Ar-CH), 128.2 (Ar-CH), 
128.2 (Ar-CH), 128.0 (Ar-CH), 124.0 (C-15), 67.3 (C-21), 66.7 (C-5), 53.3 (C-7), 39.6 (C-9), 36.6 
(C-10), 34.4 (C-8), 26.2 (C-11), 21.4 (C-19) ppm; IR (ATR): νmax 3339, 3032, 2933, 1684, 1631, 
1526, 1496, 1437, 1360, 1333, 1243, 1214, 1164, 1069, 1017, 972, 808, 713, 737, 697, 603, 
538, 475 cm-1; HRMS (ESI) 573.2429 (M + H+. C33H37N2O5S requires 573.2418), 590.2694 (M + 
NH4+. C33H40N3O5S requires 590.2683), 595.2247 (M + Na+. C33H36N3NaO5S requires 595.2237), 







6-Cbz-amino-6,6-diphenyl-hex-2-enethioic acid S-p-tolyl ester (159f) 
 
159f was synthesised using general procedure C with thioester 134 (184 mg, 1.03 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (21.6 mg, 0.0345 mmol), copper iodide (65.6 mg, 
0.345 mmol) and Cbz-amine 158f (128 mg, 0.345 mmol). 159f yielded as a pale yellow oil (112 
mg, 0.21 mmol, 62% yield) after column chromatography (12% EtOAc/hexane). 1H NMR (400 
MHz, Chloroform-d) δ 7.19 - 7.40 (m, 19 H, Ar-H), 6.92 (dt, J = 15.3, 6.9 Hz, 1 H, H-14), 6.10 (d, 
J = 15.3 Hz, 1 H, H-15), 5.72 (s, 1 H, NH), 5.02 (s, 2 H, H-5), 2.73 - 2.90 (m, 2 H, H-12), 2.37 (s, 
3 H, H-21), 2.07 - 2.17 (m, 2 H, H-13) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.3 (C-16), 
154.6 (C-6), 145.7 (C-14), 144.9 (C-8), 139.6 (C-20), 136.2 (C-4), 134.6 (C-18), 130.0 (C-19), 
128.5 (Ar-CH), 128.4 (Ar-CH), 128.2 (Ar-CH), 128.2 (Ar-CH), 128.0 (C-14), 127.1 (Ar-CH), 126.3 
(Ar-CH), 124.0 (C-17), 66.7 (C-5), 63.9 (C-7), 35.7 (C-12), 27.2 (C-13), 21.3 (C-21) ppm; IR (ATR): 
νmax 3346, 3030, 2925, 1731, 1682, 1630, 1492, 1446, 1399, 1304, 1236, 1213, 1130, 1086, 
1043, 1030, 1001, 910, 808, 776, 755, 734, 698, 647, 590, 475 cm-1; HRMS (ESI) 522.2102 (M 
+ H+. C33H32NO3S requires 522.2097), 544.1918 (M + Na+. C33H31NNaO3S requires 544.1917) 
Asymmetric cyclisation of 3,3-disubstituted pyrrolidines 
General procedure G 
Racemic 
A solution of amino-thioester (0.048 mmol) in 1,2-DCE (5 ml) was added to rac-CSA (0.145 
mmol) under N2 and the reaction heated to 50 °C for 24 hours. The reaction was cooled to 
room temperature and extracted with DCM (10 ml). The organic fraction was washed with 
saturated NaHCO3 solution (10 ml), dried with Na2SO4, filtered and concentrated in vacuo. 




A solution of amino-thioester (0.049 mmol) in cyclohexane (0.02M) was added to (R)-TRIP 
(0.098 mmol) under N2 and the reaction heated to 80 °C for 24 hours. The reaction was then 
cooled to room temperature, quenched with Et3N (0.2 ml) and concentrated in vacuo. The 





144a was synthesised using general procedure G with amino-thioester 143a (9.1 mg, 0.022 
mmol) and rac-CSA (15.5 mg, 0.067 mmol). 144a yielded as a colourless oil (7.1 mg, 0.017 
mmol, 78% yield) after column chromatography (8% EtOAc/hexane). 
Asymmetric 
144a was synthesised using general procedure G with amino-thioester 143a (12.9 mg, 0.031 
mmol) and (R)-TRIP (4.7 mg, 0.0063 mmol). 144a yielded as a colourless oil (10.0 mg, 0.024 
mmol, 78% yield, 98:2 er) after column chromatography (8% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.28 (m, 5H, Ar-H), 7.28 – 7.13 (m, 4H, H-16, H-17), 
5.20 – 5.09 (m, 2H, H-5), 4.25 – 4.13 (m, 1H, H-12), 3.54 (d, J = 10.8 Hz, 0.4H, H-7, rotamer 2), 
3.49 (d, J = 10.8 Hz, 0.6H, H-7, rotamer 1), 3.46 (dd, J = 14.8, 3.7 Hz, 0.6H, H-13, rotamer 1), 
3.42 (d, J = 10.8 Hz, 0.4H, H-7’), 3.37 (d, J = 10.7 Hz, 0.6H, H-7’), 3.19 (dd, J = 14.8, 3.7 Hz, 0.4H, 
H-13, rotamer 2), 2.73 (dd, J = 14.8, 9.8 Hz, 0.4H, H-13’, rotamer 2), 2.66 (dd, J = 14.8, 9.8 Hz, 
0.6H, H-13’, rotamer 1), 2.36 (s, 3H, H-19), 2.20 – 2.08 (m, 1H, H-11), 2.06 – 1.95 (m, 2H, H-9), 
1.95 – 1.78 (m, 5H, H-9’, H-10, H-11’) ppm; 13C NMR (101 MHz Chloroform-d) δ 196.1 (C-14), 
155.0 (C-6), 140.0(139.8) (C-18), 136.9(136.7) (C-4), 134.5 (134.4) (C-16), 130.2 (130.1) (C-17), 
128.7 (128.6) (Ar-CH), 128.1 (Ar-CH), 128.0 (127.9) (Ar-CH), 124.2(124.0) (C-15), 67.1 (66.8) 
(C-5), 58.4 (58.1) (C-7), 54.8 (54.4) (C-12), 48.3 (47.1) (C-13), 44.0 (43.5) (C-8), 43.5 (42.8) (C-
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11), 32.3 (32.0, 31.6) (C-9), 21.4 (C-19), 16.5 (16.4) (C-10) ppm; IR (ATR): νmax 3031, 2923, 2852, 
1699, 1598, 1494, 1446, 1409, 1356, 1340, 1282, 1210, 1165, 1127, 1093, 807, 769, 750, 697, 
606, 566, 523, 474 cm-1; HRMS (ESI) 410.1783 (M + H+. C24H28NO3S requires 410.1784); 






144b was synthesised using general procedure G with amino-thioester 143b (9.0 mg, 0.021 
mmol) and rac-CSA (14.8 mg, 0.064 mmol). 144b yielded as a colourless oil (8.7 mg, 0.021 
mmol, 97% yield) after column chromatography (8% EtOAc/hexane). 
Asymmetric 
144b was synthesised using general procedure G with amino-thioester 143b (15.0 mg, 0.035 
mmol) and (R)-TRIP (5.3 mg, 0.0071 mmol). 144b yielded as a colourless oil (13.0 mg, 0.031 
mmol, 87% yield, 98:2 er) after column chromatography (8% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.50 – 7.28 (m, 5H, Ar-H), 7.28 – 7.12 (m, 4H, H-16, H-17), 
5.24 – 5.04 (m, 2H, H-5), 4.25 – 4.07 (m, 1H, H-12), 3.54 (dd, J = 15.2, 3.7 Hz, 0.6H, H-13, 
rotamer 1), 3.46 (d, J = 10.7 Hz, 0.4H, H-7, rotamer 2), 3.38 (d, J = 10.7 Hz, 0.6H, H-7, rotamer 
1), 3.28 (dd, J = 15.2, 3.7 Hz, 0.4H, H-13, rotamer 2), 3.14 (d, J = 10.7 Hz, 1H, H-7’), 2.83 (dd, J 
= 15.2, 9.1 Hz, 0.6H, H-13’, rotamer 1), 2.76 (dd, J = 15.2, 9.1 Hz, 0.4H, H-13’, rotamer 2), 2.36 
(s, 3H, H-19), 2.15 – 2.00 (m, 1H, H-11), 1.77 (dd, J = 12.7, 8.1 Hz, 0.6H, H-11’, rotamer 1), 1.71 
(dd, J = 12.7, 8.1 Hz, 0.4H, H-11’, rotamer 2), 1.67 –1.35 (m, 8H, H9, H-10) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 196.1 (C-14), 155.0 (C-6), 139.9(139.7) (C-18), 136.9 (C-4), 134.5(134.4) 
(C-16), 130.2(130.1) (C-17), 128.7(128.6) (Ar-CH), 128.1 (128.0) (Ar-CH), 128.0(127.9) (Ar-CH), 
124.2 (C-15), 67.1(66.8) (C-5), 58.2(58.0) (C-7), 55.1(54.5) (C-12), 48.6(47.3) (C-13), 48.5(48.3) 
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(C-8), 44.2(43.4) (C-11), 37.7(36.2) (C-9), 24.9(24.7) (C-10), 21.4 (C-19) ppm; IR (ATR): νmax 
2923, 2857, 1701, 1494, 1448, 1410, 1356, 1284, 1210, 1175, 1111, 978, 807, 769, 697, 605, 
533, 475 cm-1; HRMS (ESI) 424.1944 (M + H+. C25H30NO3S requires 424.1941); 446.1756 (M + 





144c was synthesised using general procedure G with amino-thioester 143c (8.9 mg, 0.020 
mmol) and rac-CSA (14.2 mg, 0.061 mmol). 144c yielded as a pale-yellow oil (8.8 mg, 0.020 
mmol, 99% yield) after column chromatography (8% EtOAc/hexane). 
Asymmetric 
144c was synthesised using general procedure G with amino-thioester 143c (14.0 mg, 0.032 
mmol) and (R)-TRIP (4.8 mg, 0.0064 mmol). 144c yielded as a pale-yellow oil (13.8 mg, 0.032 
mmol, 99% yield, 97:3 er) after column chromatography (8% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.29 (m, 5H, Ar-H), 7.28 – 7.16 (m, 4H, H-17, H-18), 
5.27 – 5.05 (m, 2H, H-5), 4.19 (dddd, J = 9.1, 8.4, 7.8, 3.7 Hz, 1H, H-13), 3.64 (d, J = 11.1 Hz, 
0.4H, H-7, rotamer 2), 3.55 (d, J = 11.1 Hz, 0.6H, H-7, rotamer 1), 3.51 (dd, J = 15.0, 3.7 Hz, 
0.6H, H-14, rotamer 1), 3.25 (dd, J = 15.0, 3.7 Hz, 0.4H, H-14, rotamer 2), 2.98 (d, J = 11.1 Hz, 
1H, H-7’), 2.81 (dd, J = 15.0, 9.1 Hz, 0.6H, H-14’, rotamer 1), 2.73 (dd, J = 15.0, 9.1 Hz, 0.4H, H-
14’, rotamer 2), 2.36 (s, 3H, H-20), 2.35 – 1.94 (m, 1H, H-12), 1.64 – 1.23 (m, 11H, H-9, H-10, 
H-11, H-12’) ppm; 13C NMR (101 MHz, CHLOROFORM-D) δ 196.1 (C-15), 155.1 (C-6), 139.8 (C-
19), 137.0(136.7) (C-4), 134.5 (C-17), 130.1 (C-18), 128.7(128.6) (Ar-CH), 128.1(128.0) (Ar-CH), 
127.8 (Ar-CH), 124.2 (C-16), 67.1(66.8) (C-5), 57.0 (C-7), 54.1(53.6) (C-13), 48.9(47.5) (C-14), 
41.4(41.1) (C-8), 36.4 (C-12), 34.6 (C-9), 26.1 (C-11), 23.8(22.8) (C-10), 21.4 (C-20) ppm; IR 
(ATR): νmax 2922, 2852, 1698, 1598, 1494, 1450, 1411, 1358, 1325, 1283, 1255, 1196, 1170, 
178 
 
1115, 1016, 975, 807, 768, 750, 697, 609, 533, 474 cm-1; HRMS (ESI) 438.2087 (M + H+. 
C26H32NO3S requires 438.2097); 460.1903 (M + Na+. C26H31NNaO3S requires 460.1917); [α]D20 





144d was synthesised using general procedure G with amino-thioester 143d (19.4 mg, 0.037 
mmol) and rac-CSA (25.9 mg, 0.112 mmol). 144d yielded as a colourless oil (18.3 mg, 0.035 
mmol, 94% yield) after column chromatography (10% EtOAc/hexane). 
Asymmetric 
144d was synthesised using general procedure G with amino-thioester 143d (21.7 mg, 0.042 
mmol) and (R)-TRIP (6.3 mg, 0.0083 mmol). 144d yielded as a colourless oil (21.1 mg, 0.040 
mmol, 97% yield, 90:10 er) after column chromatography (10% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.06 (m, 19H, Ar-H), 5.32 – 5.04 (m, 2H, H-5), 4.66 
(dd, J = 11.6, 1.8 Hz, 0.4H, H-7, rotamer 2), 4.53 (dd, J = 11.6, 1.8 Hz, 0.6H, H-7, rotamer 1), 
4.13-3.96 (m, 1H, H-14), 3.72 (d, J = 11.7 Hz, 0.6H, H-7’, rotamer 1), 3.70 (d, J = 11.7 Hz, 0.4H, 
H-7’, rotamer 2), 3.50 (dd, J = 15.3, 3.4 Hz, 0.6H, H-15, rotamer 1), 3.26 (dd, J = 15.3, 3.4 Hz, 
0.4H, H-15, rotamer 2), 3.05 – 2.93 (m, 1H, H-13), 2.84 (dd, J = 15.3, 9.0 Hz, 0.6H H-15’, rotamer 
1), 2.74 (dd, J = 15.3, 9.0 Hz, 0.4H H-15’, rotamer 2), 2.58 (dd, J = 12.8, 9.0 Hz, 0.4H, H-13’, 
rotamer 2), 2.51 (dd, J = 12.8, 9.0 Hz, 0.6H, H-13’, rotamer 1), 2.36 (s, 3H, H-21) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 196.2(196.0) (C-16), 155.1(154.7) (C-6), 145.3(144.6) (C-9), 
140.0(139.8) (C-20), 136.9(136.6) (C-4), 134.6(134.5) (C-18), 130.2(130.1) (C-19), 128.8(128.7) 
(Ar-CH), 128.7(128.6) (Ar-CH), 128.2(128.1) (Ar-CH), 128.1(127.8) (Ar-CH), 126.8(126.7) (Ar-
CH), 126.6(126.4) (Ar-CH), 124.1(124.0) (C-17), 67.2(67.0) (C-5), 56.0 (C-7), 54.2(53.7) (C-14), 
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52.9(52.7) (C-8), 47.9(46.7) (C-15), 44.3(43.2) (C-13), 21.4 (C-21) ppm; IR (ATR): νmax 3029, 
2923, 1698, 1598, 1494, 1446, 1411, 1357, 1270, 1212, 1180, 1130, 1102, 1030, 1009, 981, 
911, 807, 768, 751, 729, 698, 651, 608, 585, 530, 474 cm-1; HRMS (ESI) 522.2100 (M + H+. 
C33H32NO3S requires 522.2097); 544.1913 (M + Na+. C33H31NNaO3S requires 544.1917); [α]D20 
-69.1° (c 0.585, CHCl3) 




A solution of amino-thioester 149 (21.6 mg, 0.054 mmol) in 1,2-DCE (5 ml) was added to rac-
CSA (37.9 mg, 0.163 mmol) under N2 and the reaction heated to 50 °C for 24 hours. The 
reaction was cooled to room temperature and extracted with DCM (10 ml). The organic 
fraction was washed with saturated NaHCO3 solution (10 ml), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by column chromatography (10% 
EtOAc/hexane) to afford 150 as a colourless oil (12.3 mg, 0.031 mmol, 57% yield). 
Asymmetric – (R)-TRIP, 80 °C 
A solution of amino-thioester 149 (11.7 mg, 0.029 mmol) in cyclohexane (0.02M) was added 
to (R)-TRIP (4.4 mg, 0.0059 mmol) under N2 and the reaction heated to 80 °C for 24 hours. 
The reaction was then cooled to room temperature, quenched with Et3N (0.2 ml) and 
concentrated in vacuo. The crude material was purified by column chromatography (5% 
EtOAc/hexane) to afford 150 as a colourless oil (9.0 mg, 0.023 mmol, 77% yield, 96:4 er). 
Asymmetric – (R)-TiPSY, 80 °C 
150 was synthesised using the same procedure as the (R)-TRIP conditions with amino-
thioester 149 (11.5 mg, 0.029 mmol) and (R)-TiPSY (5.0 mg, 0.0058 mmol). 150 yielded as a 
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colourless oil (2.5 mg, 0.0063 mmol, 22% yield, 76:24 er) after column chromatography (5% 
EtOAc/hexane).  
Asymmetric – (R)-TRIP, 50 °C 
150 was synthesised using the same procedure as the (R)-TRIP conditions with amino-
thioester 149 (22.3 mg, 0.056 mmol) and (R)-TRIP (8.5 mg, 0.011 mmol) and the reaction was 
heated to 50 °C for 24 hours. 150 yielded as a colourless oil (8.5 mg, 0.021 mmol, 38% yield, 
95:5 er) after column chromatography (5% EtOAc/hexane).  
Asymmetric – (R)-TRIP, 50 °C, toluene 
150 was synthesised using the same procedure as the (R)-TRIP conditions with amino-
thioester 149 (19.5 mg, 0.049 mmol) and (R)-TRIP (7.4 mg, 0.0098 mmol) in toluene (0.02M) 
and the reaction was heated to 50 °C for 24 hours. 150 yielded as a colourless oil (3.6 mg, 
0.0091 mmol, 18% yield, 96:4 er) after column chromatography (5% EtOAc/hexane).  
Asymmetric – (R)-TRIP, 50 °C, 1,2-DCE 
150 was synthesised using the same procedure as the (R)-TRIP conditions with amino-
thioester 149 (20.1 mg, 0.051 mmol) and (R)-TRIP (7.6 mg, 0.010 mmol) in 1,2-DCE (0.02M) 
and the reaction was heated to 50 °C for 24 hours. 150 yielded as a colourless oil (2.5 mg, 
0.0063 mmol, 12% yield, 95:5 er) after column chromatography (5% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.25 (m, 5H, Ar-H), 7.24 – 7.17 (m, 4H, H-15, H-16), 
5.18 – 5.10 (m, 2H, H-5), 4.42 – 4.33 (m, 1H, H-11), 3.29 (dd, J = 14.9, 3.5 Hz, 0.4H, H-12, 
rotamer 2), 3.06 (dd, J = 14.9, 3.5 Hz, 0.6H, H-12, rotamer 1), 2.71 – 2.58 (m, 1H, H-12’), 2.36 
(s, 3H, H-18), 2.12 – 1.95 (m, 1H, H-10), 1.95 – 1.82 (m, 1H, H-9), 1.81 – 1.72 (m, 2H, H-9’, H-
10’), 1.50 (s, 1.8H, H-8, rotamer 1), 1.40 (s, 1.2H, H-8, rotamer 2), 1.33 (s, 1.8H, H-8’, rotamer 
1), 1.26 (s, 1.2H, H-8’, rotamer 2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 195.8 (C-13), 
153.3 (C-6), 139.9 (C-17), 136.9 (C-4), 134.4 (C-15), 130.1 (C-16), 128.6 (Ar-CH), 128.1 (Ar-CH), 
127.9(127.9) (Ar-CH), 124.0 (C-14), 67.0(66.4) (C-5), 61.8 (C-7), 57.6(56.5) (C-11), 48.1(47.0) 
(C-12), 40.3(39.0) (C-9), 29.1(28.2) (C-8), 27.1(26.6) (C-10), 26.3(24.9) (C-8’), 21.4 (C-18) ppm; 
IR (ATR): νmax 2960, 2923, 2852, 1702, 1494, 1456, 1399, 1347, 1304, 1258, 1214, 1182, 1144, 
1071, 1004, 807, 770, 697, 676, 598 cm-1; HRMS (ESI) 398.1772 (M + H+. C23H28NO3S requires 
398.1784); 420.1588 (M + Na+. C23H27NNaO3S requires 420.1604); [α]D20 +6.12° (c 0.215, 








154 was synthesised using general procedure G with amino-thioester 153 (14.1 mg, 0.033 
mmol) and rac-CSA (23.1 mg, 0.099 mmol). 154 yielded as a colourless oil (9.2 mg, 0.22 mmol, 
65% yield) after column chromatography (8% EtOAc/hexane). 
Asymmetric 
154 was synthesised using general procedure G with amino-thioester 153 (13.2 mg, 0.031 
mmol) and (R)-TRIP (4.7 mg, 0.0062 mmol). 154 yielded as a colourless oil (12.4 mg, 0.029 
mmol, 94% yield, 92:8 er) after column chromatography (5% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.25 (m, 5H, Ar-H), 6.96 (s, 2H, H-16), 5.21 – 5.08 
(m, 2H, H-5), 4.52 – 4.28 (m, 1H, H-11), 3.38 (dd, J = 14.7, 3.4 Hz, 0.4H, H-12, rotamer 2), 3.11 
(dd, J = 14.7, 3.4 Hz, 0.6H, H-12, rotamer 1), 2.63 (dd, J = 14.7, 10.0 Hz, 1H, H-12’), 2.27 (s, 6H, 
H-19), 2.24 (s, 3H, H-18), 2.13 – 1.97 (m, 1H, H-10), 1.97 – 1.83 (m, 1H, H-9), 1.82 – 1.71 (m, 
2H, H-9’, H-10’), 1.50 (s, 1.8H, H-8, rotamer 1), 1.40 (s, 1.2H, H-8, rotamer 2), 1.33 (s, 1.8H, H-
8’, rotamer 1), 1.27 (s, 1.2H, H-8’, rotamer 2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 194.8 
(C-13), 153.3 (C-6), 142.5(142.4) (C-14), 140.1 (C-17), 136.9 (C-4), 129.3 (C-16), 128.6 (Ar-CH), 
128.1(128.0) (Ar-CH), 127.9(127.8) (Ar-CH), 123.5 (C-15), 67.0(66.4) (C-5), 61.7(61.2) (C-7), 
57.8(56.7) (C-11), 48.1(47.1) (C-12), 40.3(39.0) (C-9), 29.1(28.2) (C-8), 26.9(26.4) (C-10), 
26.3(24.8) (C-8’), 21.7 (C-19), 21.2 (C-18) ppm; IR (ATR): νmax 2963, 1694, 1602, 1498, 1455, 
1398, 1346, 1302, 1283, 1259, 1212, 1184, 1144, 1070, 1029, 1003, 971, 907, 850, 820, 770, 
734, 715, 697, 676, 600, 554 cm-1; HRMS (ESI) 426.2100 (M + H+. C25H32NO3S requires 
426.2097), 448.1919 (M + Na+. C25H31NNaO3S requires 448.1917), 464.1658 (M + K+. 









160a was synthesised using general procedure G with amino-thioester 159a (19.2 mg, 0.047 
mmol) and rac-CSA (32.7 mg, 0.14 mmol). 160a yielded as a yellow oil (13.2 mg, 0.032 mmol, 
69% yield) after column chromatography (5% EtOAc/hexane). 
Asymmetric 
160a was synthesised using general procedure G with amino-thioester 159a (19.4 mg, 0.047 
mmol) and (R)-TRIP (7.1 mg, 0.0095 mmol). 160a yielded as a yellow oil (19.2 mg, 0.047 mmol, 
99% yield, 96:4 er) after column chromatography (5% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.49 – 7.27 (m, 5H, Ar-CH), 7.25 – 7.17 (m, 4H, H-16, H-
17), 5.34 – 5.08 (m, 2H, H-5), 4z.31 (s, 1H, H-12), 3.39 – 2.54 (m, 4H, H-13, H-8), 2.36 (s, 3H, 
H-19), 2.25 – 2.14 (m, 1H, H-10), 2.04 – 1.89 (m, 1H, H-11), 1.89 – 1.79 (m, 2H, H-9, H-10’), 
1.79 – 1.67 (m, 2H, H-11’, H-8’), 1.67 – 1.56 (m, 2H, H-8’, H-9’) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 195.9 (C-14), 154.0 (C-6), 139.8 (C-18), 136.8 (C-4), 134.4 (C-16), 130.1 (C-
17), 128.6 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 124.0 (C-15), 67.1(66.4) (C-5), 64.3 (C-7), 
57.5(56.4) (C-12), 47.9 (C-13), 37.5 (C-10), 33.0(32.8) (C-8), 26.9(26.4) (C-11), 21.4 (C-19), 13.6 
(C-9) ppm; IR (ATR): νmax 2929, 2870, 1696, 1598, 1494, 1453, 1397, 1349, 1319, 1302, 1266, 
1203, 1181, 1170, 1105, 1040, 1028, 1005, 972, 939, 913, 807, 770, 746, 697, 658, 600, 533, 
474 cm-1; HRMS (ESI) 410.1788 (M + H+. C24H28NO3S requires 410.1784); 432.1601(M + Na+. 












160b was synthesised using general procedure G with amino-thioester 159b (10.0 mg, 0.024 
mmol) and rac-CSA (16.5 mg, 0.071 mmol). 160b yielded as a colourless oil (8.7 mg, 0.021 
mmol, 87% yield) after column chromatography (5% EtOAc/hexane). 
Asymmetric 
160b was synthesised using general procedure G with amino-thioester 159b (15.5 mg, 0.037 
mmol) and (R)-TRIP (5.5 mg, 0.0073 mmol). 160b yielded as a colourless oil (10.8 mg, 0.025 
mmol, 70% yield, 95:5 er) after column chromatography (5% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.27 (m, 5H, Ar-H), 7.27 – 7.16 (m, 4H, H-16, H-17), 
5.21 – 5.10 (m, 2H, H-5), 4.41 – 4.30 (m, 1H, H-12), 3.28 (dd, J = 14.9, 3.8 Hz, 0.3H, H-13, 
rotamer 2), 3.07 (dd, J = 14.9, 3.8 Hz, 0.7H, H-13, rotamer 1), 2.73 – 2.60 (m, 1H, H-13’), 2.60 
– 2.45 (m, 0.7H, H-8, rotamer 1), 2.36 (s, 3H, H-19), 2.60 – 2.26 (m, 0.3H, H-8, rotamer 2), 2.20 
– 1.64 (m, 7H, H-8, H-9, H-10, H-11), 1.56 – 1.32 (m, 4H, H-8’, H-9’) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 195.8 (C-14), 153.0 (C-6), 139.8 (C-18), 136.8 (C-4), 134.3 (C-16), 130.0 (C-
17), 128.5(128.3) (Ar-CH), 128.0 (Ar-CH), 127.9(127.8) (Ar-CH), 124.0 (C-15), 71.2 (C-7), 
67.0(66.2) (C-5), 57.0 (56.1) (C-12), 47.8(47.0) (C-13), 40.9(39.2) (C-10), 37.2(35.4) (C-8), 
27.7(27.1) (C-11), 25.0(24.8) (C-9), 21.3 (C-19) ppm; IR (ATR): νmax 3032, 2923, 2853, 1698, 
1598, 1494, 1449, 1399, 1350, 1327, 1302, 1236, 1208, 1172, 1104, 1057, 1028, 1015, 990, 
915, 807, 770, 733 ,697, 648, 602, 533, 475 cm-1; HRMS (ESI) 424.1926 (M + H+. C25H30NO3S 











160c was synthesised using general procedure G with amino-thioester 159c (10.9 mg, 0.025 
mmol) and rac-CSA (17.4 mg, 0.075 mmol). 160c yielded as a colourless oil (9.1 mg, 0.021 
mmol, 83% yield) after column chromatography (5% EtOAc/hexane). 
Asymmetric 
160c was synthesised using general procedure G with amino-thioester 159c (15.0 mg, 0.034 
mmol) and (R)-TRIP (5.2 mg, 0.0069 mmol). 160c yielded as a colourless oil (10.1 mg, 0.023 
mmol, 67% yield, 96:4 er) after column chromatography (5% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.27 (m, 5H, Ar-H), 7.27 – 7.16 (m, 4H, H-17, H-18), 
5.21 – 5.09 (m, 2H, H-5), 4.46 – 4.34 (m, 1H, H-13), 3.26 (dd, J = 14.6, 3.2 Hz, 0.3H, H-14, 
rotamer 2), 3.05 (dd, J = 14.6, 3.2 Hz, 0.7H, H-14, rotamer 1), 2.74 – 2.64 (m, 0.7H, H-8, rotamer 
1), 2.61 (dd, J = 14.6, 10.5 Hz, 1H, H-14’), 2.50 – 2.41 (m, 0.3H, H-8, rotamer 2), 2.36 (s, 3H, H-
20), 2.34 – 2.25 (m, 0.7H, H-10, rotamer 1), 2.17 (dd, J = 12.4, 6.8 Hz, 1H, H-11), 2.12 – 2.00 
(m, 0.3H, H-10, rotamer 2), 2.00 – 1.84 (m, 1H, H-12), 1.81 – 1.73 (m, 1H, H-12’), 1.73 – 1.56 
(m, 4H, H-9, H-11’), 1.44 – 1.13 (m, 5H, H-8’, H-9’, H-10’) ppm; 13C NMR (101 MHz, Chloroform-
d) δ 195.8 (C-15), 153.2 (C-6), 139.9 (C-19), 137.0 (C-4), 134.4 (C-17), 130.1 (C-18), 128.6 (Ar-
CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 124.1 (C-16), 66.3(65.8) (C-5), 57.4 (C-7), 56.3 (C-13), 
48.1(47.0) (C-14), 37.9(36.9) (C-8), 34.4(33.2) (C-11), 32.3(30.8) (C-10), 27.1(26.4) (C-12), 
25.1(24.5, 24.3) (C-9), 21.4 (C-20) ppm; IR (ATR): νmax 2923, 2854, 1701, 1494, 1454, 1397, 
1347, 1301, 1280, 1209, 1155, 1108, 1027, 1002, 807, 769, 697, 599, 476 cm-1; HRMS (ESI) 
438.2086 (M + H+. C26H32NO3S requires 438.2097); 460.1907 (M + Na+. C26H31NNaO3S requires 









160d was synthesised using general procedure G with amino-thioester 159d (9.7 mg, 0.022 
mmol) and rac-CSA (15.4 mg, 0.066 mmol). 160d yielded as a pale-yellow oil (3.7 mg, 0.0084 
mmol, 38% yield) after column chromatography (30% EtOAc/hexane). 
Asymmetric 
160d was synthesised using general procedure G with amino-thioester 159d (12.8 mg, 0.029 
mmol) and (R)-TRIP (4.4 mg, 0.0058 mmol). 160d yielded as a pale-yellow oil (7.8 mg, 0.018 
mmol, 61% yield, 96:4 er) after column chromatography (30% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.50 – 7.27 (m, 5H, Ar-CH), 7.26 – 7.15 (m, 4H, H-16, H-
17), 5.27 – 5.07 (m, 2H, H-5), 4.55 – 4.35 (m, 1H, H-12), 4.13 – 3.74 (m, 2H, H-9), 3.46 (ddd, J 
= 12.5, 12.1, 2.4 Hz, 1H, H-9’), 3.38 (ddd, J = 12.5, 12.1, 2.4 Hz, 1H, H-9’), 3.29 – 3.21 (m, 0.3H, 
H-13, rotamer 2), 3.16 – 3.08 (m, 0.7H, H-10, rotamer 1), 3.08 – 2.99 (m, 0.7H, H-13, rotamer 
1), 2.92 – 2.80 (m, 0.3H, H-10, rotamer 2), 2.78 – 2.68 (m, 0.7H, H-8, rotamer 1), 2.62 (dd, J = 
14.6, 10.2 Hz, 1H, H-13’), 2.54 – 2.49 (m, 0.3H, H-8, rotamer 2), 2.36 (s, 3H, H-19), 2.30 (dd, J 
= 12.3, 6.6 Hz, 1H, H-8), 2.03 – 1.90 (m, 1H, H-11), 1.90 – 1.80 (m, 1H, H-11’), 1.80 – 1.71 (m, 
1H, H-8’), 1.32 – 1.11 (m, 2H, H-8’, H-10’) ppm; 13C NMR (101 MHz, Chloroform-d) δ 195.7 (C-
14), 153.2 (C-6), 140.0 (C-18), 136.8 (C-4), 134.4 (C-16), 130.2 (C-17), 128.6 (Ar-CH), 128.0 (Ar-
CH), 128.0 (Ar-CH), 123.9 (C-15), 67.0(66.5) (C-5), 66.1(66.0) (C-9), 63.0 (C-7), 56.4 (C-12) 48.1 
(C-13), 37.2 (C-10), 32.9(31.8) (C-8), 26.9 (C-11), 21.4 (C-19) ppm; IR (ATR): νmax 2957, 2922, 
2851, 1697, 1598, 1494, 1452, 1397 , 1349, 1302, 1281, 1228, 1208, 119, 1104, 1052, 1027, 
1001, 921, 862, 841, 807, 734, 697, 682, 600, 549, 534, 474 cm-1; HRMS (ESI) 440.1892 (M + 
H+. C25H30NO4S requires 440.1890); 462.1704 (M + Na+. C25H39NNaO4S requires 462.1710); 





dibenzyl ester (160e) 
 
Racemic 
160e was synthesised using general procedure G with amino-thioester 159e (21.4 mg, 0.037 
mmol) and rac-CSA (26.0 mg, 0.112 mmol). 160e yielded as a yellow oil (0.8 mg, 0.0014 mmol, 
4% yield) after column chromatography (20% EtOAc/hexane to 100% EtOAc). 
Asymmetric 
160e was synthesised using general procedure G with amino-thioester 159e (54.7 mg, 0.096 
mmol) and (R)-TRIP (14.4 mg, 0.019 mmol). 160e yielded as a yellow oil (20.5 mg, 0.0358 
mmol, 37% yield, 70:30 er) after column chromatography (40% Et2O/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.79 – 7.24 (m, 10H, Ar-H), 7.24 – 7.03 (m, 4H, H-16, H-
17), 5.25 – 4.86 (m, 4H, H-5, H-21), 4.63 – 4.36 (m, 1H, H-12), 4.33 – 3.72 (m, 2H, H-9), 3.37 – 
3.01 (m, 1H, H-13), 3.00 – 2.45 (m, 5H, H-8H-9’, H-10, H-13’), 2.36 (s, 3H, H-19), 2.27 – 2.15 
(m, 1H, H-10’), 2.11 – 1.90 (m, 1H, H-11), 1.90 – 1.80 (m, 1H, H-11’), 1.81 – 1.65 (m, 1H, H-8), 
1.40 – 1.23 (m, 2H, H-8’) ppm; 13C NMR (101 MHz, Chloroform-d) δ 195.7 (C-14), 155.1 (C-20), 
153.1 (C-6), 140.0 (C-18), 136.8 (C-22), 136.5 (C-4), 134.4 (C-16), 130.2 (C-17), 128.7 (Ar-CH), 
128.6 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 123.9 (C-15), 67.2 
(C-21), 66.6 (C-7), 63.8 (C-5), 56.4 (C-12), 48.1 (C-13), 42.0 (C-9), 34.2 (C-8), 32.4 (C-10), 26.9, 
(C-11), 21.4 (C-19) ppm; IR (ATR): νmax 2924, 1699, 1496, 1432, 1358, 1244, 1159, 1074, 808, 
738, 697 cm-1; HRMS (ESI) 595.2233 (M + Na+. C33H36N2NaO5S requires 595.2237); 611.1991 











A solution of amino-thioester 159f (22.2 mg, 0.0426 mmol) in THF (2 ml) was added to NaH 
60% dispersion in mineral oil (3.4 mg, 0.0852 mmol) under N2 at 0 °C and the reaction stirred 
for 2 hours. The reaction was quenched with H2O (0.5 ml) and diluted with EtOAc (10 ml). The 
solution was dried with MgSO4, filtered and the solids washed with EtOAc (2 x 10 ml) and 
concentrated in vacuo. The crude material was purified by column chromatography (10% 
EtOAc/hexane) to afford 160f as a colourless oil (21.3 mg, 0.0408 mmol, 96% yield). 
Asymmetric 
160f was synthesised using general procedure G with amino-thioester 159f (18.4 mg, 0.0353 
mmol) and (R)-TRIP (5.3 mg, 0.00705 mmol) and the reaction was stirred at 80 °C for 48 hours. 
160f yielded as a colourless oil (2.5 mg, 0.00479 mmol, 14% yield, 77:23 er) after column 
chromatography (10% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.66 – 7.18 (m, 14H, Ar-H), 7.17 – 6.50 (m, 5H, Ar-H), 5.45 
– 4.40 (m, 3H, H-5, H-14), 3.78 (d, J = 15.0 Hz, 0.6H, H-15, rotamer 1), 3.45 (d, J = 15.0 Hz, 0.4H, 
H-15, rotamer 2), 2.83 (dd, J = 15.0, 10.2 Hz, 1H, H-15’), 2.78 – 2.67 (m, 1H, H-12), 2.51 (dt, J 
= 12.7, 5.5 Hz, 1H, H-12’), 2.37 (s, 3H, H-21), 2.08 – 1.92 (m, 1H, H-13), 1.78 – 1.65 (m, 1H, H-
13’) ppm; 13C NMR (101 MHz, Chloroform-d) δ 195.9 (C-16), 155.1 (C-6), 143.6(143.2) (C-8), 
139.8 (C-20), 134.6 (C-18), 130.2 (C-19), 128.6 (Ar-CH), 128.2 (Ar-CH), 127.9 (Ar-CH), 127.8 
(Ar-CH), 127.7 (Ar-CH), 126.9 (Ar-CH), 124.0 (C-17), 74.3 (C-7), 66.7 (C-5), 57.5 (C-14), 47.4 (C-
15), 45.3 (C-12), 29.8(28.1) (C-13), 21.5 (C-21) ppm; IR (ATR): νmax 3059, 3030, 2953, 1686, 
1598, 1493, 1447, 1399, 1343, 1287, 1241, 1211, 1128, 1059, 1032, 1026, 996, 910, 807, 755, 
697, 647, 616, 593, 535, 475 cm-1; HRMS (ESI) 522.2099 (M + H+. C33H32NO3S requires 
522.2099); 544.1920 (M + Na+. C33H31NNaO3S requires 544.1917); 560.1658 (M + K+. 
C33H31NKO3S requires 560.1656); [α]D20 -8.63° (c 0.115, CHCl3) 
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Asymmetric cyclisation of unsubstituted pyrrolidines 
Pent-4-enyl-carbamic acid benzyl ester (162) 
 
To a solution of 4-penten-1-amine (154 mg, 1.81 mmol) in dioxane (5 ml) was added K2CO3 
solution (50% w/w aq, 600mg, 2.17 mmol) followed by benzyl chloroformate (0.39 ml, 2.72 
mmol) and the reaction stirred at room temperature for 4 hours. The reaction was quenched 
with H2O (5 ml) and portioned with CH2Cl2 (5 ml). The aqueous phase was extracted with 
CH2Cl2 (2 x 5 ml) and organic fractions combined. The combined organics were washed with 
saturated brine solution (5 ml), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude residue was purified by flash column chromatography (10% EtOAc/hexane) to afford 
162 as a colourless oil (254 mg, 1.16 mmol, 64% yield). 1H NMR (400 MHz, Chloroform-d) δ 
7.28 - 7.45 (m, 5 H, Ar-H) 5.80 (ddt, J = 17.5, 10.7, 6.9 Hz, 1 H, H-10), 5.11 (s, 2 H, H-5), 5.04 
(dd, J = 17.5, 1.5 Hz, 1 H, H-11), 4.99 (dd, J = 10.7, 1.5 Hz, 1 H, H-11), 4.79 (br. s, 1 H, NH), 3.22 
(q, J = 6.9 Hz, 2 H, H-7), 2.10 (td, J = 7.2, 6.9 Hz, 2 H, H-9), 1.62 (tt, J = 7.2, 6.9 Hz, 2 H, H-8) 
ppm; 13C NMR (101 MHz, Chloroform-d) δ 156.3 (C-6), 137.7 (C-10), 136.6 (C-4), 128.5 (Ar-
CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 115.2 (C-11), 66.6 (C-5), 40.5 (C-7), 30.9 (C-9), 29.0 (C-8) 
ppm; IR (ATR): νmax 3334, 3066, 3033, 2935, 1697, 1640, 1532, 1454, 1414, 1369, 1254, 1137, 
1041, 1027, 1002, 912, 776, 736, 696, 638, 485 cm-1; HRMS (ESI) 242.1149 (M + Na+. 
C13H17NNaO2 requires 242.1151). 
 
6-Cbz-amino-hex-2-enethioic acid S-p-tolyl ester (163) 
 
163 was synthesised using general procedure C with thioester 134 (235 mg, 1.32 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (27.6 mg, 0.044 mmol), copper iodide (83.8 mg, 
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0.44 mmol) and Cbz-amine 162 (96.6 mg, 0.44 mmol). 163 yielded as a brown solid (137 mg, 
0.37 mmol, 84% yield) after column chromatography (20% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 - 7.42 (m, 5 H, Ar-H), 7.32 (d, J = 7.6 Hz, 2 H, H-14), 7.23 (d, J = 7.6 Hz, 2 
H, H-15), 6.95 (dt, J = 16.0, 6.6 Hz, 1 H, H-10), 6.20 (d, J = 16.0 Hz, 1 H, H-11), 5.11 (s, 2 H, H-
5), 4.80 (br. s., 1 H, NH), 3.25 (q, J = 7.1 Hz, 2 H, H-7), 2.39 (s, 3 H, H-17), 2.28 (td, J = 7.1, 6.6 
Hz, 2 H, H-9), 1.72 (quin, J = 7.1 Hz, 2 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.4 
(C-12), 156.4 (C-6), 144.9 (C-10), 139.7 (C-16), 136.4 (C-4), 134.6 (C-14), 130.0 (C-15), 128.5 
(Ar-CH), 128.5 (Ar-CH), 128.3 (Ar-CH), 128.2 (C-11), 123.9 (C-13), 66.7 (C-5), 40.5 (C-7), 29.4 
(C-9), 28.4 (C-8), 21.3 (C-17) ppm; IR (ATR): νmax 3345, 3032, 2980, 2884, 1720, 1691, 1631, 
1597, 1524, 1494, 1454, 1399, 1378 1336, 1248, 1140, 1104, 1091, 1026, 1017, 992, 808, 776, 
752, 737, 697, 635, 649, 615, 476 cm-1; HRMS (ESI) 392.1292 (M + Na+. C21H23NNaO3S requires 





164 was synthesised using general procedure G with amino-thioester 163 (22.6 mg, 0.061 
mmol) and rac-CSA (42.6 mg, 0.184 mmol). 164 yielded as a yellow oil (19.2 mg, 0.052 mmol, 
85% yield) after column chromatography (10% EtOAc/hexane). 
Asymmetric – (R)-TRIP, 80 °C 
164 was synthesised using general procedure G with amino-thioester 163 (98.8 mg, 0.27 
mmol) and (R)-TRIP (40.3 mg, 0.056 mmol). 164 yielded as a yellow oil (86.3 mg, 0.23 mmol, 
87% yield, 90:10 er) after column chromatography (10% EtOAc/hexane).  
Asymmetric - (R)-TiPSY, 80 °C 
164 was synthesised using general procedure G with amino-thioester 163 (9.9 mg, 0.027 
mmol) and (R)-TiPSY (4.6 mg, 0.0054 mmol). 164 yielded as a yellow oil (8.7 mg, 0.024 mmol, 
87% yield, 94:6 er) after column chromatography (10% EtOAc/hexane).  
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Asymmetric - (R)-TRIP, 50 °C 
164 was synthesised using general procedure G with amino-thioester 163 (20.0 mg, 0.054 
mmol) and (R)-TRIP (8.2 mg, 0.11 mmol) and the reaction was heated to 50 °C for 24 hours. 
164 yielded as a yellow oil (18.5 mg, 0.050 mmol, 93% yield, 91:9 er) after column 
chromatography (10% EtOAc/hexane).  
1H NMR (400 MHz, Chloroform-d) δ 7.30 - 7.44 (m, 5 H, Ar-H), 7.25 - 7.30 (m, 2 H, H-14), 7.16 
- 7.24 (m, 2 H, H-15), 5.08 - 5.26 (m, 2 H, H-5), 4.21 - 4.35 (m, 1 H, H-10), 3.38 - 3.51 (m, 2 H, 
H-7), 3.33 (dd, J = 14.9, 3.4 Hz, 0.5 H, rotamer 1, H-11), 3.10 (dd, J = 14.9, 3.4 Hz, 0.5 H, rotamer 
2, H-11), 2.75 (dd, J = 15.3, 9.9 Hz, 0.5 H, rotamer 1, H-11), 2.68 (dd, J = 15.3, 9.9 Hz, 0.5 H, 
rotamer 2, H-11), 2.38 (s, 3 H, H-17), 1.99 - 2.15 (m, 1 H, H-9), 1.78 - 1.98 (m, 3 H, H-9, H-8) 
ppm; 13C NMR (101 MHz, Chloroform-d) δ 195.8(195.7) (C-12), 154.6(154.5) (C-6), 
139.8(139.4) (C-16), 136.8(136.6) (C-4), 134.4(134.3) (C-14), 130.0(130.0) (C-15), 128.5 (Ar-
CH), 128.4 (Ar-CH), 127.9(127.8) (Ar-CH), 124.1(123.9) (C-13), 66.9(66.7) (C-5), 55.0(54.4) (C-
10), 47.7(46.7) (C-11), 46.7(46.4) (C-7), 30.9(30.2) (C-9), 23.6(22.8) (C-8), 21.3(C-17) ppm; IR 
(ATR): νmax 3031, 2955, 2923, 1697, 1597, 1494, 1449, 1409, 1356, 1336, 1306, 1281, 1211, 
1181, 1160, 1060, 1009, 985, 916, 879, 807, 768, 751, 697, 603, 551, 533, 474 cm-1; HRMS 
(ESI) 370.1467 (M + H+. C21H24NO3S requires 370.1471); 392.1289 (M + Na+. C21H23NNaO3S 
requires 392.1291); [α]D25 -21.6° (c 1.035, CHCl3) for 90:10 er. 
 
N-Cbz-6-amino-hex-2-enethioic acid 2,4,6-trimethyl-phenyl ester (165) 
 
165 was synthesised using general procedure C with thioester 152 (308 mg, 1.49 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (31.1 mg, 0.050 mmol), copper iodide (94.7 mg, 
0.50 mmol) and Cbz-amine 162 (109 mg, 0.50 mmol). 165 yielded as a pale brown solid (171 
mg, 0.43 mmol, 87% yield) after column chromatography (15% EtOAc/hexane). 1H NMR (400 
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MHz, Chloroform-d): δ7 .29 - 7.45 (m, 5 H, Ar-H), 6.99 (s, 2 H,H-15 ), 6.95 (dt, J = 15.6, 6.4 Hz, 
1 H, H-10), 6.24 (d, J = 15.6 Hz, 1 H, H-11), 5.12 (s, 2 H, H-5), 4.75 - 4.88 (br. s., 1 H, NH), 3.25 
(q, J = 6.4 Hz, 1 H, H-7), 2.32 (s, 6 H, H-18), 2.31 (s, 3 H, H-17), 2.28 (td, J = 7.3, 6.4 Hz, 2 H, H-
9), 1.72 (tt, J = 7.3, 6.4 Hz, 2 H, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 187.6 (C-12), 
156.4 (C-6), 144.5 (C-10), 142.6 (C-13), 139.9 (C-16), 136.4 (C-4), 129.2 (C-15), 128.5 (C-11), 
128.5 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 123.3 (C-14), 66.7 (C-5), 40.5 (C-7), 29.4 (C-9), 
28.3 (C-8), 21.6 (C-18), 21.1 (C-17) ppm; IR (ATR): νmax 3346, 3063, 3031, 2925, 2732, 1720, 
1699, 1684, 1630, 1602, 1586, 1527, 1454, 1246, 1189, 1139, 1102, 1026, 992, 931, 914, 851, 
798, 776, 753, 736, 715, 697, 645, 633, 614, 578, 565, 506, 489, 475, 459 cm-1; HRMS (ESI) 




166 was synthesised using general procedure G with amino-thioester 165 (14.0 mg, 0.035 
mmol) and rac-CSA (24.5 mg, 0.106 mmol). 166 yielded as a colourless oil (10.9 mg, 0.027 
mmol, 78% yield) after column chromatography (15% EtOAc/hexane). 
Asymmetric 
166 was synthesised using general procedure G with (R)-TRIP (3.9 mg, 0.0052 mmol) and 
amino-thioester 165 (10.3 mg, 0.026 mmol) 166 yielded as a colourless oil (9.4 mg, 0.024 
mmol, 91% yield, er 84:16) after column chromatography (10% EtOAc/hexane). 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.26 (m, 5H, Ar-H), 6.96 (s, 2H, H-15), 5.24 – 5.08 
(m, 2H, H-5), 4.32 – 4.23 (m, 1H, H-10), 3.46 – 3.39 (m, 2H, H-7), 3.36 (dd, J = 14.8, 3.3 Hz, 
0.5H, rotamer 1, H-11), 3.11 (dd, J = 14.8, 3.3 Hz, 0.5H, rotamer 2, H-11), 2.75 (dd, J = 14.8, 
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9.9 Hz, 0.5H, rotamer 1, H-11’), 2.67 (dd, J = 14.8, 9.9 Hz, 0.5H, rotamer 2, H-11’), 2.28 (s, 6H, 
H-18), 2.26 (s, 3H, H-17), 2.11 – 1.99 (m, 1H, H-9), 1.96 – 1.76 (m, 3H, H-8, H-9’) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 195.1 (C-12), 154.7 (C-6), 142.4 (C-13), 140.0 (C-16), 136.5 (C-4), 
129.3 (C-15), 128.6 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 123.6 (C-14), 67.1(66.8) (C-5), 
55.3(54.7) (C-10), 47.8(46.9) (C-7), 46.8(46.6) (C-11), 31.0(30.3) (C-9), 23.8(22.8) (C-8), 21.7 
(C-18), 21.2 (C-17) ppm; IR (ATR): νmax 2923, 2853, 1700, 1602, 1411, 1356, 1187, 1100, 1009, 
850, 769, 698 cm-1; HRMS (ESI) 398.1788 (M + H+. C23H28NO3S requires 398.1784); 420.1601 
(M + Na+. C23H27NNaO3S requires 420.1604); 436.1344 (M + K+. C23H27KNO3S requires 
436.1343); [α]D20 -11.9° (c 0.49, CHCl3) 
Determination of the absolute stereochemistry 
N-Cbz-(S)-2-Methoxycarbonylmethyl-pyrrolidine (169) 
 
To solution of pyrrolidine 164 (21.8 mg, 0.059 mmol, 90:10 er) in dry MeOH/DCM (1:1, 1ml) 
was added AgOTf (45.5 mg, 0.177 mmol) and the reaction was stirred for 3 hours. After that 
time the reaction was diluted with Et2O (5 ml) and filtered through a silica plug followed by 
Et2O (3 x 15 ml). The combined filtrate was concentrated in vacuo and the crude residue was 
purified by flash column chromatography (20% EtOAc/hexane) to afford 169 as a pale-yellow 
oil (10.9 mg, 0.039 mmol, 67% yield, 89:11 er).  
1H NMR (400 MHz, Chloroform-d): 7.28 - 7.41 (m, 5 H, Ar-H), 5.15 (m, 2 H, H-10), 4.18 - 4.30 
(m, 1 H, H-5), 3.67 (s, 1.8 H, rotamer 1, H-8), 3.64 (s, 1.2 H, rotamer 2, H-8), 3.38 - 3.50 (m, 2 
H, H-2), 2.99 (dd, J = 15.2, 3.9 Hz, 0.6 H, H-6 rotamer 1), 2.81 (dd, J = 15.2, 3.9 Hz, 0.4 H, H-6 
rotamer 2), 2.29 - 2.42 (m, 1 H, H-6’), 2.02 - 2.16 (m, 1 H, H-4), 1.98 – 1.83 (m, 2H, H-3), 1.83 
– 1.72 (m, 1H, H-4’) ppm; 13C NMR (101 MHz, Chloroform-d) δ 171.9(171.7) (C-7), 154.7(154.0) 
(C-9), 136.9(136.7) (C-11), 128.4 (Ar-CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 66.8(66.6) (C-10), 
54.5(54.0) (C-5), 51.6 (C-8), 46.8(46.4) (C-2), 39.1(38.1) (C-6), 31.3(30.6) (C-4), 23.5(22.7) (C-
3) ppm; IR (ATR): νmax 3032, 2953, 2880, 1736, 1699, 1498, 1436, 1411, 1336, 1306, 1284, 
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1255, 1189, 1168, 1116, 1098, 1064, 1017, 975, 918, 825, 769, 751, 698, 604, 552, 485 cm-1; 
HRMS (ESI) 300.1205 (M + Na+. C15H19NNaO4 requires 300.1206); [α]D20 -25.4° (c 0.545, CHCl3) 
[lit. [α]D20 -33.0° (c 0.54, CHCl3) for (S)-isomer]136 
Cbz deprotection 
3-p-Tolylsulfanylcarbonylmethyl-2-azonia-spiro[4.4]nonane chloride ((±)-173) 
 
Pyrrolidine (±)-144b (32.9 mg, 0.0777 mmol) was dissolved in dry CH2Cl2 (0.78 ml) and added 
to a solution of BCl3.DMS (97.5 mg, 0.544 mmol) in CH2Cl2 (0.27 ml) at room temperature 
under N2. The reaction was stirred at room temperature for 12 hours, then diluted with CH2Cl2 
(15 ml) and quenched with saturated NaHCO3 (aq) (10 ml). The aqueous fraction was 
extracted with CH2Cl2 (3 x 10 ml) and the combined organic fractions were washed with 
saturated brine solution (10 ml), dried with Na2SO4, filtered, and concentrated in vacuo to 
give (±)-173 as a pale yellow solid (24.2 mg, 0.0744 mmol, 96% yield). 
1H NMR (400 MHz, Chloroform-d) δ 9.97 – 9.48 (m, 2H, NH2+), 7.31 (d, J = 8.0 Hz, 2H, H-10), 
7.17 (d, J = 8.0 Hz, 2H, H-11), 3.95 (dt, J = 11.3, 6.4 Hz, 1H, H-6), 3.50 (dd, J = 17.0, 6.9 Hz, 1H, 
H-7), 3.17 (dd, J = 17.0, 6.6 Hz, 1H, H-7’), 3.04 (t, J = 5.4 Hz, 2H, H-1), 2.32 (s, 3H, H-13), 2.04 
(dd, J = 13.0, 6.6 Hz, 1H, H-5), 1.72 – 1.42 (m, 9H, H-3, H-4, H-5’) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 195.4 (C-8), 140.1 (C-12), 134.8 (C-10), 130.2 (C-11), 123.4 (C-9), 55.4 (C-6), 
55.0 (C-1), 49.2 (C-2), 45.1 (C-7), 43.1 (C-5), 37.6 (C-3), 36.5 (C-3’), 24.7 (C-4), 24.6 (C-4’), 21.4 
(C-13) ppm; IR (ATR): νmax 3398, 2949, 2868, 2711, 1701, 1596, 1493, 1401, 1305, 1270, 1181, 
1039, 978, 808, 764, 610, 534, 476 cm-1; HRMS (ESI) 290.1574 (M + H+. C17H24NOS requires 




Synthesis of fluorinated amines 
ethyl 2-oxo-5-hexenoate (187) 
 
A dry flask was charged with magnesium turnings (1.34 g, 55 mmol) and a single crystal of 
iodine (~50 mg) under N2, followed by addition of dry diethyl ether (50 ml) and the flask placed 
in a water bath to control the temperature of the reaction. 4-bromo-1-butene (5.05 ml, 50 
mmol) was added dropwise with rapid stirring and an exotherm was observed. The reaction 
was stirred at room temperature for 6 hours to allow for complete formation of the Grignard 
reagent. In a separate dry flask, diethyl oxalate (5.49 ml, 50 mmol) in dry diethyl ether (75 ml) 
was cooled to -78 °C under N2. The Grignard reagent was then transferred to the flask 
containing the diethyl oxalate solution via cannula addition and the reaction was allowed to 
warm to room temperature overnight with stirring. The reaction was quenched with 
saturated NH4Cl (aq) solution (50 ml) and extracted with diethyl ether (2 x 50 ml). The 
combined organic fractions were washed with saturated NH4Cl (aq) solution (50 ml) and H2O 
(2 x 50 ml), dried with MgSO4, filtered, and concentrated in vacuo. The crude residue was 
purified using flash column chromatography (10% EtOAc/hexane) to give 187 as a pale-yellow 
oil (2.05 g, 13.1 mmol, 26% yield).1H NMR (400 MHz, Chloroform-d) δ 5.79 (ddt, J = 16.9, 10.2, 
6.4 Hz, 1H, H-7), 5.05 (ddt, J = 16.9, 1.7, 1.3 Hz, 1H, H-8), 4.99 (ddt, J = 10.2, 1.7, 1.3 Hz, 1H, H-
8’), 4.30 (q, J = 7.1 Hz, 2H, H-2), 2.93 (t, J = 7.3 Hz, 2H, H-5), 2.37 (tdt, J = 7.3, 6.4, 1.7 Hz, 2H, 
H-6), 1.34 (t, J = 7.1 Hz, 3H, H-1) ppm; 13C NMR (101 MHz, Chloroform-d) δ 193.9 (C-4), 161.1 
(C-3), 136.2 (C-7), 116.0 (C-8), 62.5 (C-2), 38.5 (C-5), 27.0 (C-6), 14.1 (C-1) ppm; IR (ATR): νmax 
2984, 1793, 1725, 1642, 1445, 1401, 1370, 1277, 1246, 1064, 1025, 999, 915, 856, 731, 681, 
637 cm-1; HRMS (APCI) 157.086244 (M + H+. C8H13O3 requires 157.085921) 




A solution of keto-ester 187 (2.04 g, 13.1 mmol) in dry CH2Cl2 (45 ml) was cooled to 0 °C under 
N2. To this solution was charged catalytic ethanol (0.15 ml, 2.62 mmol), followed by dropwise 
addition of Bis(2-methoxyethyl)aminosulfur trifluoride solution (50 wt% in toluene, 8.15 ml, 
22.1 mmol), after which the reaction was allowed to warm to room temperature overnight. 
The reaction was quenched with saturated NaHCO3 (aq) solution (50 ml) and extracted with 
CH2Cl2 (2 x 50 ml). The combined organic fractions were washed with 2M HCl (2 x 50 ml) and 
saturated brine solution (50ml), dried with MgSO4, filtered, and concentrated in vacuo. The 
crude residue was purified using flash column chromatography (5% EtOAc/hexane) to give 
184 as a pale-yellow oil (1.34 g, 7.50 mmol, 57% yield). 1H NMR (500 MHz, Chloroform-d) δ 
5.81 (ddt, J = 17.1, 10.2, 6.5 Hz, 1H, H-7), 5.08 (dq, J = 17.1, 1.4 Hz, 1H, H-8), 5.03 (dq, J = 10.2, 
1.4 Hz, 1H, H-8’), 4.33 (q, J = 7.1 Hz, 2H, H-2), 2.30 – 2.21 (m, 2H, H-6), 2.21 – 2.11 (m, 2H, H-
5), 1.36 (t, J = 7.1 Hz, 3H, H-1) ppm; 13C NMR (126 MHz, Chloroform-d) δ 164.2 (t, 2JCF = 32.8 
Hz, C-3), 135.9 (C-7), 116.0 (t, 1JCF = 250.4 Hz, C-4), 115.9 (C-8), 62.8 (C-2), 33.8 (t, 2JCF = 23.4 
Hz, C-5), 25.7 (t, 3JCF = 4.8 Hz, C-6), 14.0 (C-1) ppm; 19F NMR (471 MHz, Chloroform-d) δ -106.1 
(t, JFH = 16.2 Hz, 2F) ppm  
2,2-difluoro-5-hexenoic acid (188) 
 
A solution of fluoro-ester 184 (1.32 g, 7.41 mmol) in THF (20 ml) was added to LiOH (0.933 g, 
22.2 mmol) in H2O (5 ml) at 0 °C and the reaction was allowed to warm to room temperature 
overnight. The reaction was diluted with H2O (25 ml) and extracted with diethyl ether (25 ml). 
The aqueous fraction was then acidified to pH 1 with 2M HCl and extracted with diethyl ether 
(3 x 25 ml). The combined second extraction was dried with MgSO4, filtered, and concentrated 
in vacuo to give 188 as a colourless oil (0.985 g, 6.56 mmol, 89% yield). 1H NMR (500 MHz, 
Chloroform-d) δ 8.06 (br s, 1H, COOH), 5.83 (ddt, J = 17.1, 10.2, 6.3 Hz, 1H, H-5), 5.11 (dq, J = 
17.1, 1.5 Hz, 1H, H-6), 5.06 (dq, J = 10.2, 1.5 Hz, 1H, H-6’), 2.38 – 2.26 (m, 2H, H-4), 2.26 – 2.10 
(m, 2H, H-3) ppm; 13C NMR (126 MHz, Chloroform-d) δ 168.2 (t, 2JCF = 33.7 Hz, C-1), 135.6 (C-
5), 116.2 (C-6), 115.7 (t, 1JCF = 250.1 Hz, C-2), 33.6 (t, 2JCF = 23.0 Hz, C-3), 25.6 (t, 3JCF = 4.7 Hz, 
C-4) ppm; 19F NMR (471 MHz, Chloroform-d) δ -106.7 (t, JFH = 16.3 Hz, 2F) ppm; IR (ATR): νmax 
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3084, 2982, 2940, 2533, 1752, 1644, 1450, 1420, 1365, 1269, 1191, 1156, 1082, 1045, 994, 
955, 877, 771, 690, 655, 609, 554 cm-1; HRMS (ESI) 149.0421 (M - H. C6H7F2O2 requires 
149.0420) 
phenyl 2,2-difluoro-5-hexenoate (189) 
 
To a solution of fluoro-acid 188 (149 mg, 0.99 mmol) in toluene (10 ml) was added 
triethylamine (0.17 ml, 1.19 mmol) and diphenylphosporyl azide (0.24 ml, 1.09 mmol) under 
N2. The reaction was heated to 90 °C for 2 hours, after which the reaction was cooled to room 
temperature, quenched with H2O (10 ml) and extracted with ethyl acetate (2 x 20 ml). The 
combined organic fractions were washed with H2O (2 x 20 ml) and saturated brine solution (2 
x 20ml), dried with Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified using flash column chromatography (2-50% EtOAc/hexane) to give 189 as a pale-
yellow oil (77 mg, 0.34 mmol, 34% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.52 – 7.36 (m, 
2H, H-2), 7.34 – 7.24 (m, 1H, H-1), 7.23 – 7.12 (m, 2H, H-3), 5.85 (ddt, J = 17.1, 10.4, 6.2 Hz, 
1H, H-9), 5.13 (dd, J = 17.1, 1.5 Hz, 1H, H-10), 5.07 (dd, J = 10.4, 1.5 Hz, 1H, H-10’), 2.42 – 2.24 
(m, 4H, H-7, H-8) ppm; 13C NMR (101 MHz, Chloroform-d) δ 162.7 (t, 2JCF = 33.7 Hz, C-5), 149.9 
(C-4), 135.7 (C-9), 129.8 (C-2), 126.9 (C-1), 121.0 (C-3), 116.4 (C-10), 116.2 (t, 1JCF = 251.1 Hz, 
C-6), 34.0 (t, 2JCF = 23.2 Hz, C-7), 25.9 (t, 3JCF = 4.8 Hz, C-8) ppm; 19F NMR (376 MHz, Chloroform-
d) δ -106.6 (t, JFH = 16.0 Hz, 2F) ppm; IR (ATR): νmax 3081, 2936, 2199, 2159, 1780, 1742, 1644, 
1591, 1492, 1457, 1419, 1340, 1295, 1262, 1208, 1187, 1160, 1141, 1072, 1047, 1025, 1001, 
954, 853, 810, 745, 687, 635, 608, 575, 555, 527, 499 cm-1; HRMS (APCI) 227.087301 (M + H+. 





To a dry flask was added copper powder (5.95 g, 93.6 mmol) followed by anhydrous DMSO 
(30 ml) and ethyl difluorobromoacetate (6 ml, 46.8 mmol) and the reaction heated to 55 °C 
for 1 hour. Allyl bromide (4.86 ml, 56.2 mmol) was added and the reaction stirred at 55 °C for 
24 hours. The reaction was quenched with saturated brine solution (200 ml) and extracted 
with Et2O (3 x 100 ml). The combined organics were washed with saturated brine solution (2 
x 100 ml) and 2M HCl (100 ml), dried with MgSO4, filtered and concentrated in vacuo. The 
crude material was dissolved in THF (15 ml) and ammonium hydroxide solution (15 ml) was 
added dropwise and the reaction was stirred at room temperature for 15 hours. After stirring 
the reaction was quenched with H2O (30 mL) and concentrated to remove excess ammonia 
and organic solvents, followed by extraction with CH2Cl2 (4 x 50 ml). The combined organic 
fractions were washed with H2O (2 x 50 ml) and saturated brine solution (2 x 50 ml), dried 
with MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
column chromatography (30% EtOAc/hexane) to afford 183 as a orange solid (758 mg, 5.61 
mmol, 12% yield over 2 steps). 1H NMR (400 MHz, Chloroform-d) δ 6.46 – 5.83 (m, 2H, NH2), 
5.75 (ddt, J = 17.9, 9.9, 6.8 Hz, 1H, H-4), 5.30 (d, J = 17.9 Hz, 1H, H-5), 5.27 (d, J = 9.9 Hz, 1H, 
H-5’), 2.85 (td, J = 16.9, 6.8 Hz, 2H, H-3) ppm; 13C NMR (101 MHz, Chloroform-d) δ 166.2 (t, 
2JCF = 30.5 Hz, C-1), 127.1 (t, 3JCF = 5.4 Hz, C-4), 122.1 (C-5), 116.9 (t, 1JCF = 253.1 Hz, C-2), 38.4 
(t, 2JCF = 23.9 Hz, C-3) ppm; 19F NMR (376 MHz, Chloroform-d) δ -105.8 (t, JFH = 16.8 Hz, 2F) 
ppm; IR (ATR): νmax 3386, 3198, 1684, 1622, 1648, 1448, 1432, 1318, 1300, 1257, 1180, 1157, 
1098, 1032, 992, 932, 885, 811, 774, 741, 676, 625, 606, 536, 481 cm-1; HRMS (APCI) 
136.056206 (M + H+. C5H8F2NO requires 136.056847), mp. 33-35 °C 
N-Cbz-2,2-difluoro-4-pentenamine (178) 
 
To a suspension of LiAlH4 (77 mg,  2.03 mmol) in dry diethyl ether (2.5 ml) at 0 °C under N2 
was added amide 183 (137 mg, 1.01 mmol) in dry diethyl ether (2.5 ml) over 5 mins and the 
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reaction stirred at 0 °C for 30 mins. The reaction was then warmed to room temperature and 
stirred for 1.5 hours. The reaction was cooled to 0 °C and quenched with H2O (0.1 ml), 
followed by NaOH solution (15% w/w aq, 0.1 ml), followed by H2O (0.3 ml) and the reaction 
warmed to rt. MgSO4 was added and the suspension was filtered through Celite®, followed by 
washings with diethyl ether (10 ml). To the ether solution was added 4M HCl in dioxane (0.75 
ml) dropwise and solution concentrated in vacuo to give the amine HCl salt as a colourless oil 
(114 mg) which was used without further purification. Amine HCl salt (93 mg) was dissolved 
in dioxane (10 ml) to which was added K2CO3 solution (50% w/w aq, 408 mg, 1.48 mmol) 
followed by benzyl chloroformate (0.10 ml, 0.708 mmol) and the reaction stirred at room 
temperature for 13 hours. The reaction was quenched with H2O (10 ml) and portioned with 
CH2Cl2 (10 ml). The aqueous phase was extracted with CH2Cl2 (2 x 10 ml) and organic fractions 
combined. The combined organics were washed with saturated brine solution (10 ml), dried 
with MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
column chromatography (15% EtOAc/hexane) to afford 178 as a white solid (108 mg, 0.423 
mmol, 42% yield over 2 steps). 1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.27 (m, 5H, Ar-H), 
5.80 (ddt, J = 16.8, 10.0, 7.3 Hz, 1H, H-10), 5.23 (d, J = 16.8 Hz, 1H, H-11), 5.22 (d, J = 10.0 Hz, 
1H, H-11’), 5.12 (s, 2H, H-5), 5.09 (s, 1H, NH), 3.57 (td, J = 13.9, 6.6 Hz, 2H, H-7), 2.63 (td, J = 
16.3, 7.3 Hz, 2H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 156.4 (C-6), 136.2 (C-4), 128.7 
(Ar-CH), 128.5 (t, 3JCF = 5.9 Hz, C-10), 128.4 (Ar-CH), 128.3 (Ar-CH), 121.8 (t, 1JCF = 244.0 Hz, C-
8)121.1 (C-11), 67.4 (C-5), 45.1 (t, 2JCF = 29.6 Hz, C-7), 39.1 (t, 2JCF = 24.7 Hz, C-9) ppm; 19F NMR 
(376 MHz, Chloroform-d) δ -103.72 (p, JFH = 15.0 Hz, 2F) ppm; IR (ATR): νmax 3332, 3035, 2952, 
1710, 1645, 1532, 1455, 1431, 1388, 1341, 1248, 1164, 1120, 1005, 927, 880, 806, 776, 738, 








6-Cbz-amino-5,5-difluoro-hex-2-enethioic acid S-p-tolyl ester (194) 
 
194 was synthesised using general procedure C with thioester 134 (106 mg, 0.90 mmol), 
Hoveyda-Grubbs Catalyst™ 2nd generation (18.8 mg, 0.030 mmol), copper iodide (57.1 mg, 
0.30 mmol) and Cbz-amine 178 (76.5 mg, 0.30 mmol). 194 yielded as a pale brown oil (55.1 
mg, 0.136 mmol, 45% yield) after column chromatography (30% EtOAc/hexane). 1H NMR (400 
MHz, Chloroform-d) δ 7.40 – 7.32 (m, 5H, Ar-H), 7.30 (d, J = 8.2 Hz, 2H, H-14), 7.22 (d, J = 8.2 
Hz, 2H, H-15), 6.88 (dt, J = 15.5, 7.5 Hz, 1H, H-10), 6.30 (d, J = 15.5 Hz, 1H, H-11), 5.16 (s, 1H, 
NH), 5.13 (s, 2H, H-5), 3.59 (td, J = 13.2, 6.6 Hz, 2H, H-7), 2.78 (td, J = 16.4, 7.5 Hz, 2H, H-9), 
2.38 (s, 3H, H-17) ppm; 13C NMR (101 MHz, Chloroform-d) δ 188.0 (C-12), 156.4 (C-6), 140.0 
(C-16), 136.0 (C-4), 134.7 (t, 3JCF = 5.2 Hz, C-10), 134.6 (C-14), 132.6 (C-11), 130.2 (C-15), 128.7 
(Ar-CH), 128.5 (Ar-CH), 128.3 (Ar-CH), 123.7 (C-13), 120.02 (t, 1JCF = 242.6 Hz, C-8), 67.5 (C-5), 
45.36 (t, 2JCF = 30.2 Hz, C-7), 37.35 (t, 2JCF = 25.0 Hz, C-9), 21.5 (C-17) ppm; 19F NMR (376 MHz, 
Chloroform-d) δ -102.6 (p, J = 14.9 Hz, 2F) ppm; IR (ATR): νmax 3341, 3032, 2952, 1708, 1682, 
1639, 1597, 1523, 1494, 1455, 1427, 1399, 1240, 1240, 1164, 1107, 1060, 1004, 973, 896, 835, 
808, 774, 754, 737, 697, 646, 619, 575, 538, 489, 475 cm-1; HRMS (ESI) 428.1092 (M + Na+. 
C21H21F2NNaO3S requires 428.1102). 





204 was synthesised using general procedure A diisopropylamine (4.29 ml, 30.6 mmol), n-
BuLi (2.5 M in hexanes, 33.4 mmol), isobutyronitrile (2.5 ml, 27.9 mmol) and 3-bromo-2-
methylpropene (3.09 ml, 30.6 mmol). 204 yielded as a colourless oil (1.73 g, 14.1 mmol, 50% 
yield) after column chromatography (1% EtOAc/hexane). 1H NMR (400 MHz, Chloroform-d) δ 
4.95 - 5.00 (m, 1 H, H-6), 4.83 - 4.85 (m, 1 H, H-6), 2.26 (s, 2 H, H-4), 1.90 (s, 3 H, H-7), 1.37 (s, 
6 H, H-3) ppm; 13C NMR (101 MHz, Chloroform-d) δ 140.6 (C-5), 125.4 (C-1), 116.1 (C-6), 48.5 
(C-4), 31.3 (C-20), 27.0 (C-3), 23.6 (C-7) ppm; IR (ATR): νmax 3078, 2978, 2937, 2234, 1711, 
1645, 1469, 1449, 1390, 1378, 1369, 1292, 1260, 1197, 1134, 1028, 898, 826, 739, 668, 610, 
503 cm-1; HRMS (APCI) 124.112127 (M + H+. C8H14N requires 124.112076) 
(2,2,4-Trimethyl-pent-4-enyl)-carbamic acid benzyl ester (201) 
 
Nitrile 204 (426 mg, 3.46 mmol) was reduced using general procedure B with LiAlH4 (197 mg, 
5.19 mmol) to give the amine as a pale-yellow oil (320 mg, 2.52 mmol, 73% yield). Amine (163 
mg, 1.28 mmol) was Cbz protected with K2CO3 solution (50% w/w aq, 425 mg, 1.54 mmol) and 
benzyl chloroformate (0.22 ml, 1.54 mmol). 201 yielded as a colourless oil (260 mg, 1.00 
mmol, 78% yield) after column chromatography (8% EtOAc/hexane). 1H NMR (400 MHz, 
Chloroform-d) δ 7.30 - 7.41 (m, 5 H), 5.11 (s, 2 H), 4.87 - 4.91 (m, 1 H), 4.83 (br. s., 1 H), 4.64 - 
4.71 (m, 1 H), 3.07 (d, J = 6.4 Hz, 2 H), 1.97 (s, 2 H), 1.79 (s, 3 H), 0.87 - 0.95 (m, 6 H) ppm; 13C 
NMR (101 MHz, Chloroform-d) δ 156.7 (C-6), 142.8 (C-11), 136.6 (C-4), 128.5 (Ar-CH), 128.2 
(Ar-CH), 128.1 (Ar-CH), 114.8 (C-12), 66.7 (C-5), 51.4 (C-7), 47.5 (C-10), 35.3 (C-8), 25.3 (C-9), 
25.2 (C-13) ppm; IR (ATR): νmax 3343, 3070, 3033, 2962, 1702, 1640, 1521, 1468, 1455, 1407, 
1389, 1374, 1331, 1240, 1180, 1132, 1049, 1002, 892, 824, 774, 751, 735, 696, 574, 495, 460 
cm-1; HRMS (ESI) 262.1799 (M + H+. C16H24NO2 requires 262.1802), 284.1619 (M + Na+. 
C16H23NNaO2 requires 284.1621) 
201 
 
2-Methyl-thioacrylic acid S-p-tolyl ester (203)  
 
203 was synthesised using the same procedure as 134 with a solution of NaOH (15% w/w aq. 
5.2 ml), NaBH4 (0.011 g, 0.292 mmol), p-thiocresol (1.21 g, 9.74 mmol), butylated 
hydroxytoluene (0.032 g, 0.146 mmol) and methacryloyl chloride (1.07 ml, 14.6 mmol). 203 
yielded as a yellow oil (1.61 g, 8.35 mmol, 86% yield) after column chromatography (1% 
Et2O/hexane).1H NMR (400 MHz, Chloroform-d) δ 7.33 (d, J = 7.6 Hz, 2 H, H-6), 7.25 (d, J = 7.6 
Hz, 2 H, H-7), 6.22 (s, 1 H, H-1), 5.70 (s, 1 H, H-1), 2.40 (s, 3 H, H-9), 2.02 (s, 3 H, H-3) ppm; 13C 
NMR (101 MHz, Chloroform-d) δ 191.9 (C-4), 143.5 (C-2), 139.6 (C-8), 134.9 (C-6), 130.0 (C-7), 
124.0 (C-5), 123.6 (C-1), 21.3 (C-9), 18.2 (C-3) ppm; IR (ATR): νmax 2923, 1676, 1630, 1598, 
1493, 1449, 1400, 1375, 1281, 1181, 1104, 1023, 1017, 983, 969, 933, 904, 887, 807, 655, 605, 
526, 474 cm-1; HRMS (ESI) 215.0503 (M + Na+. C11H12NNaOS requires 215.0501) 
Total Syntheses of Irnidine and Bgugaine 
N-Cbz-(S)-2-(2-oxoethyl)pyrrolidine (234) 
  
A solution of pyrrolidine 164 (72.9 mg, 0.197 mmol) in CH2Cl2 (0.4 M) was cooled to -78 °C 
and a solution of DIBAL-H (1 M in hexanes, 0.6 ml) was added dropwise with and stirred for 1 
h. The reaction was quenched with MeOH (1 ml) at -78 °C and allowed to warm to room 
temperature. The reaction was partitioned with an aqueous solution of Rochelle’s salt (2 ml) 
and extracted with CH2Cl2 (3 x 10 ml). The combined organic fraction was dried with MgSO4, 
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filtered and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (15% EtOAc/hexane) to afford 234 as a colourless oil (15.9 mg, 0.0643 mmol, 
33% yield). 1H NMR (400 MHz, Chloroform-d) δ 9.78 (s, 0.6H, H-12, rotamer 1), 9.66 (s, 0.4H, 
H-12, rotamer 2), 7.43 – 7.26 (m, 5H, Ar-H), 5.16 – 5.04 (m, 2H, H-5), 4.33 – 4.28 (m, 1H, H-
10), 3.54 – 3.35 (m, 2H, H-7), 2.98 (dd, J = 16.5, 3.7 Hz, 0.6H, H-11, rotamer 1), 2.81 (dd, J = 
16.5, 3.7 Hz, 0.4H, H-11, rotamer 2), 2.49 (dd, J = 16.5, 7.6 Hz, 1H, H-11’), 2.19 – 2.06 (m, 1H, 
H-9), 1.91 – 1.80 (m, 2H, H-8), 1.70 – 1.62 (m, 1H, H-9’) ppm; 13C NMR (101 MHz, Chloroform-
d) δ 200.9(200.7) (C-12), 155.0 (C-6), 136.9(136.6) (C-4), 128.6 (Ar-CH), 128.2(128.1) (Ar-CH), 
128.0 (Ar-CH), 67.1(66.9) (C-5), 53.1(52.3) (C-10), 49.4(48.7) (C-11), 46.9(46.5) (C-7), 
32.1(31.3) (C-9), 23.8(23.1) (C-8) ppm; IR (ATR): νmax 2955, 1722, 1697, 1414, 1357, 1337, 
1187, 1104, 729, 698 cm-1; HRMS (ESI) 248.1278 (M + H+. C14H18NO3 requires 248.1281); 
270.1100 (M + Na+. C14H17NNaO3 requires 270.1101); 286.0838 (M + K+. C14H17KNO3 requires 
286.0840); [α]D20 -31.3° (c 0.35, CHCl3) 
2-(4-bromobutyl)anisole (238) 
 
A solution of 2-bromoanisole (2.0 ml, 16.0 mmol) in dry THF (30 ml) was cooled to -78°C under 
N2 and s-BuLi (1.4 M in cyclohexane, 20.9 mmol) was added over 10 minutes. The solution 
was stirred for 2 hours then quenched with 1,4-dibromobutane (2.7 ml, 22.5 mmol) and 
allowed to warm to room temperature overnight. The reaction was quenched with water (30 
ml) and extracted with Et2O (3 x 20 ml). The organic fractions were combined, washed with 
water (2 x 30 ml) and saturated brine solution (30 ml), dried with MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by column chromatography (0-2% 
Et2O/hexane) to give 238 as a colourless oil (1.29 g, 5.31 mmol, 33 % yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.17 (ddd, J = 8.0, 7.8, 1.8 Hz, 1H, H-3), 7.11 (dd, J = 7.3, 1.8 Hz, 1H, H-5), 6.88 
(ddd, J = 7.8, 7.3, 1.2 Hz, 1H, H-4), 6.84 (dd, J = 7.8, 1.2 Hz, 1H, H-2), 3.81 (s, 3H, H-7), 3.42 (t, 
J = 6.9 Hz, 2H, H-11), 2.63 (t, J = 7.4 Hz, 2H, H-8), 1.98 – 1.82 (m, 2H, H-10),  1.77 – 1.67 (m, 
2H, H-9) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.5 (C-1), 130.3 (C-6), 129.9 (C-5), 127.2 
(C-3), 120.5 (C-4), 110.3 (C-2), 55.3 (C-7), 34.0 (C-11), 32.6 (C-10), 29.3 (C-8), 28.5 (C-9) ppm; 
IR (ATR): νmax 2937, 2859, 2835, 1601, 1587, 1493, 1463, 1438, 1289, 1241, 1176, 1133, 1108, 
203 
 
1051, 1032, 752, 644, 559 cm-1; HRMS (APCI) 243.0368 (M + H+. C11H1679BrO requires 




A solution of 238 (0.93 g, 3.8 mmol) in dry THF (5.7 ml) was cooled to 0 °C under N2. 
Allylmagnesium bromide (1 M in Et2O, 5.7 mmol) was then added dropwise over 5 minutes, 
and the reaction allowed to warm to room temperature overnight with stirring. The reaction 
was quenched with NH4Cl (aq) (10 ml) and extracted with Et2O (3 x 20 ml). The combined 
organic fractions were washed with NH4Cl (aq) (20 ml) and saturated brine solution (20 ml), 
dried with MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
column chromatography (0-1% Et2O/hexane) to give 239 as a colourless oil (0.37 g, 1.8 mmol, 
47 % yield). 1H NMR (400 MHz, Chloroform-d) δ 7.16 (ddd, J = 8.0, 7.8, 1.8 Hz, 1H, H-3), 7.12 
(dd, J = 7.3, 1.8 Hz, 1H, H-5), 6.87 (dd, J = 7.8, 7.3 Hz, 1H, H-4), 6.83 (d, J = 8.0 Hz, 1H, H-2), 
5.81 (ddt, J = 17.0, 10.1, 6.6 Hz, 1H, H-13), 4.98 (dd, J = 17.0, 2.0 Hz, 1H, H-14), 4.92 (dd, J = 
10.1, 2.0 Hz, 1H, H-14’), 3.81 (s, 3H, H-7), 2.59 (t, J = 8.0 Hz, 2H, H-8), 2.04 (td, J = 7.2, 6.6 Hz, 
2H, H-12), 1.64 – 1.53 (m, 2H, H-9), 1.48 – 1.29 (m, 4H, H-10, H-11) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 157.5 (C-1), 139.3 (C-13), 131.3 (C-6), 129.8 (C-5), 126.9 (C-3), 120.4 (C-4), 
114.2 (C-14), 110.3 (C-2), 55.3 (C-7), 33.9 (C-12), 30.2 (C-8), 29.8 (C-9), 29.2 (C-11), 28.9 (C-10) 
ppm; IR (ATR): νmax 3074, 2998, 2926, 2855, 2835, 1640, 1601, 1587, 1493, 1463, 1433, 1325, 
1289, 1240, 1177, 1160, 1128, 1050, 1031, 993, 908, 816, 749, 730, 636, 566, 539, 463 cm-1; 






1-Dodecene (0.22 ml, 1.0 mmol) was cooled to 0 °C under N2 and a solution of 9-BBN (0.5 M 
in THF, 1.00 mmol) was added dropwise. The solution stirred for 1 hour at 0 °C and 2 hours at 
room temperature to afford the dodecyl-borane solution (0.5 M, 1.00 mmol).  
A degassed solution of pyrrolidine 164 (38.2 mg, 0.103 mmol, 94:6 er) in dry THF (0.1 M) was 
added to CuTC (23.7 mg, 0.124 mmol), Pd(PPh3)4 (6.0 mg, 0.00517 mmol), and Cs2CO3 (36.5 
mg, 0.103 mmol) under N2 followed by dodecyl-borane solution (0.5 M, 0.248 ml, 0.124 
mmol). The solution was then degassed and backfilled with N2 3 times and heated to 45 °C for 
20 hours. The reaction was cooled to room temperature, diluted with Et2O (20 ml) and 
partitioned with 2M HCl (10 ml). The organic fraction was washed with 2M NH3 (3 x 10 ml) 
and saturated brine solution (10 ml), dried with MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by column chromatography (10% EtOAc/hexane) to give 235 
as a colourless oil (32.9 mg, 0.0792 mmol, 77 % yield) 
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.26 (m, 5H, Ar-H), 5.19 – 5.04 (m, 2H, H-5), 4.23 – 
4.15 (m, 1H, H-10), 3.50 – 3.34 (m, 2H, H-7), 3.14 (dd, J = 16.2, 3.3 Hz, 0.6H, rotamer 1, H-11), 
2.86 (dd, J = 16.2, 3.3 Hz, 0.4H, rotamer 2, H-11), 2.49 – 2.31 (m, 2H, H-11’, H-13), 2.30 – 2.20 
(m, 1H, H-13’), 2.15 – 2.01 (m, 1H, H-9), 1.92 – 1.74 (m, 2H, H-8), 1.72 – 1.56 (m, 1H, H-9’), 
1.55 – 1.36 (m, 3H, CH2), 1.34 – 1.10 (m, 17H, CH2), 0.86 (t, J = 6.8 Hz, 3H, H-24) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 209.9(209.7) (C-12), 154.7 (C-6), 137.0 (C-4), 128.6 (Ar-CH), 128.0 
(Ar-CH), 127.9 (Ar-CH), 66.9(66.7) (C-5), 54.2(53.4) (C-10), 47.6(46.8) (C-11), 46.6(46.5) (C-7), 
43.5(43.3) (C-13), 32.1(32.0) (C-9), 31.7(31.0) (C-22), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 
(CH2), 29.4 (CH2), 29.3 (CH2), 26.3 (CH2), 23.8(22.9) (C-14), 23.7(22.8) (C-8),  22.1(C-23), 14.2 
(C-24) ppm; IR (ATR): νmax 3406, 2923, 2853, 1701, 1498, 1452, 1410, 1357, 1338, 1300, 1211, 
1183, 1103, 1029, 977, 916, 875, 769, 734, 697, 600, 552, 460 cm-1; HRMS (ESI) 416.3156 (M 
+ H+. C26H42NO3 requires 416.3159); 438.2976 (M + Na+. C26H41NNaO3 requires 438.2979); 












Olefin 239 (43.1 mg, 0.211 mmol) was cooled to 0 °C under N2 and a solution of 9-BBN (0.5 M 
in THF, 0.211 mmol) was added dropwise. The solution stirred for 1 hour at 0 °C and 2 hours 
at room temperature to afford the 239-borane solution (0.5 M, 0.211 mmol).  
A degassed solution of pyrrolidine 164 (64.8 mg, 0.176 mmol, 94:6 er) in dry THF (0.1 M) was 
added to CuTC (40.2 mg, 0.211 mmol), Pd(PPh3)4 (10.2 mg, 0.0088 mmol), and Cs2CO3 (62.1 
mg, 0.176 mmol) under N2 followed by 239-borane solution (0.5 M, 0.422 ml, 0.211 mmol). 
The solution was then degassed and backfilled with N2 3 times and heated to 45 °C for 20 
hours. The reaction was cooled to room temperature, diluted with Et2O (20 ml) and 
partitioned with 2M HCl (10 ml). The organic fraction was washed with 2M NH3 (3 x 10 ml) 
and saturated brine solution (10 ml), dried with MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by column chromatography (15% EtOAc/hexane) to give 236 
as a colourless oil (58.1 mg, 0.129 mmol, 73 % yield) 
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.26 (m, 5H, Ar-H), 7.16 (dd, J = 8.2, 7.6 Hz, 1H, H-
23), 7.12 (d, J = 7.4 Hz, 1H, H-21), 6.87 (dd, J = 7.6, 7.4 Hz, 1H, H-22), 6.83 (d, J = 8.2 Hz, 1H, H-
24), 5.22 – 5.05 (m, 2H, H-5), 4.25 – 4.16 (m, 1H, H-10), 3.80 (s, 3H, H-26), 3.44 – 3.36 (m, 2H, 
H-7),3.15 (dd, J = 16.7, 3.4 Hz, 0.6H, rotamer 1, H-11), 2.86 (dd, J = 16.7, 3.4 Hz, 0.4H rotamer 
2, H-11), 2.59 (t, J = 7.6 Hz, 2H, H-19), 2.44 – 2.34 (m, 2H, H-11’, H-13), 2.29 – 2.21 (m, 1H, H-
13’), 2.16 – 2.02 (m, 1H, H-9), 1.87 – 1.79 (m, 2H, H-8), 1.71 – 1.62 (m, 1H, H-9’), 1.58 – 1.42 
(m, 3H, H-18, H-14), 1.40 – 1.13 (m, 7H, H-14’, H-15, H-16, H-17) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 209.8(209.6) (C-12), 157.5 (C-25), 154.7 (C-6), 137.0(136.8) (C-4), 131.3 (C-
20), 129.8 (C-21), 128.6 (Ar-CH), 128.1 (Ar-CH), 128.0(127.9) (Ar-CH), 126.9 (C-23), 120.4 (C-
22), 110.3 (C-24), 66.9(66.7) (C-5), 55.3 (C-26), 54.2(53.4) (C-10), 47.6(46.8) (C-11), 46.6(46.5) 
(C-7), 43.4(43.3) (C-13), 31.8(31.0) (C-9), 30.2 (C-19), 29.9 (C-18), 29.5 (CH2), 29.4 (CH2), 29.3 
(CH2), 23.8 (C-14), 23.7(22.9) (C-8) ppm; IR (ATR): νmax 2928, 2855, 1698, 1600, 1493, 1455, 
1411, 1356, 1336, 1241, 1178, 1103, 1049, 1029, 752, 698 cm-1; HRMS (ESI) 452.2795 (M + H+. 
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C28H38NO4 requires 452.2795); 474.2616 (M + Na+. C28H37NNaO4 requires 474.2615); 490.2356 
(M + K+. C28H37NKO4 requires 490.2354); [α]D20 -22.6° (c 1.00, CHCl3) 
 
1,1-Dimethyl-(S)-2-(2-methylsulfanylthiocarboxyoxy-tetradecyl)-pyrrolidinium iodide 
(mixture of diastereomers) (240) 
  
A solution of pyrrolidine ketone 235 (39.0 mg, 0.0938 mmol) in dry THF (0.5 mL) was added 
dropwise to a stirred solution of LiAlH4 (17.8 mg, 0.469 mmol) in dry THF (0.5 mL) at 0 °C under 
N2. The reaction was stirred at 0 °C for 1 hour then allowed to warm to room temperature 
and stirred overnight. The reaction was cooled to 0 °C and  diluted with diethyl ether (2 ml) 
quenched with H2O (0.1 ml), followed by NaOH solution (15% w/w aq, 0.1 ml), followed by 
H2O (0.3 ml) and the reaction warmed to rt. MgSO4 was added and the suspension was filtered 
through Celite®, followed by washings with diethyl ether (10 ml). The filtrate was 
concentrated in vacuo and the crude residue was further purified by silica plug filtration 
(1:10:90 NH3/MeOH/DCM) to give crude the hydroxy pyrrolidine (22.7 mg, 0.0763 mmol). The 
hydroxy pyrrolidine was dissolved in dry THF (1 mL) and added to NaH (60% in mineral oil, 6.1 
mg, 0.153 mmol) and imidazole (0.1 mg, 0.00153 mmol) in a dry flask under N2 at room 
temperature and the reaction was stirred for 30 mins. Carbon disulfide (0.023 mL, 0.381 
mmol) was added dropwise and the reaction stirred for 30 mins, followed by dropwise 
addition of methyl iodide (0.024 ml, 0.381 mmol). The reaction was stirred for 16 hours, then 
quenched with H2O (1 mL) and partitioned with diethyl ether (20 mL). The organic fraction 
was washed with H2O (20 mL) and saturated brine solution (20 mL), dried with MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified using sodium iodide 
coated silica gel, eluting with 5% MeOH/CH2Cl2.162 The isolated salt was then washed on a 
charcoal column with water, followed by MeOH to remove excess sodium iodide, then 
isolated by washing with 1:1 MeOH/CH2Cl2 to give the quaternary ammonium 240 as a pale-
orange oil (27.8 mg, 0.0525 mmol, 56% yield over two steps).  1H NMR (400 MHz, Chloroform-
d) δ 5.83 – 5.70 (m, 1H, H-7), 4.33 (dt, J = 11.4, 5.4 Hz, 0.7H, H-2, diastereomer 1), 4.24 (ddd, 
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J = 11.1, 8.1, 2.5 Hz, 0.3H, H-2, diastereomer 2), 3.90 – 3.54 (m, 2H, H-2’, H-5), 3.53 (s, 0.9H, 
H-1, diastereomer 1), 3.47 (s, 2.1H, H-1, diastereomer 2), 3.20 (s, 2.1H, H-1’, diastereomer 1), 
3.11 (s, 0.9H, H-1’, diastereomer 2), 2.56 (s, 2.1H, H-21, diastereomer 1), 2.55 (s, 0.9H, H-21, 
diastereomer 2), 2.47 – 2.36 (m, 1H, H-6), 2.28 – 2.10 (m, 2H, H-3), 2.10 – 1.64 (m, 4H, H-6, H-
8, CH2), 1.37 – 1.09 (m, 19H, CH2), 0.84 (t, J = 6.7 Hz, 3H, H-19) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ 216.7(215.9) (C-20), 81.1(80.2) (C-7), 73.9(73.4) (C-5), 67.1(66.6) (C-2), 
51.7(51.5) (C-1), 45.7(45.3) (C-1’), 34.5(34.2) (C-8), 33.0(32.9) (C-6), 32.0 (C-17), 29.7 (CH2), 
29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 28.2(28.0) (C-4), 
25.2(25.1) (C-9), 22.8 (C-18), 19.8(19.6) (C-3), 19.5(19.3) (C-21), 14.2 (C-19) ppm; IR (ATR): νmax 
3454, 2923, 2853, 1467, 1221, 1206, 1128, 1051, 965, 722 cm-1; HRMS (ESI) 402.2858 (M+. 
C22H44NOS2 requires 402.2859);  
(S)-2-[9-(2-Methoxy-phenyl)-2-methylsulfanylthiocarboxyoxy-nonyl]-1,1-dimethyl-
pyrrolidinium iodide (mixture of diastereomers) (241) 
  
A solution of pyrrolidine ketone 236 (50.7 mg, 0.112 mmol) in dry THF (0.5 mL) was added 
dropwise to a stirred solution of LiAlH4 (21.3 mg, 0.561 mmol) in dry THF (0.5 mL) at 0 °C under 
N2. The reaction was stirred at 0 °C for 1 hour then allowed to warm to room temperature 
and stirred overnight. The reaction was cooled to 0 °C and  diluted with diethyl ether (2 ml) 
quenched with H2O (0.1 ml), followed by NaOH solution (15% w/w aq, 0.1 ml), followed by 
H2O (0.3 ml) and the reaction warmed to rt. MgSO4 was added and the suspension was filtered 
through Celite®, followed by washings with diethyl ether (10 ml). The filtrate was 
concentrated in vacuo and the crude residue was further purified by silica plug filtration 
(1:10:90 NH3/MeOH/DCM) to give crude the hydroxy pyrrolidine (33.6 mg, 0.101 mmol). The 
hydroxy pyrroldine was dissolved in dry THF (1 mL) and added to NaH (60% in mineral oil, 8.1 
mg, 0.201 mmol) and imidazole (0.2 mg, 0.00201 mmol) in a dry flask under N2 at room 
temperature and the reaction was stirred for 30 mins. Carbon disulfide (0.03 mL, 0.504 mmol) 
was added dropwise and the reaction stirred for 30 mins, followed by dropwise addition of 
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methyl iodide (0.03 ml, 0.504 mmol). The reaction was stirred for 16 hours, then quenched 
with H2O (1 mL) and partitioned with diethyl ether (20 mL). The organic fraction was washed 
with H2O (20 mL) and saturated brine solution (20 mL), dried with MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified using sodium iodide coated silica gel, 
eluting with 5% MeOH/CH2Cl2.162 The isolated salt was then washed on a charcoal column 
with water, followed by MeOH to remove excess sodium iodide, then isolated by washing 
with 1:1 MeOH/CH2Cl2 to give the quaternary ammonium 241 as a yellow oil (22.6 mg, 0.0400 
mmol, 36% yield over two steps). 1H NMR (400 MHz, Chloroform-d) δ 7.13 (ddd, J = 8.2, 7.6, 
1.8 Hz, 1H, H-18), 7.09 (dd, J = 7.3, 1.8 Hz, 1H, H-16), 6.84 (dd, J = 7.6, 7.3 Hz, 1H, H-17), 6.81 
(d, J = 8.2 Hz, 1H, H-19)5.81 – 5.73 (m, 1H, H-7), 4.36 – 4.27 (m, 0.7H, H-2, diastereomer 1), 
4.27 – 4.18 (m, 0.3H, H-2, diastereomer 2),3.89 – 3.80 (m, 0.3H, H-5, diastereomer 1), 3.78 (s, 
3H, H-21), 3.76 – 3.64 (m, 1H, H-2), 3.62 – 3.53 (m, 0.7H, H-5 diastereomer 2), 3.51 (s, 0.9H, 
H-1, diastereomer 1), 3.46 (s, 2.1H, H-1, diastereomer 2),3.19 (s, 2.1H, H-1’, diastereomer 1), 
3.10 (s, 0.9H, H-1’, diastereomer 2), 2.56 (s, 3H, H-23), 2.55 (t, J = 7.8 Hz, 2H, H-14),2.46 – 2.36 
(m, 1H, H-6),2.28 – 2.10 (m, 2H, H-3), 2.07 – 2.00 (m, 1H, H-6’), 2.00 – 1.79 (m, 3H, H-8, CH2), 
1.79 – 1.67 (m, 1H, H-8’), 1.56 – 1.48 (m, 2H, H-13), 1.42 – 1.24 (m, 8H, CH2) ppm; 13C NMR 
(101 MHz, Chloroform-d) δ 216.7(216.0) (C-22), 157.5 (C-20), 131.3 (C-15), 129.8 (C-16), 126.9 
(C-18), 120.4 (C-17), 110.3 (C-19), 81.1(80.2) (C-7), 73.4 (C-5), 67.1 (C-2), 55.4 (C-21), 51.7 (C-
1), 45.7 (C-1’), 34.5(34.2) (C-8), 33.0(32.8) (C-6), 30.2 (C-14), 29.8 (CH2), 29.5 (CH2), 29.4 (CH2), 
29.3 (CH2), 28.2 (C-4), 25.2(25.1) (C-9), 19.8 (C-3), 19.6 (C-23) ppm; IR (ATR): νmax 3452, 2926, 
2854, 1706, 1599, 1492, 1464, 1289, 1241, 1223, 1125, 1052, 965, 754 cm-1; HRMS (ESI) 
438.2496 (M+. C24H40NO2S2 requires 438.2495)  




A solution of pyrrolidine ketone 235 (47.8 mg, 0.115 mmol) in dry MeOH (5 mL) was cooled 
to 0 °C and NaBH4 (8.7 mg, 0.230 mmol) was added portion wise. The reaction was stirred for 
1 hour, then quenched with 2M HCl (5 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic fractions were washed with saturated aqueous NaHCO3 solution (2 x 20 
mL), dried with MgSO4, filtered, and concentrated in vacuo without further purification to 
give 242 as a colourless oil (47.3 mg, 0.113 mmol, 98% yield). 1H NMR (400 MHz, Chloroform-
d) δ 7.45 – 7.26 (m, 5H, Ar-H), 5.19 – 5.05 (m, 2H, H-5), 4.71–4.14 (m, 0.4H, OH), 4.14–3.14 
(m, 4H, H-7, H-10, H-12), 2.07 – 1.55 (m, 5H, CH2), 1.57 –1.02 (m, 23H, CH2), 0.91 – 0.77 (m, 
3H, H-24) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.0(155.6) (C-6), 137.0(136.8) (C-4), 
128.6(128.6) (Ar-CH), 128.1(128.0) (Ar-CH), 128.0(127.9) (Ar-CH), 70.8(70.3)(67.7) (C-12), 
67.2(66.9) (C-5), 56.2(54.7) (C-10), 46.4(46.3) (C-7), 43.9(43.5) (CH2), 38.2(37.1) (CH2), 
32.1(32.0) (CH2), 31.3 (CH2), 29.9(29.8) (CH2), 29.7(CH2), 29.7(CH2), 29.5(CH2), 27.5(26.9) 
(CH2), 26.3(26.2) (CH2), 25.8 (CH2), 23.9 (CH2), 22.8 (CH2), 22.1 (CH2), 14.2 (C-24) ppm; IR (ATR): 
νmax 3418, 2922, 2852, 1681, 1498, 1453, 1411, 1357, 1337, 1300, 1260, 1211, 1187, 1164, 
1101, 1029, 979, 912, 870, 803, 768, 732, 696, 675, 602 cm-1; HRMS (ESI) 418.3319 (M + H+. 
C26H44NO3 requires 418.3316); 440.3135 (M + Na+. C26H43NNaO3 requires 440.3135). 
 
N-Cbz-(S)-2-[2-Hydroxy-9-(2-methoxy-phenyl)-nonyl]-pyrrolidine (mixture of 
diastereomers) (243) 
 
A solution of pyrrolidine ketone 236 (90.0 mg, 0.199 mmol) in dry MeOH (5 mL) was cooled 
to 0 °C and NaBH4 (15.1 mg, 0.399 mmol) was added portion wise. The reaction was stirred 
for 1 hour, then quenched with 2M HCl (5 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic fractions were washed with saturated aqueous NaHCO3 solution (2 x 20 
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mL), dried with MgSO4, filtered, and concentrated in vacuo without further purification to 
give 243 as a colourless oil (90.3 mg, 0.199 mmol, 100% yield). 1H NMR (400 MHz, Chloroform-
d) δ 7.45 – 7.25 (m, 5H, Ar-H), 7.16 (ddd, J = 7.8, 7.8, 1.8 Hz, 1H, H-23), 7.12 (dd, J = 7.5, 1.8 
Hz, 1H, H-21), 6.88 (ddd, J = 7.8, 7.5, 1.1 Hz, 1H, H-22), 6.84 (dd, J = 7.8, 1.1 Hz, 1H, H-24), 5.23 
– 5.01 (m, 2H, H-5), 4.69 (s, 0.3H, O-H), 4.32 – 3.98 (m, 1H, H-10), 3.81 (s, 3H, H-26), 3.69 – 
3.47 (m, 1H, H-12), 3.47 – 3.29 (m, 2H, H-7), 2.60 (t, J = 7.5 Hz, 2H, H-19), 2.10 – 1.24 (m, 18H, 
CH2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.5(157.0) (C-25), 155.6(155.0) (C-6), 
137.0(136.8) (C-4), 131.4 (C-20), 129.8 (C-21), 128.6(128.6) (Ar-CH), 128.1(128.1) (Ar-CH), 
128.0(127.9) (Ar-CH), 126.9 (C-23), 120.4 (C-22), 110.3 (C-24), 70.8(70.3) (C-12 diastereomer 
1), 69.8(67.7) (C-12 diastereomer 2),67.2(66.9) (C-5), 56.2(54.7) (C-10), 55.3 (C-26), 46.5(46.3) 
(C-7), 43.9(43.5) (CH2), 38.2(37.1) (CH2), 32.1(31.3) (CH2), 30.2(30.0) (CH2), 30.0(29.9) (CH2), 
29.8(29.8) (CH2), 29.7(29.6) (CH2), 26.2(25.8) (CH2), 23.9(23.7) (CH2),22.4(22.1) (CH2) ppm; IR 
(ATR): νmax 3424, 2924, 2853 , 1678, 1600, 1587, 1493, 1454, 1411, 1356, 1336, 1290, 1240, 
1212, 1187, 1162, 1101, 1049, 1029, 978, 913, 871, 808, 768, 751, 697, 675, 603, 542, 464 cm-
1; HRMS (ESI) 454.2954 (M + H+. C28H40NO4 requires 454.2952); 476.2773 (M + Na+. 
C28H39NNaO4 requires 476.2771). 
 
3-Dodecyl-hexahydro-pyrrolo[1,2-c][1,3]oxazin-1-one (mixture of diastereomers) (244) 
 
A solution of hydroxy pyrrolidine 242 (47.3 mg, 0.113 mmol) in dry THF (2 mL) was added to 
NaH (60% in mineral oil, 9.1 mg, 0.227 mmol) and imidazole (0.2 mg, 0.00227 mmol) in a dry 
flask under N2 at room temperature and the reaction was stirred for 30 mins. Carbon disulfide 
(0.04 mL, 0.566 mmol) was added dropwise and the reaction stirred for 30 mins, followed by 
dropwise addition of methyl iodide (0.04 ml, 0.566 mmol). The reaction was stirred for 16 
hours, then quenched with H2O (2 mL) and partitioned with CH2Cl2 (20 mL). The organic 
fraction was washed with 1M HCl (20 mL), saturated aqueous NaHCO3 solution (20 mL), and 
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H2O (20 mL) dried with MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified with flash column chromatography (25-75% EtOAC/hexane) to give 244 as a white 
solid (23.4 mg, 0.0756 mmol, 67% yield, 5:1 dr). 1H NMR (400 MHz, Chloroform-d) δ 4.44 – 
4.35 (m, 0.1H, H-7 diastereomer 1), 4.24 – 4.13 (m, 0.9H, H-7 diastereomer 2), 3.62 – 3.40 (m, 
3H, H-2, H-5), 2.19 – 1.90 (m, 3H, CH2), 1.84 – 1.61 (m, 2H, CH2), 1.61 – 1.13 (m, 23H, CH2), 
0.86 (t, J = 6.7 Hz, 3H, H-19) ppm; 13C NMR (101 MHz, Chloroform-d) δ 153.5 (C-1), 77.5 (C-7), 
56.6 (C-5), 46.5 (C-2), 35.3 (CH2), 33.8 (CH2), 33.3 (CH2), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.9 (CH2), 23.1 (CH2), 22.8 
(CH2), 14.2 (C-19) ppm; IR (ATR): νmax 2954, 2917, 2849, 1688, 1519, 1463, 1437, 1378, 1324, 
1306, 1243, 1200, 1155, 1127, 1050, 1015, 971, 905, 887, 802, , 754, 729, 670, 655, 631, 588, 
523, 483, 458 cm-1; HRMS (ESI) 310.2740 (M + H+. C19H36NO2 requires 310.2741); 332.2555 (M 
+ Na+. C19H35NNaO2 requires 332.2560); mp. 63.1-66.4 °C 
3-[7-(2-Methoxy-phenyl)-heptyl]-hexahydro-pyrrolo[1,2-c][1,3]oxazin-1-one (mixture of 
diastereomers) (245) 
  
A solution of hydroxy pyrrolidine 243 (90.3 mg, 0.199 mmol) in dry THF (2 mL) was added to 
NaH (60% in mineral oil, 15.9 mg, 0.398 mmol) and imidazole (0.3 mg, 0.00398 mmol) in a dry 
flask under N2 at room temperature and the reaction was stirred for 30 mins. Carbon disulfide 
(0.06 mL, 0.995 mmol) was added dropwise and the reaction stirred for 30 mins, followed by 
dropwise addition of methyl iodide (0.06 ml, 0.995 mmol). The reaction was stirred for 16 
hours, then quenched with H2O (2 mL) and partitioned with CH2Cl2 (20 mL). The organic 
fraction was washed with 1M HCl (20 mL), saturated aqueous NaHCO3 solution (20 mL), and 
H2O (20 mL) dried with MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified with flash column chromatography (25-75% EtOAC/hexane) to give 245 as a pale 
yellow oil (43.0 mg, 0.124 mmol, 63% yield, 7:1 dr). 1H NMR (400 MHz, Chloroform-d) δ 7.14 
(ddd, J = 7.8, 7.4, 1.8 Hz, 1H, H-16), 7.10 (dd, J = 7.4, 1.8 Hz, 1H, H-18), 6.86 (dd, J = 7.4, 7.4 
Hz, 1H, H-17), 6.82 (d, J = 7.8 Hz, 1H, H-19), 4.50 – 4.30 (m, 0.1H, H-7 diastereomer 1), 4.27 – 
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4.11 (m, 0.9H, H-7 diastereomer 2), 3.80 (s, 3H, H-21), 3.66 – 3.35 (m, 3H, H-2, H-5), 2.58 (t, J 
= 7.8 Hz, 2H, H-14), 2.17 – 2.05 (m, 2H, CH2), 2.03 – 1.91 (m, 1H, CH2), 1.86 –1.43 (m, 7H, CH2), 
1.43 – 1.17 (m, 8H, CH2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.5 (C-20), 153.5 (C-1), 
131.3 (C-15), 129.8 (C-16), 126.9 (C-18), 120.4 (C17), 110.3(C19), 77.5 (C-7), 56.6(55.3) (C-5), 
55.4 (C-21), 46.5 (C-2), 35.3 (CH2), 33.8 (CH2), 33.3 (C-4), 30.2 (C-14), 29.9 (CH2), 29.6 (CH2), 
29.5 (CH2), 29.5 (CH2), 24.9 (CH2), 23.1 (C-3) ppm;  IR (ATR): νmax 2925, 2854, 1689, 1600, 1587, 
1493, 1462, 1423, 1370, 1342, 1312, 1289, 1240, 1201, 1176, 1117, 1049, 1029, 924, 887, 753, 
653, 568, 477 cm-1; HRMS (ESI) 346.2375 (M + H+. C21H32NO3 requires 346.2377); 368.2194 (M 
+ Na+. C21H31NNaO3 requires 368.2196). 
N-Cbz-(S)-2-(2-Dodecyl-[1,3]dithiolan-2-ylmethyl)-pyrrolidine (250) 
 
Pyrrolidine ketone 235 (42.4 mg, 0.102 mmol) and 1,2-ethanedithiol (0.17 ml, 2.04 mmol) was 
dissolved in dry CH2Cl2 (0.7 mL, 0.16M) under N2. BF3.Et2O (0.15 ml, 1.22 mmol) was added 
dropwise and the reaction stirred for 4 hours. The reaction was quenched with acetone (0.6 
ml), diluted with saturated aqueous NaHCO3 solution (10 mL), and extracted with CH2Cl2 (2 x 
10 mL). The combined organic fractions were dried with MgSO4, filtered and concentrated in 
vacuo. The crude material was purified by column chromatography (10% EtOAc/hexane) to 
give 250 as a colourless oil (14.9 mg, 0.0303 mmol, 30% yield). 1H NMR (400 MHz, Chloroform-
d) δ 7.39 – 7.23 (m, 5H, Ar-H), 5.18 – 5.05 (m, 2H, H-5), 4.20 – 4.01 (m, 1H, H-10), 3.43 – 3.30 
(m, 2H, H-7), 3.32 – 3.00 (m, 4H, H-25, H-26), 2.52 (d, J = 14.2 Hz, 0.5H, H-11), 2.31 (d, J = 14.2 
Hz, 0.5H, H-11), 2.11 – 2.07 (m, 1H, H-9), 2.01 – 1.76 (m, 6H, CH2), 1.55 – 1.00 (m, 20H, CH2), 
0.86 (t, J = 6.7 Hz, 3H, H-24) ppm; 13C NMR (101 MHz, Chloroform-d) δ 154.8 (C-6), 134.9 (C-
4), 128.5 (Ar-CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 69.8 (C-12),  66.9 (66.6) (C-5), 56.4 (55.8) (C-
10), 46.0 (C-7), 45.4 (C-11), 44.6 (CH2), 39.6 (C-25), 39.1 (C-26), 32.1(31.6) (C-9), 32.0 (CH2), 
29.8 (CH2), 29.6 (CH2), 29.5 (CH2), 26.8 (CH2), 24.0(23.2) (C-8),  22.8 (C-23), 14.2 (24) ppm; IR 
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(ATR): νmax 2923, 2852, 1700, 1497, 1455, 1408, 1356, 1337, 1186, 1029, 768, 750, 697, 602 
cm-1; HRMS (ESI) 492.2950 (M + H+. C28H46NO2S2 requires 492.2964); 514.2778 (M + Na+. 
C28H45NNaO2S2 requires 514.2784); 530.2717 (M + K+. C28H45KNO2S2 requires 530.2733); [α]D25 
-23.6° (c 0.71, CHCl3) 
N-Cbz-(S)-2-{2-[7-(2-Methoxy-phenyl)-heptyl]-[1,3]dithiolan-2-ylmethyl}-pyrrolidine (251) 
  
Pyrrolidine ketone 236 (55.9 mg, 0.124 mmol) and 1,2-ethanedithiol (0.21 ml, 2.48 mmol) was 
dissolved in dry CH2Cl2 (0.8 mL, 0.16M) under N2. BF3.Et2O (0.18 ml, 1.49 mmol) was added 
dropwise and the reaction stirred for 4 hours. The reaction was quenched with acetone (0.6 
ml), diluted with saturated aqueous NaHCO3 solution (10 mL), and extracted with CH2Cl2 (2 x 
10 mL). The combined organic fractions were dried with MgSO4, filtered and concentrated in 
vacuo. The crude material was purified by column chromatography (15% EtOAc/hexane) to 
give 251 as a colourless oil (21.3 mg, 0.0404 mmol, 33% yield). 1H NMR (400 MHz, Chloroform-
d) δ 7.39 – 7.25 (m, 5H, Ar-H), 7.15 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H, H-23), 7.11 (dd, J = 7.3, 1.8 
Hz, 1H, H-21), 6.87 (dd, J = 7.4, 7.3 Hz, 1H, H-22), 6.83 (d, J = 8.1 Hz, 1H, H-24), 5.19 – 5.02 (m, 
2H, H-5), 4.21 – 4.03 (m, 1H, H-10), 3.80 (s, 3H, H-26), 3.47 – 3.31 (m, 2H, H-7), 3.32 – 3.01 (m, 
4H, H-27, H-28), 2.58 (t, J = 7.5 Hz, 2H, H-19), 2.52 (d, J = 14.2 Hz, 0.5H, H-11, rotamer 1), 2.31 
(d, J = 14.6 Hz, 0.5H, H-11, rotamer 2), 2.11 – 2.07 (m, 1H, H-9), 2.03 – 1.75 (m, 6H, CH2), 1.59 
– 1.12 (m, 10H, CH2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.5 (C-25), 154.8 (C-6), 131.4 
(C-20), 129.8 (C-21),128.5 (Ar-CH), 128.1 (Ar-CH), 127.9 (Ar-CH), 126.8 (C-23), 120.4 (C-22), 
110.3 (C-24), 69.8 (C-12), 67.0(66.5) (C-5), 56.4(55.7) (C-10), 55.3 (C-26), 46.0 (45.3) (C-11), 
44.6 (CH2), 39.6 (C-27), 39.0 (C-28), 32.1 (31.6) (C-9), 30.2 (CH2), 29.9 (CH2), 29.8 (CH2), 29.7 
(CH2), 29.5 (CH2), 26.8 (CH2), 24.0(23.2) (C-8) ppm; IR (ATR): νmax 2927, 2854, 1698, 1493, 
1455, 1409, 1356, 1336, 1288, 1241, 1185, 1101, 1050, 1030, 752, 697, 602 cm-1; HRMS (ESI) 
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528.2609 (M + H+. C30H42NO3S2 requires 528.2601); 550.2426 (M + Na+. C30H41NNaO3S2 
requires 550.2420); [α]D20 -20.8° (c 0.915, CHCl3) 
N-Cbz-(R)-2-Tetradecyl-pyrrolidine (252) 
 
Ketone 235 (48.4 mg, 0.116 mmol) was dissolved in MeOH (5 ml) and added to p-
toluenesulfonyl hydrazide (32.5 mg, 0.175 mmol) followed by AcOH (cat. ~0.1 ml). The 
reaction was stirred at room temperature for 24 hours, then concentrated in vacuo. The crude 
material was filtered through a pad of silica (25% EtOAc/hexane) to give the tosylhydrazone 
as a brown residue (59.4 mg, 0.102 mmol, 88 % yield). A portion of the tosylhydrazone (16.5 
mg, 0.0283 mmol) in anhydrous MeOH (1 ml) was added to NaBH3CN (8.9 mg, 0.141 mmol) 
and ZnCl2 (9.6 mg, 0.0707 mmol) under N2 and the reaction heated to reflux for 16 hours. The 
reaction was quenched with 5% NaOH (aq) (5 ml) extracted with Et2O (3 x 10 ml). The 
combined organic fractions were washed with water (10 ml) and saturated brine solution (10 
ml), dried with MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
column chromatography (10% Et2O/hexane) to give 252 as a yellow oil (9.2 mg, 0.0229 mmol, 
81 % yield). 1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.25 (m, 5H, Ar-H), 5.20 – 5.05 (m, 2H, 
H-5), 3.89 – 3.74 (m, 1H, H-10), 3.50 – 3.31 (m, 2H, H-7), 2.01 – 1.61 (m, 5H, CH2), 1.38 – 1.00 
(m, 25H, CH2), 0.87 (t, J = 7.4 Hz, 3H, H-24) ppm; 13C NMR (101 MHz, Chloroform-d) δ 154.1 
(C-6), 128.5 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 66.7(66.5) (C-5), 58.2(57.4) (C-10), 
46.7(46.3) (C-7), 34.6(34.0) (CH2), 32.0 (CH2), 30.6(30.4) (CH2), 29.9 (CH2), 29.8 (CH2), 29.8 
(CH2), 29.7 (CH2), 29.7 (CH2), 29.5 (CH2), 29.4 (CH2), 26.5 (CH2), 26.3 (CH2), 23.9 (CH2), 23.1 
(CH2), 22.8 (C-23), 14.2 (C-24) ppm; IR (ATR): νmax 2923, 2853, 1703, 1618, 1456, 1410, 1357, 
1334, 1185, 1100, 768, 696 cm-1; HRMS (ESI) 402.3372 (M + H+. C26H44NO2 requires 402.3367); 









Ketone 236 (55.0 mg, 0.122 mmol) was dissolved in MeOH (5 ml) and added to p-
toluenesulfonyl hydrazide (34.0 mg, 0.183 mmol) followed by AcOH (cat. ~0.1 ml). The 
reaction was stirred at room temperature for 24 hours, then concentrated in vacuo. The crude 
material was filtered through a pad of silica (30% EtOAc/hexane) to give the tosylhydrazone 
as a brown residue (66.8 mg, 0.108 mmol, 88 % yield). A portion of the tosylhydrazone (5.7 
mg, 0.00920 mmol) in anhydrous MeOH (1 ml) was added to NaBH3CN (2.9 mg, 0.0460 mmol) 
and ZnCl2 (3.1 mg, 0.0230 mmol) under N2 and the reaction heated to reflux for 16 hours. The 
reaction was quenched with 5% NaOH (aq) (5 ml) extracted with Et2O (3 x 10 ml). The 
combined organic fractions were washed with water (10 ml) and saturated brine solution (10 
ml), dried with MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
column chromatography (15% Et2O/hexane) to give 253 as a yellow oil (1.6 mg, 0.00366 
mmol, 40 % yield). 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.25 (m, 5H, Ar-H), 7.15 (dd, J = 
8.4, 7.8 Hz, 1H, H-23), 7.12 (d, J = 7.6 Hz, 1H, H-21), 6.87 (t, J = 7.8, 7.6 Hz, 1H, H-22), 6.83 (d, 
J = 8.4 Hz, 1H, H-24), 5.20 – 5.05 (m, 2H, H-5), 3.89 – 3.77 (m, 1H, H-10), 3.81 (s, 3H, H-26), 
3.52 – 3.31 (m, 2H, H-7), 2.58 (t, J = 7.8 Hz, 2H, H-19), 1.98 – 1.61 (m, 5H, CH2), 1.59 – 1.51 (m, 
2H, CH2), 1.42 – 1.13 (m, 13H, CH2) ppm; 13C NMR (101 MHz, Chloroform-d) δ 157.5 (C-25), 
154.9 (C-6), 131.4 (C-20), 129.8 (C-21), 128.5 (Ar-CH), 127.9 (Ar-CH), 127.9 (Ar-CH), 126.8 (C-
23), 120.4 (C-22), 110.3 (C-24), 66.5 (C-5), 58.2 (C-10), 55.3 (C-26), 46.7 (C-7), 34.0(C-11), 30.7 
(C-9), 30.2(C-19), 29.9 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 26.4 (C-12), 23.9 
(CH2), 23.1 (C-8) ppm; IR (ATR): νmax 2924, 2853, 1701, 1601, 1587, 1493, 1455, 1410, 1356, 
1334, 1288, 1259, 1241, 1178, 1097, 1050 1029, 913, 864, 802, 763, 751, 697, 600 cm-1; HRMS 







A solution of pyrrolidine 252 (9.2 mg, 0.0229 mmol) in dry THF (0.25 ml) was added to a 
solution of LiAlH4 (8.7 mg, 0.229 mmol) in dry THF (0.25 ml) at 0 °C under N2. The reaction was 
allowed to warm to room temperature with stirring for 15 hours. The reaction was cooled to 
0 °C, diluted with Et2O (5 ml), quenched with 5% NaOH solution (0.1 ml) and dried with MgSO4. 
The mixture wa filtered through celite and concentrated in vacuo. The crude material was 
purified by column chromatography (1:10:90 NH3/MeOH/DCM) to give 207 as a yellow oil (4.4 
mg, 0.0156 mmol, 68% yield. 1H NMR (400 MHz, Chloroform-d) δ 3.05 (ddd, J = 9.1, 7.8, 2.2 
Hz, 1H, H-2), 2.29 (s, 3H, H-1), 2.10 (ddd, J = 9.1, 9.1, 8.7 Hz, 1H, H-2’), 1.99 – 1.84 (m, 2H, H-
5, CH2), 1.80 – 1.69 (m, 1H, CH2), 1.69 – 1.58 (m, 2H, CH2), 1.48 – 1.34 (m, 1H, CH2), 1.34 – 1.06 
(m, 25H, CH2), 0.84 (t, J = 7.1 Hz, 3H, H-19) ppm;13C NMR (101 MHz, Chloroform-d) δ 66.5 (C-
5), 57.3 (C-2), 40.4 (C-1), 33.8 (C-6), 31.9 (C-17), 30.8 (C-4), 30.0 (C-8), 29.7-29.6 (C-9-C-15), 
29.4 (C-16), 26.7 (C-7), 22.7 (C-18), 21.8 (C-3), 14.1 (C-19) ppm; IR (ATR): νmax 2922, 2852, 
2772, 1457, 1376, 1350, 1215, 1163, 1114, 1042, 896, 721, 573 cm-1; HRMS (ESI) 282.3159 (M 





A solution of pyrrolidine 253 (10.8 mg, 0.0247 mmol) in dry THF (0.25 ml) was added to a 
solution of LiAlH4 (9.4 mg, 0.247 mmol) in dry THF (0.25 ml) at 0 °C under N2. The reaction was 
allowed to warm to room temperature with stirring for 15 hours. The reaction was cooled to 
0 °C, diluted with Et2O (5 ml), quenched with 5% NaOH solution (0.1 ml) and dried with MgSO4. 
The mixture wa filtered through celite and concentrated in vacuo. The crude material was 
purified by column chromatography (1:10:90 NH3/MeOH/DCM) to give 208 as a yellow oil (6.9 
mg, 0.0217 mmol, 88% yield. 1H NMR (400 MHz, Chloroform-d) δ 7.15 (td, J = 8.2, 7.4, 1.8 Hz, 
1H, H-18), 7.11 (dd, J = 7.3, 1.8 Hz, 1H, H-16), 6.86 (ddd, J = 7.4, 7.3, 1.2 Hz, 1H, H-17), 6.83 
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(dd, J = 8.2, 1.2 Hz, 1H, H-19), 3.81 (s, 3H, H-21), 3.05 (ddd, J = 9.5, 7.8, 2.1 Hz, 1H, H-2), 2.58 
(t, J = 7.8 Hz, 2H, H-14), 2.29 (s, 3H, H-1), 2.18 – 2.05 (m, 1H, H-2’), 2.04 – 1.84 (m, 2H, H-5, 
CH2), 1.84 – 1.60 (m, 3H, CH2), 1.60 – 1.50 (m, 2H, CH2), 1.49 – 1.11 (m, 14H, CH2) ppm; 13C 
NMR (101 MHz, Chloroform-d) δ 157.4 (C-20), 131.3 (C-15), 129.7 (C-16), 126.7 (C-18), 120.2 
(C-17), 110.1 (C-19), 66.6 (C-5), 57.2 (C-2), 55.2 (C-21), 40.2 (C-1), 33.5 (C-6), 30.6 (C-4), 30.1 
(C-14), 30.0 (C-13), 29.8 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 26.7 (C-7), 21.7 
(C-3) ppm; IR (ATR): νmax 2925, 2853, 2775, 1672, 1601, 1493, 1463, 1289, 1241, 1176, 1127, 
1050, 1031, 751 cm-1; HRMS (ESI) 318.2790 (M + H+. C21H36NO requires 318.2791); [α]D20 -




1-(but-3-enyl)pent-4-enylamine 282 was synthesised using previously reported 
procedures.163 A solution of 1-(but-3-enyl)pent-4-enylamine 282 (150 mg, 1.08 mmol) was 
dissolved in 1,4-dioaxane (5 ml) and added to a stirred solution of K2CO3 (178 mg, 1.29 mmol) 
in H2O (0.18 ml). Benzyl chloroformate (0.18 ml, 1.29 mmol) was added dropwise to the 
reaction and stirred for 18 hours. The reaction was diluted with H2O (5 ml) and extracted with 
CH2Cl2 (3 x 5 ml). The combined organics were washed with saturated brine solution (5 ml), 
dried with MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
column chromatography (10% EtOAc/hexane) to give Cbz-amine 281 as a colourless oil (253 
mg, 0.925 mmol, 86% yield).1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.26 (m, 5H, Ar-H), 
5.79 (ddt, J = 16.8, 10.2, 6.5 Hz, 2H, H-10), 5.08 (s, 2H, H-5), 5.00 (dd, J = 16.8, 1.9 Hz, 2H, H-
11), 4.95 (dd, J = 10.2, 1.9 Hz, 2H, H-11’), 4.51 (d, J = 9.5 Hz, 1H, NH), 3.74 – 3.60 (m, 1H, H-7), 
2.20 – 2.00 (m, 4H, H-9), 1.69 – 1.52 (m, 2H, H-8), 1.52 – 1.39 (m, 2H, H-8’) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 156.1 (C-6), 138.1 (C-10), 136.7 (C-4), 128.6 (Ar-CH), 128.2(Ar-CH), 
128.1 (Ar-CH), 115.1 (C-11), 66.7 (C-5), 50.7 (C-7), 34.7 (C-8), 30.2 (C-9) ppm; IR (ATR): νmax 
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3321, 3074, 2935, 2852, 1691, 1640, 1531, 1451, 1415, 1330, 1299, 1243, 1215, 1045, 1027, 
993, 909, 774, 735, 696, 642, 458 cm-1; HRMS (ESI) 274.1798 (M + H+. C17H24NO2 requires 
274.1802), 296.1616 (M + Na+. C17H23NNaO2 requires 296.1621), 312.1359 (M + K+. 
C17H23KNO2 requires 312.1360) 
N-Cbz-6-amino-undeca-2,9-diene-bis-thioic acid di-S-p-tolyl ester (280) 
 
A solution of thioester 134 (363 mg, 2.04 mmol) in 1,2-DCE (7.5 ml) was added under N2 to a 
dry flask containing Hoveyda-Grubbs Catalyst™ 2nd generation (21.2 mg, 0.034 mmol) and 
copper iodide (57.1 mg, 0.34 mmol) while stirring. A solution of Cbz-amine 281 (92.8 mg, 0.34 
mmol) in 1,2-DCE (7.5 ml) was added under N2 and the reaction heated to 50 °C for 7 hours. 
The reaction was then cooled to room temperature, exposed to air and concentrated in 
vacuo. The crude residue was purified by flash column chromatography (10-50% 
EtOAc/hexane) to afford 280 as a pale brown oil (150 mg, 0.261 mmol, 77% yield). 1H NMR 
(400 MHz, Chloroform-d) δ 7.49 – 7.32 (m, 5H, Ar-H), 7.31 (d, J = 7.8 Hz, 4H, H-14), 7.22 (d, J 
= 7.8 Hz, 4H, H-15), 6.93 (dt, J = 15.7, 6.9 Hz, 2H, H-10), 6.18 (d, J = 15.7 Hz, 2H, H-11), 5.22 – 
5.01 (m, 2H, H-5), 4.62 (d, J = 9.4 Hz, 1H, NH), 3.88 – 3.55 (m, 1H, H-7), 2.37 (s, 6H, H-17), 2.32 
– 2.17 (m, 4H, H-9), 1.81 – 1.58 (m, 2H, H-8), 1.58 – 1.34 (m, 2H, H-8’) ppm; 13C NMR (101 
MHz, Chloroform-d) δ 188.5 (C-12), 156.2 (C-6), 145.2 (C-10), 139.8 (C-16), 136.5 (C-4), 134.7 
(C-14), 130.1 (C-15), 128.7 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 128.2 (C-11), 124.1 (C-13), 
67.0 (C-5), 51.0 (C-7), 34.1 (C-8), 29.0 (C-9), 21.5 (C-17) ppm; IR (ATR): νmax 3345, 3030, 2931, 
1683, 1630, 1525, 1493, 1449, 1287, 1237, 1140, 1053, 1016, 975, 807, 738, 698, 649, 536, 
475 cm-1; HRMS (ESI) 596.1900 (M + Na+. C33H35NNaO4S2 requires 596.1900), 612.1640 (M + 









A solution of amino-thioester 280 (22.1 mg, 0.039 mmol) in 1,2-DCE (5 ml) was added to rac-
CSA (22.6 mg, 0.116 mmol) under N2 and the reaction heated to 50 °C for 24 hours. The 
reaction was cooled to room temperature and extracted with DCM (10 ml). The organic 
fraction was washed with saturated NaHCO3 solution (10 ml), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by column chromatography (25% 
EtOAc/hexane) to afford 279 as a colourless oil (14.7 mg, 0.026 mmol, 60% yield). 
Asymmetric 
A solution of amino-thioester 280 (36.2 mg, 0.0631 mmol) in cyclohexane (0.02M) was added 
to (R)-TRIP (9.5 mg, 0.0126 mmol) under N2 and the reaction heated to 80 °C for 24 hours. 
The reaction was then cooled to room temperature, quenched with Et3N (0.2 ml) and 
concentrated in vacuo. The crude material was purified by column chromatography (20% 
Et2O/hexane) to afford 279 as a colourless oil (27.7 mg, 0.048 mmol, 77% yield, dr 92:8, major 
er: 93:7, minor er: 56:44 ). 
Major diastereomer:  
1H NMR (400 MHz, Chloroform-d) δ 7.50 – 7.17 (m, 13H, Ar-H), 6.97 (dt, J = 15.5, 6.7 Hz, 0.5H, 
H-13, rotamer 1), 6.88 (dt, J = 15.5, 6.7 Hz, 0.5H, H-13, rotamer 2), 6.24 (d, J = 15.5 Hz, 0.5H, 
H-14, rotamer 1), 6.14 (d, J = 15.5 Hz, 0.5H, H-14, rotamer 2), 5.29 – 5.08 (m, 2H, H-5), 4.38 – 
4.28 (m, 1H, H-7), 3.94 – 3.79 (m, 1H, H-10), 3.38 (dd, J = 14.8, 3.2 Hz, 0.5H, H-21, rotamer 1), 
3.08 (dd, J = 14.8, 3.2 Hz, 0.5H, H-21, rotamer 2), 2.69 (dd, J = 14.8, 9.7 Hz, 0.5H, H-21’, rotamer 
1), 2.62 (dd, J = 14.8, 9.7 Hz, 0.5H, H-21’, rotamer 2), 2.39 (s, 6H, H-20, H-27), 2.30 – 1.76 (m, 
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6H, CH2), 1.76 – 1.65 (m, 1H, CH2), 1.53 – 1.39 (m, 1H, CH2) ppm; 13C NMR (101 MHz, 
Chloroform-d) δ195.9(195.8) (C-22), 188.4(188.3) (C-15), 154.0(153.8) (C-6),  145.3, 145.0 (C-
13), 139.9, 139.7 (C-19), 139.7, 139.6 (C-26), 136.6(136.6) (C-4), 134.6(134.5) (C-17), 
134.4(134.3) (C-24), 130.1(130.1) (C-18), 130.0(130.0) (C-25), 128.6(128.6) (Ar-CH), 
128.2(128.2) (Ar-CH), 128.1(128.1) (Ar-CH), 128.1(128.1) (C-14), 124.1(124.1) (C-16), 
124.0(123.9) (C-23), 66.9(66.9) (C-5), 57.9(57.2) (C-10), 55.1(54.6) (C-7), 47.1(45.6) (C-21), 
32.2(30.9) (C-11), 29.4, (29.3) (C-12), 28.3(27.4) (C-8), 27.4(26.5) (C-9), 21.4 (C-20, C-27) ppm; 
IR (ATR): νmax 3030, 2923, 2853, 1693, 1631, 1597, 1493, 1453, 1404, 1353, 1330, 1304, 1210, 
1181, 1116, 1102, 1060, 1016, 989, 807, 771, 752, 733, 698, 647, 603, 534, 474 cm-1; HRMS 
(ESI) 574.2069 (M + H+. C33H36NO4S2 requires 574.2080), 591.2339 (M + NH3+. C33H39N2O4S2 
requires 591.2346), 596.1895 (M + Na+. C33H35NNaO4S2 requires 596.1900), 612.1656 (M + K+. 




9.1. HPLC data for cyclised compounds 
N-Cbz-3,3-dimethyl-(S)-5-p-Tolyloxycarbonylmethyl-pyrrolidine (127c) 
 
HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.05 325636.750 94.962 0.297





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.76 4395871.500 49.967 0.289









































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.67 10851146.000 97.931 0.302





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.89 2444530.250 49.414 0.327































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.93 6110395.500 97.677 0.340









HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.23 2949471.000 50.196 0.309









































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.15 8030335.000 98.139 0.319





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 







































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.07 3063161.000 50.784 0.306









































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.05 1187544.500 97.045 0.300





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.59 2987208.500 49.646 0.304






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.59 6442181.000 89.927 0.310






HPLC analysis CHIRALPAK IC column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 9.44 4442656.000 49.614 1.695
2 16.29 4511810.500 50.386 1.682  






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 9.42 19048088.000 96.075 0.848
2 16.43 778222.750 3.925 1.305    
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No. tR Peak Area
(Y units*ms)
Area Percent Width
1 9.41 7742961.500 76.345 1.269
2 16.33 2399111.500 23.655 1.578  






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 9.37 26652556.000 94.640 1.007





HPLC analysis CHIRALPAK IC column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 





























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.82 11354936.000 49.911 1.323






































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 8.90 26545430.000 91.823 1.004






HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 6.95 5707584.000 49.875 0.266








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 6.82 5138018.500 95.609 0.264





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 6.97 2636100.250 48.918 0.279








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 7.03 8773789.000 94.521 0.289





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (95:5), flow rate: 1.0 mL/min, 25 °C, 








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 6.89 2331830.750 48.834 0.291








































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 6.91 10262474.000 95.675 0.304







HPLC analysis CHIRALPAK IB column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 



















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 11.04 1795499.875 50.167 0.468




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 10.99 4534995.000 96.293 0.475




dibenzyl ester (160e) 
 
HPLC analysis CHIRALPAK IB column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 





























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 20.40 1139909.500 49.641 0.948




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 20.45 1121332.500 70.284 0.950





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 12.67 119961.375 49.566 0.890




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 12.64 42114.402 23.827 0.585






HPLC analysis CHIRALPAK IC column, hexane/2-propanol (80:20), flow rate: 1.0 mL/min, 25 






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 17.30 3642330.000 49.879 0.780
2 33.23 3659963.000 50.121 1.650  
 




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 17.13 33881044.000 89.855 1.808
2 33.16 3825307.250 10.145 2.156  
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No. tR Peak Area
(Y units*ms)
Area Percent Width
1 16.99 43907212.000 93.627 1.778
2 32.96 2988478.500 6.373 2.227  




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 17.07 83726000.000 90.807 1.846





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (97:3), flow rate: 1.0 mL/min, 25 °C, 






























































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 14.03 4092547.250 50.141 0.675





















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 26.19 3932123.500 84.434 1.496





HPLC analysis CHIRALPAK IB column, hexane/2-propanol (99:1), flow rate: 1.0 mL/min, 25 °C; 




















































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 17.06 312242.625 88.576 0.608








HPLC analysis CHIRALPAK IG column, hexane/2-propanol (50:50), flow rate: 0.7 mL/min, 25 
°C, λ = 254 nm; tR 29 min (minor diastereomer, minor enantiomer), 31 min (minor 
diastereomer, major enantiomer), 58 min (major diastereomer, minor enantiomer) and 62 






































































































































































































































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 29.01 510349.719 4.152 1.611
2 31.41 530868.500 4.319 1.745
3 57.62 5641569.000 45.899 3.349







































































































































































































































































































































































No. tR Peak Area
(Y units*ms)
Area Percent Width
1 29.02 444878.438 3.280 1.600
2 31.34 574038.750 4.232 1.736
3 57.64 834827.313 6.155 3.106






(R)-anth (R)-3,3’-Bis(9-anthracenyl)-1,1’-binaphthyl-2,2’-diyl hydrogenphosphate 
(R)-phe (R)-3,3′-Bis(9-phenanthryl)-1,1′-binaphthalene-2,2′-diyl hydrogen phosphate 




4Å MS 4 Ångström molecular sieves 
Ac acetyl 
AIBN azobisisobutyronitrile 















DAST diethylaminosulfur trifluoride 
DIBAL-H diisobutylaluminium hydride 
DIPT diisopropyl tartrate 
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMS dimethyl sulfide 
DMSO dimethylsulfoxide 
DPP diphenyl hydrogen phosphate 
DPPA diphenylphosphoryl azide 
dr diastereomeric ratio 
DTBMP 2,6-di-tert-butyl-4-methylpyridine 
ee enantiomeric excess 
eq. equivalents 
er enantiomeric ratio 
ESI electrospray ionisation 
Et ethyl 
FDA U.S. Food and Drug Administration 




HIV human immunodeficiency virus 
HMBC heteronuclear multiple bond coherence 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSQC heteronuclear single quantum coherence 
IC50 half maximal inhibitory concentration  
i-Pr isopropyl 
IR infra-red 
J coupling constant (Hz) 
KHMDS potassium bis(trimethylsilyl)amide 
LC50 median lethal concentration 
LCMS liquid chromatography mass spectrometry 
LDA lithium diisopropylamide 
LiHMDS lithium bis(trimethylsilyl)amide 
m multiplet 
mCPBA m-chloroperoxybenzoic acid 
Me methyl 
Mes mesityl (1,3,5-trimethylbenzene) 
Mp melting point 
Ms mesyl 
MTBE methyl tert-butyl ether 
NBS N-bromosuccinimide 
n-Bu n-butyl 
NMR nuclear magnetic resonance 
Ns p-nitrobenzenesulfonyl 
Ph phenyl 
PMP p-methoxyphenyl  
Pr propyl 
q quartet 
rac-CSA racemic camphorsulfonic acid 





TBACl tetrabutylammonium chloride 
TBAF tetrabutylammonium fluoride 
t-Bu tert-butyl 
Tf triflate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
THP tetrahydropyran 
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